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Antibody–drug conjugates (ADCs) are a particularly promising class of antibody-based
therapeutics. They are commonly referred to as “magic-bullet” therapy due to the ability
to seek and destroy primarily diseased cells within the body (e.g. cancer cells). Critical
to this strategy is the availability of effective methodologies to link an antibody to other
molecules (e.g. cytotoxic drugs, prodrugs).
Although current approaches offer great promise for the development of ADC constructs,
they often are not selective and yield heterogeneous product mixtures. Other strategies
require mutations with natural or unnatural amino acids, which are generally associated
with low expression yields and post-translational issues, whilst some result in the loss of
vital disulfide bonds. Furthermore, most of the current peptide/payload linker technologies
have the potential to attach only one moiety, greatly limiting their scope and flexibility.
To tackle these issues, a novel class of tuneable reagents based on pyridazinedione (PD)
moieties was developed. These reagents are readily accessible from inexpensive starting
materials in 3 – 4 scalable steps and overcome the problems stated above. Indeed, the
PD-based reagents have exquisite selectivity towards cysteines over lysines, even at high
temperature and/or with an excess of reagent. When reacted with reduced native disulfide
bonds of antibodies or antibody fragments, PDs rapidly and quantitatively form a stable
and rigid 2-carbon bridge between the two cysteines side-chains without affecting the
structure and biological activity of antibodies. The resulting conjugates have also been
demonstrated to have exceptional resistance to hydrolysis at various extreme pHs and
temperatures over an extended period of time. Finally, the PD-conjugates possess two
orthogonal handles that were readily modified with two different moieties to generate
highly functionalised homogeneous constructs with application not only in antibody
therapeutics but also in imaging and diagnostics.
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Introduction
1.1 Chemical modification of proteins
Decoding the chemistry of life is the ultimate goal for biochemists and chemical biologists.
The enormous complexity of chemical and biochemical pathways, however, represents
a major obstacle towards achieving this aim. A significant step in this direction was
the decoding of the entire human genome sequence, which provided a vast trove of
genetic information.1,2 Whilst the human genome consists of 25 000 – 30 000 genes,1 the
human proteome is much more complex, consisting of more than 1 million proteins.3 It
is therefore essential to understand the functions of these encoded proteins to gain a
thorough understanding of the chemistry of life.4
To achieve that goal, proteins have been artificially modified and advances in protein
modification by chemical means have led to the development of a range of protein
conjugation methodologies.5 These methodologies have been successfully applied to
a number of fields such as the fluorescent tagging of proteins6 or the development
of therapeutic protein conjugates7,8 to treat indications such as HIV,9 cancer,10 and
malaria.11 Chemically modified proteins have also been utilised as diagnostics.12
The use of synthetic methodology to modify proteins has to overcome many major
obstacles, the most significant of which is the need for high selectivity. For example,
modifying only one amino acid type by discriminating against all the other natural
amino acids in a protein is essential for selective modification.13 Moreover, these
modifications must be carried out in aqueous media, at near-physiological pH and
1
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at ambient temperature to prevent the denaturing of proteins. In addition, these
reactions should be unaffected by surfactants, that are often required for protein stability.14
Despite these challenges, a large number of approaches have been developed for protein
modification over the years.15 These approaches can be divided into two categories: (i)
modification of natural amino acids; and (ii) modification of unnatural amino acids
(uAAs). Each of these methods has their own unique advantages and disadvantages. As
it is of most relevance, the modification of natural amino acids is described in further
detail below. A detailed review on the modification of uAAs has been reported by
Mastrobattista et al. and it will not be discussed in detail here.16
1.2 Modification of natural amino acids
There is an ever increasing interest in the development of methods for the “traditional”
chemical modification of proteins,13 which focuses on modifying the 20 available natural
amino acids in a selective manner. Most of the residues have been explored in this context
and reagents for the selective modification of cysteine, serine, lysine, histidine, tyrosine,
aspartic acid, tryptophan, arginine, threonine as well as glutamate and even methionine,
have been developed (Figure 1.1).
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NH2
Figure 1.1: Some of the proteinogenic amino acids side chains targeted for chemical
modification. Left to right: cysteine, serine, lysine, histidine, tyrosine and aspartic acid.
Classically, most of the work on the site-selective modification of natural amino acids
has focused on reactions with cysteine and lysine17 as these two residues bear the most
nucleophilic side chain groups, a thiol and amine, respectively.
1.2.1 Modification of lysines
The majority of chemically modified biologicals that have obtained FDA approval
to date have been prepared via lysine modification, typically through amine-reactive
succinimidyl esters.18 This amino acid is often targeted when site-selective modification
Chapter 1. Introduction 3
is not essential.19 Lysine can form irreversible amide linkages with N -hydroxysuccinimide
(NHS) esters at physiological pH in the absence of any exogeneous reagents. At higher
pH (9 – 9.5), lysine residues react quantitatively with isothiocyanates or isocyanates,
forming thioureas or ureas respectively. Over the years, a plethora of reagents have been
developed to target lysines residues on the surface of proteins (Scheme 1.1).20–23
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Scheme 1.1: Main reactions for lysine modification.
Nevertheless, this technique is now often considered to be non-ideal due to the high
abundance of this amino acid.24,25 Virtually all proteins contain many solvent exposed
lysines in addition to the amine of the N-terminus, thus leading to a heterogeneous
mixture of products upon conjugation with a wide distribution of loading levels.26 When
preparing therapeutics, for example, this would result in a narrow therapeutic window27
as too many modifications per protein raise problems with solubility28 and faster clearance
rates from a patient’s blood.29 This is mainly due to the loss in surface charges upon
conversion of the charged ammonium groups on lysine residues to neutral moieties.
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In addition, lysine residues in or near the active or binding site of the protein might
be targeted, which would lead to abrogation of activity.30 Furthermore, heterogeneity
complicates product analysis,31 and the most widely used reagents for lysine-modification,
NHS esters, have limited storage stability due to moisture sensitivity.32 Moreover, control
over the reaction at lysines is often limited and can only be achieved to a certain extent if
carried out under strict pH control33 or by the use of conditions that only allow reaction
to take place at an extremely slow rate,34 so that only the most reactive lysines react.
Against this background, the naturally occurring amino acid that offers the greatest
potential for site-specific modification is cysteine.
1.2.2 Modification of single cysteines
Free cysteines are extremely rare in proteins35 and make up only 0.2% of all naturally
occurring amino acids.36 This, together with the fact that the thiol side chain has the
highest reactivity of all proteinogenic groups at physiological conditions,37 makes it a
useful target for the selective and site-specific modification of proteins. Additionally,
with the possibility of site-directed mutagenesis, cysteine residues can easily be inserted
at a specific position on a protein.
Cysteine-targeting chemistry is well established and widely employed to create bioconju-
gates,38–41 probe enzyme activity,42 label proteins,43 probe cellular oxidation status,44
or obtain structural information.45–47 A wide variety of cysteine modifying reagents are
available from a number of leading biochemical companies (e.g. Pierce and Aldrich) with
even more being synthesised in laboratories around the world for specific applications.
The main reaction modes that are employed to modify cysteine residues are alkylation,
disulfide formation and oxidation (Scheme 1.2).48 The choice of reagent depends mostly
on the specific application.
The most widely used compounds for alkylation are maleimides. These Michael acceptors
tend to react more rapidly and selectively with thiols than α-halocarbonyls. As such, a
number of chemical probes linked to maleimides (e.g. fluorophores, PEG chains, cytotoxic
drugs and biotin) are now commercially available.49 Recently, bromomaleimide and
related derivatives have been developed which allow for reversible cysteine modification.50
Bromomaleimides react as rapidly as conventional maleimides, but revert to free cysteines
in the presence of a reducing agent such as 2-mercaptoethanol.51 Novel pyridazinedione
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Scheme 1.2: Main reactions for cysteine modification.
based reagents have also been developed.52 These molecules offer the potential for four
points of attachment and are stable to hydrolysis, unlike conventional maleimide reagents.
Pyridazinedione-based reagents have also been shown to be highly selective for cysteine
over lysine and the resultant conjugates are reversible in an environment of an excess of
reducing reagent (Scheme 1.3).52
In proteins, free cysteine has an abundance of around 0.2% but the total proportion of
this residue is 1.7%.15 The remaining 1.5% are tied up in disulfide bonds. Due to their
thiol reactivity and increased abundance, these disulfide bonds present themselves as an
attractive target for the site-selective chemical modification of proteins.
1.2.3 Modification of disulfide bonds
The disulfide bonds of a protein are generally considered to be vital for protein stability
and activity.53 Accordingly, the rupture of these covalent links may destabilise many
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Scheme 1.3: Cysteine modifications with (a) maleimide, (b) bromomaleimide and
(c) bromopyridazinedione.
proteins.54 When functionalising a reduced disulfide, it is therefore desirable to covalently
re-connect the free thiols. This can be accomplished by the insertion of a non-natural
bridge into the disulfide bond which would join the two thiols and also directly carry
either a functional group of interest (e.g. a fluorophore or a drug) or a chemical handle
allowing for further functionalisation. The first successful attempt to modify proteins
via disulfide bonds whilst retaining their near-native structure was reported by Shaunak
et al. in 2006.55 In this work, an enone-sulfonyl reagent was synthesised. This reagent
reacts with one of the two free thiols, generated from disulfide reduction, via a conjugate
addition and elimination step, followed by a second conjugate addition reaction with the
other free thiol, thereby re-connecting the side chains of the cysteines via a three-carbon
bridge (Scheme 1.4).
An efficient and elegant approach to rebridge disulfide bonds has also been developed by
Smith et al.51 It was postulated that incorporation of two leaving groups on a maleimide
double bond would enable two addition-elimination sequences to occur on reaction with
the two free thiols to generate a bisthioether maleimide (Scheme 1.5).
Using the peptide somatostatin, a peptide hormone with poor in vivo stability, as a
disulfide bearing protein model, Schumacher et al. selectively introduced a stabilising
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Scheme 1.4: Mechanism of the insertion of a three-carbon bridge into a disulfide bond.
Modified from Shaunak et al.55
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Scheme 1.5: Bridging of a reduced disulfide bond with dibromomaleimide.51
group, PEG, whilst retaining the biological activity of unlabelled somatostatin.56 This
methodology allowed selective modification, and bridging, of a native disulfide bond
yielding a homogeneous product. It is simple and inexpensive and under certain conditions
the labelled peptide, or protein, could, in principle, be decoupled from its label in the
cytoplasm of cells where there is a relatively high concentration of glutathione.57 Although
current approaches offer great promise, the current peptide/payload linker technologies
only tend to attach one functional group of interest, thus limiting their scope. In
recent years, proteins such as antibodies have been extensively modified for a variety of
applications.
1.3 Antibodies and antibody fragments
1.3.1 Antibodies
Antibodies (also known as Ig because they were used historically to define the term
immunoglobulin) are macromolecular Y-shaped protein complexes of ca. 150 kDa and
above (vide infra, Figure 1.2, page 10). They are produced by B-cells in the blood upon
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activation of the immune system. Antibodies target their specific antigen binding partner
with exquisite selectivity and have therefore received much attention in recent years as
targeted therapeutics alone, via antibody-dependent cell-mediated cytotoxicity (ADCC),
and as vehicles for drug delivery and imaging.
Antibodies have differences in their biological properties, functional locations and ability
to deal with different antigens. Therefore, they are subdivided into different varieties
known as isotypes, or classes (Table 1.1). The isotype depends on the structure of
the constant domains of the heavy chains (vide infra, Figure 1.2, page 10); in placental
mammals, γ, α, µ, ε and δ chains correspond to IgG, IgA, IgM, IgE and IgD, respectively.58
To reflect smaller differences in between heavy chains, some classes are also subdivided
into Ig allotypes, or subclasses. For example, humans have 4 different types of IgG
(IgG1, 2, 3 and 4) and 2 of IgA (IgA1 and IgA2) with more than 95% similarity in their
sequences. Human light chains of antibodies also have isotypes named κ and λ.
Location Proportion Valency Function
IgG (γ) Blood 70%− 75% 2 Immunity against invadingpathogens
IgA (α) Mucosal areas,gland secretions 10%− 15% 2− 4
a Agglutination, immunity
against invading pathogens
IgM (µ) B cells, blood 10% 2−10b Agglutination, initiation ofclassical complement pathway
IgE (ε) Mast cells,basophils ≤ 1% 2
Allergy, protection against
parasitic worms
IgD (δ) B cells ≤ 1% 2 Activation of B cells
Table 1.1: Properties of the different antibody isotypes of placental mammals.
aIgAs can be released as dimers. bThe value of 10 is purely theoretical. Indeed, even if
IgM are mostly pentameric, the steric hindrance generated when they are bound to the
antigen epitopes makes the “real” valency closer to 5.
1.3.2 Antibody fragments
Specific enzymatic or chemical cleavage of antibodies allows for the isolation of different
fragments (vide infra, Figure 1.2, page 10):
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• Fv fragment (variable). It is the smallest fragment that retains the binding
properties of the antibody to a specific antigen. It is composed of the variable
regions (VL and VH). More specifically, in VL and VH, variable loops of β-strands
are responsible for binding to the antigen. These loops are referred to as the
complementarity determining regions (CDRs). Fv fragments are monovalent with a
molecular weight of ca. 25 kDa.
• Fab fragment (antigen-binding). It has the same affinity for the antigen as that
of the full antibody. It is composed of the whole light chain (VL and CL) and
of part of the heavy chain (VH and CH1). Fab fragments are monovalent with a
molecular weight of ca. 50 kDa.
• F(ab’)2 fragment. It corresponds to the association of two Fab fragments linked
together by the disulfide-containing part of the CH chains and, therefore, has the
same affinity for the antigen as the full antibody. This small linking region is
referred to as the hinge region. F(ab’)2 fragments are divalent with a molecular
weight of ca. 110 kDa.
• Fc fragment (crystallisable). It carries some of the biological properties of the
immunoglobulin, in particular its ability to be recognised by effectors of immunity
(by interacting with cell surface receptors) or to activate the complement system.
It is composed of two (or three, depending on the class of the antibody)59 identical
CH2 fragments, derived from the heavy chains constant domains of the antibody.
Fc fragments do not recognise the corresponding antigen. They bind monovalently
to various cell receptors and complement proteins and have a molecular weight of
ca. 50 kDa.
Antibody fragments have altered physiochemical features. For instance, smaller sized
fragments can penetrate into tissues inaccessible to full-size monoclonal antibodies
(mAbs).60,61 Another advantage lies in the ability of prokaryotic systems to express
antibody fragments when mAbs require more costly eukaryotic systems. However, most
fragments lack the Fc domain that serves to both stabilise full-size antibodies and
allow FcR-mediated recycling. As a consequence, fragments are rapidly degraded in
humans and have short circulating half-lives.62 Several strategies have been developed to
extend the half-life of fragments and reduce immunogenicity; they include conjugation to
proteins such as albumin63 and PEGylation,64–67 which was applied to the FDA-approved
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Figure 1.2: General structure of an IgG1 with its fragments highlighted.
anti-TNFα Fab, certolizumab pegol. However, any biomanufacturing advantage gained
in operating with antibody fragments would be lost if the stabilising technology was
expensive and/or excessively technically challenging.
From a more fundamental point of view, antibody fragments also offer several advantages
over full-size antibodies for use in certain immunochemical techniques and experimental
applications, including:
• Reduced non-specific binding from Fc interactions (many cells have receptors that
bind to the Fc region).68
• Ability to control Fc-binding to Protein A or Protein G in experiments involving
immunoprecipitation and Western blotting.69
• More efficient penetration of tissue sections.60,61,70,71
• Potentially higher sensitivity in antigen detection in solid phase applications as a
result of reduced steric hindrance from large protein epitopes.
• Elimination of Fc-associated effector functions (e.g. complement fixation) in antigen-
antibody binding studies.72
• Simpler system for studying the structural basis for immune recognition using X-ray
crystallography or NMR.73
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1.4 Antibody–drug conjugates
Antibody–drug conjugates (ADCs) are a type of targeted therapeutics. They consist
of an antibody armed with potent cytotoxic drugs using various conjugation and linker
technologies. The binding region of the antibody allows selective targeting of certain
cell types (i.e. allowing for discrimination between healthy and diseased tissue) and
the potent cytotoxic drug element effects cell-killing independent of antibody-dependent
cell-mediated cytotoxicity (ADCC). Hence, ADCs offer the prospect for delivery of a
toxic payload directly to a target, with minimisation of “off-target” toxicity. This in turn
allows for the use of particularly toxic drug molecules that are conventionally excluded
from use in chemotherapy.
The concept of delivering a toxic payload to cancer cells using a targeting agent dates
back to 1913 when Paul Ehrlich described a “haptophore” that can deliver a “toxophore”
selectively to a tumor.74 However, it took 45 years for such a species to be constructed in
the form of an ADC.75 In the 1970’s, ADCs were first tested on animals76,77 and less than
a decade later the first tests on humans showed promising results.78 The first ADCs based
on chimeric and humanised mAbs were reported in the 1990’s,79 and throughout this
decade, ever increasing payload potency and improved target selection were achieved.80
These advances finally led, in 2000, to the first US Food and Drug Administration (FDA)
approved ADC (Mylotarg™, gemtuzumab ozogamicin).81
Despite promising preliminary results, Mylotarg™ was voluntarily withdrawn from the
market in June 2010 as post-approval clinical trials for patients with acute myeloid
leukemia showed that the ADC offered no clinical benefit over standard chemotherapy.
Nevertheless, this class of targeted therapy showed considerable promise in the following
years with two further ADCs gaining FDA approval (i.e. Adcetris™ 2, brentuximab
vedotin in 201182,83 and Kadcyla™ 1, trastuzumab emtansine in 201384,85). It is estimated
that there are ca. 40 ADCs currently in the clinic and it is predicted that the market for
ADCs will grow rapidly in coming years.86
Both Kadcyla™ 1 and Mylotarg™ were generated by modifying accessible lysine residues
on the surface of the relevant antibody.84,85 In fact, many ADCs are conjugated through
lysine modification. However, with ca. 90 accessible lysines, any chemical modification
strategy that is non-selective has the potential to generate complex mixtures, with
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up to 106 distinct species statistically possible when targeting drug-to-antibody ratios
(DARs) of 2 – 4. Such heterogeneous mixtures of ADCs may differ in both drug loading
and conjugation site and this can result in a narrow therapeutic window with major
pharmacokinetic implications. Although this non-specific conjugation technique has been
used in FDA-approved ADCs, the use of non-selective approaches is now considered
suboptimal in developing next generation ADCs.
In order for ADCs to deliver their full potential, sophisticated conjugation technologies to
connect the cytotoxic drug to the antibody are needed. In a promising early development,
Adcetris 2 was obtained by reacting some of the eight free cysteines generated by reduction
of the four interchain disulfides of an antibody (vide infra, section 1.5.2.1, page 19). Whilst
this approach still generates ca. 15 different species when targeting typical average DARs
of 2 – 4, it offers a significant improvement over lysine modification strategies in terms of
reduced heterogeneity.87 There is a growing appreciation of the importance of developing
site-specific methods, with several reports highlighting the advantages for generating
near-homogeneous conjugates due to a better defined and improved pharmacokinetic
(PK) profile.87–89
One of the keys to the ADC approach lies in the availability of effective methodologies
to link an antibody to a payload. Most of the linking technologies in the clinical pipeline
present drawbacks, such as lack of selectivity, poor yields and/or loss of structural integrity
(Figure 1.3), limiting their usability and reducing their therapeutic index.
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Figure 1.3: Main drawbacks in existing technologies.
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1.5 Current methods for site-selective attachment of drugs
to antibodies
1.5.1 Engineered antibody modification
With the rapid advances in protein engineering, methods to site-specifically functionalise
antibodies have become more accessible in recent years. There are three main strategies
to generate site-selectively modified ADCs with re-engineered mAbs: (i) insertion of
cysteine residues in the antibody sequence by mutagenesis;90,91 (ii) enzymatic conjugation
(e.g. transglutaminases (TGs), formylglycine-generating enzymes (FGEs);92 and (iii)
insertion of an unnatural amino acid with a functional group that can be chemoselectively
reacted.93–95
1.5.1.1 Engineered cysteines
The thiol moiety of the cysteine side chain has the highest nucleophilicity of all
proteinogenic amino acid functional groups under physiological conditions. This makes it
a useful target for the selective and site-specific modification of antibodies. Moreover,
with the use of site-directed mutagenesis, cysteine residues can readily be inserted at a
specific position on a protein. (vide supra, section 1.2.2, page 4).
In 2008, Junutula et al. (Genentech) described a method for the introduction of additional
cysteine residues on a mAb using site-directed mutagenesis.96 This procedure is non-trivial
for an antibody as the engineered cysteine residues can pair with other free cysteines
(e.g. to form protein dimers or to scramble disulfides), which could reduce or remove
activity.97,98 However, by screening conjugation sites on an antibody against the ovarian
cancer antigen MUC16, an engineered thio-antibody (THIOMAB 3) containing two new
cysteine sites for attachment was generated successfully (Scheme 1.6).
Although the engineered cysteines were introduced successfully, they were mostly found
as mixed disulfides with glutathione. As no reliable method to target reduction of these
mixed disulfides over native disulfides was achieved, an alternative strategy was needed for
engineered thiol unmasking. To do this, both the mixed and native interchain disulfides
were reduced initially to yield 4. This was followed by mild re-oxidation of the interchain
disulfides with a gentle oxidant (e.g. CuSO4) to afford antibody 5 with all of its native
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Scheme 1.6: Preparation of THIOMAB.
Reagents and Conditions: (i) TCEP or DTT, PBS, 25 °C, 90min; (ii) CuSO4 or dhAA,
PBS, 25 °C, 3 h.
disulfide bonds intact and two reduced engineered cysteines available for conjugation
(Scheme 1.6).
Using this strategy, ADCs comprised of a monomethyl auristatin E (MMAE) derivative
and an anti-MUC16 mAb were generated (Scheme 1.7). They were judged to have an
average drug-to-antibody ratio (DAR) of 1.9 with more than 90% homogeneity and
were active in vitro and in vivo.91 The THIOMAB–drug conjugates were also shown to
be significantly less toxic in rat and cynomolgus monkey models when compared with
ADCs obtained by lysine conjugation with an average DAR of 4. Moreover, as described
by Hamblett et al., despite having half the average drug load, the THIOMAB–drug
conjugates were as efficacious in vivo.87,91
1.5.1.2 Enzyme-directed modification
Another approach to achieving site-selective modification is via enzymes that react
with a particular amino acid in a specific amino acid sequence. This has been used to
site-selectively attach drugs to antibodies.
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Scheme 1.7: Conjugation to THIOMAB.
Reagents and Conditions: (i) MMAE derivative, 25 °C, 1 h.
Transglutaminases
Transglutaminases (TGs) play an important role in biological processes which depend on
the covalent crosslinking of proteins,99 where they catalyse the formation of amide bonds
between the primary amine of a lysine and the amide group of a glutamine. However,
bacterial TG isolated from Streptoverticillium mobaraense has an atypical catalytic site
compared to other TGs.100,101 It does not catalyse a reaction with any of the naturally
occurring glutamine residues in the constant regions of an antibody, but will recognise a
“glutamine tag” (i.e. LLQG).27
By appraising the merits of incorporation of this sequence into 12 surface accessible
regions of an anti-M1S1 IgG1, Strop et al. (Rinat-Pfizer) found two optimal locations for
the “Q-tag”. Two ADCs based on monomethyl dolastatin 10 (MMAD, a potent tubulin
inhibitor) were then generated (Scheme 1.8).
These conjugates were found to have good biophysical properties and a DAR of ca. 1.9.102
Furthermore, when compared with an analogous ADC with a higher drug loading (average
DAR of 3.6) based on cysteine alkylation post-native interchain disulfide reduction, the
glutamine-tagged ADCs showed similar activity in vitro and in vivo and were better
tolerated in vivo. This differential in toxicity profile suggests that either the selected
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Scheme 1.8: Conjugation with transglutaminase.
Reagents and Conditions: (i) MMAD derivative, TG (1 – 2%), TRIS·HCl pH 8.0,
25 – 37 °C, 16 h.
position of the drug and/or the lower loading offers the possibility for improvement of
the therapeutic index of ADCs.
Formylglycine-generating enzymes
Formylglycine-generating enzymes (FGE) catalyse the selective conversion of a cysteine
to an aldehyde when in a CXPXR sequence (where X is usually serine, threonine, alanine
or glycine). The incorporated aldehyde can then be readily functionalised with aminooxy-
or hydrazine-functionalised molecules.103 Using this approach, Drake et al. (Redwood
Bioscience) recently produced and characterised a series of functionalised antibodies
bearing the aldehyde tag at different sites on trastuzumab.104 They then used hydrazino-
iso-Pictet-Spengler (HIPS) chemistry to conjugate a cytotoxic maitansine derivative (a
potent microtubule-targeted agent) at three different positions (Scheme 1.9).
As observed with other methods, the site of conjugation had a significant impact on
in vivo efficacy and PK profile in rats. Unfortunately, this method suffers from the
hydration of the aldehyde from formyglycine in water to form an unreactive gem-diol,
which lowers the yield of the process.94
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Scheme 1.9: Conjugation by formylglycine-generating enzymes approach.
Reagents and Conditions: (i) Maitansine derivative, citrate buffer pH 5.5, 37 °C, 72 h.
1.5.1.3 Unnatural amino acid incorporation
Recent advances in development of methods for the incorporation of unnatural amino
acids (uAAs) into proteins have presented opportunities for the site-selective modification
of antibodies.95,105 Three uAAs, p-acetylphenylalanine 11, p-azidomethyl-phenylalanine
12 and azidohomoalanine 13 (Figure 1.4) have been particularly useful in generating
conjugates through oxime ligation and classical click chemistry, respectively (vide infra,
section 1.6, page 25).
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Figure 1.4: Common uAA used is site-specific modification of proteins.
Axup et al. described the incorporation of p-acetylphenylalanine into several residues in
the constant region of trastuzumab to construct several modified antibodies ready for
site-specific ADC synthesis.95 Using this unique functional group, monomethyl auristatin
F (MMAF), a potent tubulin inhibitor, was coupled through a stable oxime ligation
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process to yield several near-homogeneous ADCs with a DAR of ca. 2.0 (Scheme 1.10).
The resulting conjugates demonstrated good PK properties, potent in vitro cytotoxic
activity against HER2-positive cancer cells and complete tumor regression in rodents.
When compared with ADCs prepared by cysteine alkylation post-native interchain
disulfide reduction, site-specific uAA-based ADCs were shown to have increased in vitro
cytotoxicity and in vivo efficacy. They also had superior in vitro serum stability and an
improved toxicology profile in rats.106,107
SS SS
S S
S S
H
N
O
N
O
N
H
NN
O
O
O
(i)
=
SS SS
S S
S S
N
H
O
O O
O O N N
O O
14 15
Scheme 1.10: Conjugation by unnatural amino acid incorporation approach.
Reagents and Conditions: (i) MMAF derivative, acetate buffer pH 4.5, 37 °C, 4 days.
Zimmerman et al. (SutroBiopharma) recently observed a similar trend in vitro by
incorporating p-azidomethyl-phenylalanine into trastuzumab and using the strain-
promoted azide–alkyne cycloaddition (SPAAC) reaction to conjugate an ADIBO-
functionalised MMAF (Figure 1.5).105
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Figure 1.5: Structure of ADIBO-functionalised MMAF used by Zimmerman et al.
Even though these uAA methods offer the possibility of generating homogeneous
conjugates by attachment of a drug at virtually any accessible site on a mAb, the
potential immunogenicity of uAAs is not yet fully understood and more studies are
needed to ensure the safety of these engineered ADCs.
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1.5.2 Native antibody modification
Although the aforementioned methods offer the possibility to synthesise near-homogeneous
ADCs they require site-directed mutagenesis and optimisation of cell culture conditions,
which can increase the overall manufacturing cost of an ADC. The alternative is to
develop methods which avoid the requirement for re-engineering by direct site-selective
manipulation of native mAbs (vide supra, section 1.2, page 2).
1.5.2.1 Reduced inter-chain disulfides for site-selective modification
Whilst antibodies typically have approximately 90 accessible lysine residues, reduction
of the 4 accessible interchain disulfides yields only 8 nucleophilic cysteine residues.
Hence, conjugation to antibodies by reaction with cysteines thiols liberated from reduced
interchain disulfides will inherently generate a smaller subpopulation of immunoconjugates
compared with modification via lysine. Moreover, despite its known impact on
complement-dependent cytotoxicity,108 reduction of native interchain disulfide bonds
was thought to have a limited effect on antibody structure and stability since assembly
of light and heavy chains does not depend primarily on covalent disulfide linkages, but
rather on non-covalent interactions.109
Conjugation of thiols liberated from reduced interchain disulfides
In 2003, Doronina et al. (Seattle Genetics) described the use of conjugation to thiols
generated by reduction of the native interchain disulfides of a mAb as an ADC construction
strategy. Initially, the 4 interchain disulfide bonds of a chimeric anti-CD30 mAb (i.e.
cAC10) were reduced and the liberated thiols side chains were reacted with a MMAE
derivative via a maleimide linker. This provided an ADC that was potent and selective
for CD30-positive hematologic malignancies (Scheme 1.11).110
Originally, the 8 sulfhydryl groups generated by reduction of the interchain disulfides
were alkylated using maleimide-MMAE, yielding a near-homogeneous conjugate with
a DAR of 8. However, further analysis by Hamblett et al. and Beckley et al. showed
that the high drug-loading had a significant impact on the conjugate PK (i.e. poor
tolerability, high plasma clearance rate and decreased efficacy in vivo) and propensity
to aggregate,87,111 and that a lower DAR resulted in a larger therapeutic window.87 In
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Scheme 1.11: Alkylation of thiols liberated from reduced interchain disulfides.
Reagents and Conditions: (i) DTT, PBS pH 8.0, 37 °C, 30min; (ii) MMAE derivative,
PBS/MeCN, 4 °C, 1 h.
particular, they showed that an ADC with a DAR of 4 was significantly less toxic to
mice than higher loaded conjugates.
These observations, along with a screening of various reduction/re-oxidation strategies,
resulted in a novel site-selectively modified antibody, Adcetris 2, with an average DAR
of 4 with isomeric homogeneities up to 75% (vide supra, Figure 1.3, page 12).109 One of
the main drawbacks of this strategy comes from the use of maleimide chemistry in that
the generated conjugate is known to undergo retro-Michael reactions with blood thiols,
resulting in the transfer of drug to thiol-bearing proteins and thus leading to off-site
toxicity.112–114 Recently, however, several strategies to overcome this issue and to obtain
thiol-stable conjugates have been developed (vide infra, section 5.1, page 85).113–117
Re-bridging of cysteines liberated from reduced interchain disulfides
To target a DAR of 4 and increase the overall homogeneity of their conjugates, Badescu
et al. (PolyTherics) explored the possibility that reduction of the interchain disulfide
bridges could be followed by functional re-bridging of the disulfide. This would allow
insertion of a single cytotoxic payload per disulfide and retain a covalent link between
the protein chains. Their method is based on bis-cysteine-selective sulfone reagents that
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allow for an addition-elimination-addition sequence onto the reduced disulfide bonds of
either Fabs or mAbs (vide supra, Scheme 1.4, page 7).
Using MMAE as the toxic payload on both trastuzumab 19 and its Fab, FabHer 127,
they successfully demonstrated increased efficacy over drug alone whilst retaining binding
and antigen-selective cytotoxicity in vitro, along with efficacy in vivo (Scheme 1.12).118
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Scheme 1.12: Rebridging reduced interchain disulfides.
Reagents and Conditions: (i) DTT, PB pH 7.4, rt, 30min; (ii) MMAE derivative, PB
pH 7.4, rt, 3 h.
Other groups (i.e. Chudasama, Baker and Caddick) have also developed reagents that
allow for the efficient functional re-bridging of interchain disulfides (vide supra, Scheme 1.5,
page 7).119 Using these reagents on trastuzumab 19, Nunes et al. have successfully
generated near-homogeneous, MMAE-functionalised ADCs with in vitro efficacy.120
1.5.2.2 Glycan targeting for synthesis of antibody–drug conjugates
All antibodies are glycosylated at conserved positions in their constant regions; they
possess an N -glycosylation site at the conserved Asn-297 residue of the Fc region (vide
supra, Figure 1.2, page 10). Thus, this serves as a potentially interesting (and generic)
site for antibody modification.
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In this context, the use of hydrazone chemistry to attach a cytotoxic agent onto the glycans
of an unmodified native antibody has found considerable utility.121,122 Sodium periodate
at high concentration has been used to oxidise carbohydrate residues in the native glycans
to provide aldehydes which are used for ligation to afford relatively homogeneous ADCs
(Scheme 1.13).122
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Scheme 1.13: Oxidation and functionalisation of the glycans.
Reagents and Conditions: (i) NaIO4, acetate buffer pH 5.5, 4 °C, 30min;
(ii) Calicheamicin derivative, acetate buffer pH 5.5, rt, 3 h.
The main drawback of this approach arises from the harsh oxidation conditions required
to generate the aldehydes, which can result in oxidation of methionine residues located
close to FcRn binding site. This over-oxidation is known to affect FcRn binding and to
generally reduce serum half-life (Scheme 1.14).123 To alleviate this issue, milder enzymatic
methods have been developed.
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Scheme 1.14: Oxidation of methionine during glycans oxidation.
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Neuraminidases
Through sequentially using neuraminidases to cleave the glycosidic linkages of neuraminic
acids and Gal oxidase to oxidise the galactose residues of an anti-CEA mAb, Stan
et al. site-selectively attached doxorubicin 143 via reductive amination on the generated
aldehydes (Scheme 1.15).88 The resulting ADC had a DAR of 3.7 and was four times
more toxic in vitro than its counterpart generated by lysine conjugation with a DAR of
7.8. This demonstrates once again the importance of, and therapeutic opportunities for,
site-specificity in ADC construction.
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Scheme 1.15: Reagents and Conditions: (i) Neuraminidases, PB pH 5.5, 37 °C, 16 h;
(ii) Gal oxidase, PBS pH 7.4, 37 °C, 48 h; (iii) Doxorubicin 143, pyridine borane, PBS
pH 7.4, 37 °C, 48 h.
Glycosyltransferases
Recently, Zhou et al. (Sanofi-Genzyme) described another approach using post-
translational modification of trastuzumab to introduce sialic acid moieties onto the
native glycans on Asn-297.124 To achieve site-specific modification, a mixture of
galactosyltransferase and sialyltransferase was used to transfer galactose and sialic acid
residues onto the native glycans. These sialic acid residues were then oxidised to yield
aldehyde-functionalised trastuzumab.
Even though these conditions led to partial oxidation of the methionines proximal to the
FcRn binding site, which compromised FcRn binding by ca. 25%, it had a negligible effect
on serum half-life.124 The enzymatically modified mAb was then conjugated by oxime
ligation with aminooxy drug linkers to generate site-selectively modified ADCs. Using
MMAE and MMAD, an average DAR of 1.6 was obtained and these glyco-conjugated
ADCs exhibited antigen-dependent activity in vitro and were efficacious in vivo.
Chapter 1. Introduction 24
A similar strategy that avoids the oxidation step by utilising azido-modified sialic acid
and SPAAC click chemistry with a suitable doxorubicin derivative has recently been
applied to an anti-CD22 antibody. This resulted in a near-homogeneous ADC which has
been shown to selectively target and kill lymphoma cells in vitro (Scheme 1.16).125
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Scheme 1.16: Reagents and Conditions: (i) UDP-Gal, galactosyltransferase, CIAP,
MOPS buffer pH 7.2, 37 °C, 24 h; (ii) CMP sialic acid azide, sialyltransferase, CIAP,
cacodylate buffer pH 7.6, 37 °C, 48 h; (iii) Doxorubicin derivative, cacodylate buffer
pH 7.6, rt, 2 h.
The main limitations of these glycan-based modifications stem from the complex and
heterogeneous population of glycans in mAbs, as well as their reliance on the presence of
galactose on an IgG1. These characteristics of antibodies may reduce the homogeneity of
the final ADC construct and/or mean that additional steps are required to homogenise
the glycan population.126
1.5.3 Summary of the current methods used
A variety of methods have been developed for the site-selective modification of monoclonal
antibodies to produce antibody–drug conjugates, each with their own advantages and
limitations (Table 1.2).
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Table 1.2: Summary of the advantages and limitations of the main site-selective
methods for antibody modification.
Although the use of engineered mAbs for ADC construction offers controlled homogeneity,
this is offset by their construction and modification often being technically challenging.
Modification of native mAbs, on the other hand, involves simple reaction protocols but
with the caveat of difficulties in achieving homogeneous modification. Thus there is no
leading technology at present for the site-selective attachment of drugs to antibodies and
although recent methods for the construction of ADCs have gone some way to addressing
the challenging issues of making homogeneous ADCs, significant hurdles still remain.
1.6 Bioorthogonal reactions and click chemistry
Bioorthogonal chemistry describes reactions between two groups with the following
properties: (i) they are mutually reactive but do not cross-react or interact in noticeable
ways with biological functionalities or reactions in a cell; (ii) they and their products are
stable and non-toxic in physiological settings; and (iii) ideally, their reaction is highly
specific and fast.17
Click chemistry has been defined as a set of reactions that are modular, stereospecific,
wide in scope, high yielding, generate only inoffensive by-products, have simple reaction
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conditions and generate products that are easy to purify.127 Bioorthogonal chemistry and
click chemistry therefore overlap significantly, reflecting the same underlying chemical
principles. Indeed, click reactions generally offer water compatible chemistry and, their
potential for bioorthogonal, regioselective and high-yielding conjugation under mild
conditions make them ideal candidates for the functionalisation of proteins with effector
moieties. For these reasons, click reactions have been used extensively in biological
context.
Due to its ever-growing importance, click chemistry on proteins has been reviewed
extensively in the past few years and will not be discussed in detail here.128–133
One of the most popular reactions within the bioorthogonal click chemistry concept is the
copper-catalysed azide–alkyne Huisgen cycloaddition (CuAAC) or its strained-promoted,
copper-free variant with strained alkynes (SPAAC). Both these reactions are compatible
with water and have a very high degree of bioorthogonality.
1.6.1 Azide–alkyne Huisgen cycloaddition
In 1902, Dimroth was the first to describe the 1,3-dipolar cycloaddition between an
azide and a terminal or internal alkyne to give a 1,2,3-triazole.134 Some sixty years later,
Huisgen realised the scope of this organic reaction which initially required heat to occur
and applied it to a large variety of substrates.135
Four decades later, Sharpless et al. and Meldal et al. reported independently that Cu(I)
catalysis resulted in a 1,4 regioselectivity along with an enormous rate acceleration of
107 to 108 compared to the uncatalysed 1,3-dipolar cycloaddition (Scheme 1.17).136,137
However, the usefulness of this click reaction for bioconjugation was limited by the
requirement for potentially toxic use of metal which could degrade proteins through
oxidative damage from reactive oxygen species formed by the copper catalysts.138
There has been some development of ligands to prevent biomolecule damage and facilitate
removal in in vitro applications.138 However, it has been found that different ligand
environments of complexes can still affect metabolism and uptake, introducing an
unwelcome perturbation in cellular function.139
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Scheme 1.17: Mechanism of copper-catalysed azide–alkyne Huisgen cycloaddition
(CuAAC).
1.6.2 Strain-promoted azide–alkyne cycloaddition
To tackle this limitation, Bertozzi et al. introduced the strain-promoted azide–alkyne
cycloaddition (SPAAC) as a metal-free, activated variant of CuAAC.140 Cyclooctynes
were selected as the smallest stable alkyne ring which increases reactivity through ring
strain to allow 1,3-dipolar cycloaddition with azides at room temperature. Importantly,
in addition to being water-compatible, these reactions were found to have kinetics
compatible with most of the biological applications (Scheme 1.18).
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Scheme 1.18: Mechanism of strain-promoted azide–alkyne cycloaddition (SPAAC).
CuAAC and SPAAC are orthogonal reactions as non-activated alkynes will not react
with azides at room temperature without a catalyst, whereas strained alkynes will. This
orthogonality makes the pair a suitable candidate to be used for dual modifications of
proteins.
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1.7 Dual modification of proteins
While a number of methods are available for site-selective single protein modification,
the site-selective, orthogonal, dual modification of proteins has remained challenging.
Nevertheless, certain applications require two different functional groups to be introduced
into a protein, e.g. targeted theranostic biopharmaceuticals (vide infra, section 4.5.2,
page 83)141,142 or protein–drug therapeutics stabilised with conjugated half-life extension
chemistry (vide infra, section 4.5.1, page 83).143
The main approaches to dually modify biomolecules can be classified in two separate
categories (Figure 1.6). The first one involves the modification of two distinct amino
acids on the proteins using various methods that include: exploiting the difference
of accessibility or reactivity of amino acids,144–146 functionalisation of the C- and N-
terminus of proteins,147 use of unnatural amino acids,148–150 use of specific enzymes150
or a combination of these strategies. The second category involves conjugation of a
bifunctional linker to the protein of interest. The multifunctional scaffold can then be
reacted to give a dually modified conjugate.151–155
(a) (b)
Figure 1.6: Different approaches for the introduction of two functional moieties to a
protein. (a) Via two distinct amino acids; (b) Via a multifunctional scaffold containing
the two reactive handles.
It is noteworthy that practically all the aforementioned approaches use click reactions
for one or for the two modifications of the target biomolecule.
1.7.1 Amino acid-based dual-click approach
Dual functionalisation of biomolecules using click chemistry can be achieved by targeting
directly amino acids with orthogonal reactivity. The insertion of two uAAs in proteins is
often dependent on the availability of unnatural protein expression methods to incorporate
orthogonal chemical handles for subsequent bioorthogonal reactions.156,157
Chapter 1. Introduction 29
A common strategy to introduce two orthogonal chemical handles is to combine nonsense
and quadruplet codon suppressions.158–161 Although recombinant expression strains have
been engineered to improve incorporation efficiency, this dual-labelling approach is often
associated with low protein yields.162–164 The main reasons for these low yields are the
competition of uAA incorporation with translational frame shifting or termination and low
catalytic efficiency of engineered aminoacyl-tRNA synthetases.165 Thus, strategies often
comprised unnatural protein expression with the site-directed modification of canonical
amino acids (e.g. cysteine).
Simon et al. reported a dual-labelling approach for Designed Ankyrin Repeat Proteins
(DARPins) using a combination of uAA and cysteine functionalisation.148 Azidohomoala-
nine was introduced at the N-terminus of the protein and a cysteine was introduced at a
second position of interest via site-directed mutagenesis. SPAAC reaction was utilised
for orthogonal functionalisation of azidohomoalanine, followed by maleimide modification
of the single cysteine residue to obtain homogeneous dually functionalised DARPin
(Scheme 1.19).
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Scheme 1.19: DARPin dual functionalisation using SPAAC followed by thiol
modification.
This uAA/cysteine pair has also been used by van Kasteren et al. to install two distinct
moieties in β-glycosidase from the archaeon Sulfolobus solfataricus and reacting them
using a sequential CuAAC and disulfide bond formation, respectively.4 In addition,
Brustad et al. successfully incorporated ketone-containing uAAs (i.e. p-azidomethyl-
phenylalanine) and cysteines in a T4 lysozyme to generate mutants used in the study of
T4 lysozyme folding at single-molecule resolution using fluorescence resonance energy
transfer (FRET).166
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To alleviate some issues associated with the incorporation and the reaction of cysteines
(e.g. disulfide bond formation, reaction reversibility, side-reactions), Mühlberg et al.
recently described a dual-labelling strategy for proteins that combines residue-specific
incorporation of uAA with chemical oxidative aldehyde formation at the N-terminus of a
protein.149 They selectively introduced two different functional moieties in thermophilic
lipase from Thermoanaerobacter thermohydrosulfuricus via CuAAC and oxime ligation
(Scheme 1.20). This method was applied to the conjugation of biotin and β-linked
galactose residues to yield an enzymatically active thermophilic lipase.
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Scheme 1.20: Lipase dual functionalisation using oxime ligation followed by thiol
modification.
1.7.2 Reagent-based dual-click approach
A more straightforward approach to achieve dual modifications on proteins is to combine
the reactive handles onto a single multifunctional scaffold that could be conjugated to
proteins.131 Although many commercially available scaffolds contain bifunctional linkers,
relatively few of them possess three well-defined orthogonal handles to enable attachment
to a protein followed by dual modification.
Efforts have been made towards the development of such platforms but with limited
success, due to the potentially complex synthesis of a branched structure with orthogonal
handles. Furthermore, these platforms have often been exemplified on small molecules
or short peptides but rarely on proteins, which can represent an additional layer of
difficulty. For example, trifunctional scaffold 32 was reacted with three small molecules
(i.e. drug and fluorophores) and clickable decapeptide scaffold 33 was attached to a
glucose derivative and two short peptides, but they were not trialled on larger proteins
(Figure 1.7).
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Figure 1.7: Multifunctional platforms with the potential to enable the dual
functionalisation of proteins.
To date, there are very few examples of reagent-based dual modifications of proteins.
Rashidian et al. described a method to site-specifically prenylate proteins containing a C-
terminal CaaX-box amino acid sequence with various isoprenoids using Protein Farnesyl
Transferase (PFTase). Triorthogonal reagent 34 was synthesised to allow incorporation
of an alkyne and an aldehyde group simultaneously into a protein (Figure 1.8).153
P O O
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Figure 1.8: Triorthogonal prenylation reagent used by Rashidian et al.
To illustrate the capabilities of this approach, a model protein (i.e. GFP) and a
therapeutically useful protein (i.e. ciliary neurotrophic factor) with engineered CaaX-box
were enzymatically modified with 34 followed by oxime ligation and CuAAC reaction to
incorporate a series of “clickable” molecules in a one-pot procedure (Scheme 1.21).153
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Scheme 1.21: Dual modification using triorthogonal prenylation reagent 34.
Reagents and Conditions: (i) Prenylation reagent 34, PFTase, MgCl2, ZnCl2, KCl, DTT,
Tris·HCl buffer pH 7.5, 30 °C, 4 h; (ii) Aminooxy-derivative, azido-derivative, CuSO4,
TCEP, TBTA, m-phenylenediamine, PB, DMSO, rt, 15 h.
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Beal et al. developed a heterotrifunctional template that utilises click reactions (both
copper-free and copper-mediated) to effect sequential biomolecule conjugations in a
one-pot process.
The synthesis of the template was achieved using readily available Fmoc-Lys(Boc)-OH 38.
Initial amide formation to incorporate the terminal alkyne using HATU gave 39. Fmoc
deprotection of 39 using 4-methylpiperidine to give 40 was followed by amide coupling
with S-acetylthioacetic acid to give 41. Subsequent Boc deprotection of 41 followed
by coupling to 1-fluorocyclooct-2-yne carboxylic acid 74 yielded the heterotrifunctional
molecule 42. This route enabled the preparation of the template in 5 steps with a 6.3%
overall yield as a 1:1 mixture of diastereomers (Scheme 1.22).
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Scheme 1.22: Reagents and Conditions: (i) HATU, propargylamine, DIPEA, CH2Cl2,
rt, 12 h; (ii) 4-Methylpiperidine, CH2Cl2, rt, 12 h; (iii) (COCl2)2, 2-(acetylthio)acetic
acid, NEt3, DMF, CH2Cl2, rt, 12 h; (iv) 4m HCl in dioxane, rt, 12 h; (v) HATU,
1-fluorocyclooct-2-yne carboxylic acid 74, DIPEA, CH2Cl2, rt, 12 h.
Following the preparation of substrate 42, SPAAC followed by CuAAC was used to react
its two alkynes handles and give dually modified template 44 which was purified by HPLC.
Finally, 44 was reacted with a maleimide-functionalised BSA modified via its lysines
with an average of 15 – 25maleimides per protein to yield heterogeneous dually modified
BSA 45 (Scheme 1.23). The scope of compatible substrates was illustrated through
conjugation of peptide, sugar, lipid, fluoroalkane, biotin and fluorophore molecules.154
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Scheme 1.23: Dual modification using heterotrifunctional template 42.
Reagents and Conditions: (i) Azido-dervative, DMSO, rt, 6 h; (ii) Azido-derivative,
sodium ascorbate, CuSO4, DMSO, rt, 2 h; (iii) BSA-maleimide, NH2OH ·HCl, EDTA,
PBS, pH 4, DMSO, rt, 2 h.
Temming et al. described a dual-functionalisation method where the two handles were
introduced directly by modifying a serine residue on the N-terminus of a peptide (i.e.
cell-penetrating peptide human lactoferrin) or proteins (i.e. enhanced GFP mutant and
heat shock protein HspB2).152 They argued that this approach potentially alleviates
the need for lengthy syntheses of complex platforms used in exogeneous modification
strategies.
The methods consists of a careful oxidation of the requisite N-terminal serine residue
46 with NaIO4 as the oxidising agent followed by reaction of the resulting aldehyde 47
with 50 equivalents of N -propargylhydroxylamine to yield dually “clickable” protein 48
(Scheme 1.24).
Following this, the first functional label was introduced by strain-promoted alkyne–nitrone
cycloaddition (SPANC) with a “clickable” BCN-biotin derivative. The terminal acetylene
of 49 then served as the second anchor point for a CuAAC reaction with azido-containing
fluorescein to give dually modified construct 50 (Scheme 1.25).
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Scheme 1.24: Preparation of dually “clickable” GFP by terminal serine modification.
Reagents and Conditions: (i) NaIO4, NH4OAc buffer pH 6.8, rt, 65min then p-
methoxybenzenethiol, MeCN, rt, 16 h; (ii) p-Anisidine, N -propargylhydroxylamine,
NH4OAc buffer pH 6.8, MeCN, rt, 65min.
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Scheme 1.25: Dual modification of GFP mutant using terminal serine modification.
Reagents and Conditions: (i) BCN-biotin, NH4OAc buffer pH 6.8, MeCN, rt, 4 h;
(ii) Azido-fluorescein, ascorbate, CuSO4, TBTA, PB pH 7.6; t-BuOH, DMSO, rt, 19 h.
Multifunctional scaffolds have a myriad of uses and can find significant utility in the
biotherapeutic area. In the area of oncology, in particular, antibody–drug conjugates can
benefit from the conjugation of monoclonal antibodies to multiple cytotoxic agents or
stabilising groups (vide supra, section 1.4, page 11). The permutations and combinations
for these functional molecules appear endless, but they rely heavily on the ability of
chemistry to enable these “plug-and-play” strategies. Hence, there is great need for a
straightforward and practical method for the simultaneous introduction of two functional
moieties into proteins.
Recently, Chudasama et al. reported that pyridazinedione based reagents could be used
as a platform to dually modify cysteine-containing biomolecules.52 Indeed, in addition
to the two cysteine-reactive centres, these compounds possess two additional points of
attachment that can easily be functionalised (Figure 1.9).
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Figure 1.9: General structure of dibromopyridazinedione-based reagents.
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1.8 Project aims
This project involves the development, synthesis and biological evaluation of new, stable
and easy to use linker technologies based on pyridazinedione chemistry to site-selectively
conjugate a peptide or protein to two functional units.
The strategy aims to introduce two orthogonal reactive handles onto proteins by
modification of disulfide bonds or cysteines residues. The method should have the
following features (Figure 1.10):
• The functionalisation should be fast, quantitative and should not require lengthy
and complex purifications.
• The functionalisation should not impact the structure and biological activity of the
peptide or protein of interest.
• The resulting conjugate should be stable under various conditions, depending on
the desired application.
• The resulting conjugate should be able to undergo dual functionalisations using
versatile chemistries such as click reactions.
• The dual functionalisation should be compatible with both small and large payloads
(i.e. > 10 kDa).
• The dual functionalisation should allow the payloads to retain their main charac-
teristics (e.g. fluorescence, cytotoxicity).
NN
O O
X X
Orthogonal ‘‘clickable’’
handles
Exquisite selectivity
Rigid 2-carbon 
bridge
Resistance to
hydrolysis
Figure 1.10: Structure and ideal characteristics of PD-based linkers.
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Synthesis of Pyridazinediones
2.1 Introduction
Pyridazinedione derivatives offer a similar and yet distinct reactivity profile for cysteine
conjugation compared with maleimides. Recently, Chudasama et al. showed that both
mono- and dibromo-1,2-dihydro-pyridazine-3,6-diones (PDs) derivatives are suitable for
conjugation to proteins with cysteine residues and disulfide bonds, respectively (vide
supra, Scheme 1.3, page 6).52 Unlike maleimides, when a vast excess of PDs were used
to effect conjugation (up to 100 equivalents at 37 °C for 16 h), no lysine modification
was observed. Moreover, the conjugates generated demonstrated exceptional hydrolytic
stability with the potential for four points of chemical attachment. In view of the project
aims, it was decided to synthesise pyridazinedione derivatives containing “clickable”
reactive handles (e.g. an azide and an alkyne moiety, and an alkyne and a strained alkyne
moiety) to allow further functionalisation of the modified protein via two orthogonal,
selective and sequential click reactions (vide supra, section 1.6, page 25).
2.2 Synthesis of Azide-Alkyne Pyridazinedione (Azal PD)
The azide fragment of Azal PD 61 was prepared via a Sandmeyer reaction on p-toluidine
51 to give azide 52 in 94% yield.167 Azide 52 was then selectively brominated at the
benzylic position using NBS and AIBN to give bromide 53 in 80% yield (Scheme 2.1).168
36
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Scheme 2.1: Reagents and Conditions: (i) NaNO2, HCl(aq), H2O, −5 °C, 5 min;
(ii) NaN3, NaOAc, H2O, 0 °C, 2 h; (iii) NBS, AIBN, C6H6, reflux, 8 h.
Treatment of Boc-protected hydrazine 54 with propargyl bromide under phase transfer
conditions gave monoalkylated hydrazine derivative 55 in 86% yield. Gratifyingly, only
a small amount of dialkylated product was observed despite the use of excess propargyl
bromide.169 Alkyne 55 was then alkylated with bromide 53 to give tetrasubstituted
hydrazine 56 in 93% yield (Scheme 2.2).
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Scheme 2.2: Reagents and Conditions: (i) Propargyl bromide, TBAB, toluene/5%
NaOH(aq), rt, 16 h; (ii) Azide 53, Cs2CO3, DMF, rt, 16 h.
Bromopyridazinediones are commonly synthesised by either: (i) treating bromomaleic
anhydride 58 with a hydrazine derivative and heating the reaction under reflux in
AcOH to carry out dehydrative cyclisation;50 (ii) treating maleic anhydride 57 with
a hydrazine derivative and heating the reaction under reflux in AcOH, followed by
a bromination-elimination sequence;52 or (iii) using milder conditions and treating a
hydrazine derivative with N -methoxycarbonylmaleimide 60.170 In this particular case the
bromination-elimination sequence is not compatible with alkynes and was therefore
not evaluated. As such, it was decided to attempt formation of PDs under both
applicable conditions. For this purpose, dibromomaleic anhydride 58 and dibromo
N -methoxycarbonylmaleimide 60 had to be synthesised. Treatment of maleic anhydride
57 with Br2 gave dibromomaleic anhydride 58 in 83% yield and treatment of maleimide
59 with methyl chloroformate gave carbamate 60 in 97% yield (Scheme 2.3).
With precursors 58 and 60 in hand, it was decided to investigate the two methods for
the formation of the pyridazinedione ring. Interestingly, the milder method involving
reaction with carbamate 60 resulted in the formation of 61 in a low 21% yield whereas
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Scheme 2.3: Reagents and Conditions: (i) Br2, AlCl3, 160 °C, 16 h;
(ii) N -Methylmorpholine, methylchloroformate, THF, rt, 20 min.
reaction of deprotected 56 with maleic anhydride derivative 58 gave Azal PD 61 in a
higher, although still limited, 35% yield (Scheme 2.4).
N
N
BocBoc
N3
21% 35%
(i), (ii) (i), (iii) N
N
O
O
N3
Br
Br
N
N
O
O
N3
Br
Br
61 56 61
Scheme 2.4: Reagents and Conditions: (i) TFA, CH2Cl2, rt, 30 min; (ii) Carbamate
60, NEt3, CH2Cl2, rt, 16 h; (iii) Anhydride 58, AcOH, reflux, 16 h.
Unfortunately, Azal PD 61 was poorly soluble in H2O and thus was not ideal for reaction
onto proteins as it required the use of a significant amount of organic solvent, which is
often poorly tolerated by proteins. As such, it was decided to construct a more water
soluble, dually “clickable” dibromopyridazinedione.
2.3 Synthesis of PEG-Azide-Alkyne Pyridazinedione
(Pazal PD)
Organic molecules are known to have increased water solubility when linked to
polyethylene glycol chains (PEGs). It was therefore decided to introduce a small PEG
chain between the azide residue and the pyridazinedione ring to improve the solubility of
the construct.
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O-Mesylated azide 63 was prepared by mono-mesylation of PEG4 62 to obtain mesylate
63 in 64% yield. This was followed by displacement of the mesylate with sodium azide to
obtain 64 in 95% yield. The remaining hydroxyl group of azide 64 was then mesylated
to give azide-mesylate 65 in a quantitative yield (Scheme 2.5).171
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Scheme 2.5: Reagents and Conditions: (i) MsCl, Ag2O, CH2Cl2, rt, 16 h; (ii) NaN3,
DMF, 110 °C, 16 h; (iii) MsCl, NEt3, CH2Cl2, 0 °C then rt, 2 h.
Trisubstituted hydrazine derivative 55 was next alkylated with mesylate 65 to give water
soluble alkyne-azide precursor 66 in 94% yield (Scheme 2.6).
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Scheme 2.6: Reagents and Conditions: (i) Mesylate ester 65, Cs2CO3, DMF, rt, 16 h.
The two applicable methods for the formation of the pyridazinedione ring were next
investigated (vide supra, section 2.2, page 36). The high temperature used for the
method involving refluxing the reaction in AcOH with maleic anhydride derivative 57
proved to be incompatible with substrate 66. All that was identified under the reaction
conditions, perhaps due to the flexibility of the PEG chain, was an inseparable mixture
of regioisomers 67 and 68 derived from thermally promoted intramolecular azide–alkyne
Huisgen cycloaddition (Scheme 2.7).
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Scheme 2.7: Reagents and Conditions: (i) TFA, CH2Cl2, rt, 30 min then 57, AcOH,
reflux, 16 h.
The use of the mild method, however, afforded Pazal PD 69 in 27% yield with no
azide–alkyne cycloaddition products observed (Scheme 2.8).
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Scheme 2.8: Reagents and Conditions: (i) TFA, CH2Cl2, rt, 30 min then carbamate
60, NEt3, CH2Cl2, rt, 16 h.
2.4 Synthesis of Alkyne-Strained Alkyne Pyridazinedione
(Astra PD)
To expand the scope of this dual modification strategy, it was envisaged that 69 could
be functionalised with a strained alkyne to form an alkyne/strained alkyne construct
that could be sequentially dually functionalised via a SPAAC reaction, followed by a
CuAAC reaction. Strained alkyne 74 was synthesised following literature procedure in a
56% overall yield (Scheme 2.9).172
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Scheme 2.9: Reagents and Conditions: (i) NaH, dimethylcarbonate, benzene, 90 °C,
2 h; (ii) Selectfluor™, CH3CN, 55 °C, 8 h; (iii) KHMDS, Tf2NPh, THF, −78 °C, 1 h then
rt, 5 h; (iv) LiOH, MeOH, H2O, 50 °C, 10 min then rt, 2 h.
It was envisaged that a Staudinger reduction of azide 69 would yield amine 75 which
could then be coupled with acid 74. Although reaction of triphenylphosphine with azide
69 resulted in complete conversion, it yielded a complex mixture of inseparable products
(Scheme 2.10). It was thought that the resultant amine 75 might have undergone an
intra and/or intermolecular Michael addition and that this would account for the complex
mixture of products observed.
In order to prevent a possible Michael addition, attempts were made to trap the highly
nucleophilic nitrogen atom of the iminophosphorane intermediate in the Staudinger
reaction pathway with acid 74 which had been pre-activated in situ with DCC.
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Scheme 2.10: Reagents and Conditions: (i) PPh3, H2O, THF, rt, 16 h.
Unfortunately, this Staudinger ligation strategy returned a mixture of unidentified
products (Scheme 2.11).
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Scheme 2.11: Reagents and Conditions: (i) PPh3, THF, rt, 1 h then acid 74, DCC,
HOBt, MeCN, 0 °C, 1 h then rt, 16 h.
In view of the unsuccessful attempts to synthesise alkyne 76, another approach was
adopted for the synthesis of an alkyne-strained alkyne pyridazinedione (Astra PD)
construct. It was then envisaged that Azal PD 61 could be converted into the desired
construct as its azide moiety could undergo a mono SPAAC with a bis-strained alkyne.
To construct a bis-strained alkyne, bis-amine-PEG4 77 was coupled to acid 74 and gave
bis-cyclooctyne 78 in 54% yield (Scheme 2.12). The PEG spacer was chosen to improve
the water solubility of the final construct as the two cyclooctyne rings would increase the
hydrophobicity of the final construct once attached to the pyridazinedione moiety.
54%
(i)
H2N
O NH2 +
F
N
H
O
HO2C
F F
N
H
O
O
3
3
77 74 78
Scheme 2.12: Reagents and Conditions: (i) HBTU, DIPEA, DMF, rt, 4 h.
To form the desired Astra PD construct, Azal PD 61 was reacted with bis-cyclooctyne
78 to give Astra PD 79 in 36% yield as a mixture of regio- and diastereoisomers
(Scheme 2.13).
Although the synthesis of an alkyne/strained alkyne pyridazinedione was successfully
demonstrated, it was decided to improve upon the construct as it was a mixture of regio-
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Scheme 2.13: Reagents and Conditions: (i) Strained alkyne 78, CH2Cl2, rt, 16 h.
and diastereoisomers. Furthermore, the route to Astra PD 79 proceeded in only 3%
overall yield and, the aryl and cyclooctene moieties decrease the water solubility of the
final construct, which may proved troublesome for future use in conjugation to protein. It
was therefore envisaged to design alternative routes for the synthesis of dually “clickable”
PDs.
2.5 Improved synthesis of Astra PD
2.5.1 Solastra PD — Direct attachment
The synthesis of a more water-soluble MFCO-Astra PD (Solastra PD) construct was initi-
ated by alkylation of trisubstituted hydrazine derivative 55 with tert-butylbromoacetate
to give ester 80 in 97% yield. Ester 80 was then deprotected with TFA and reacted
with dibromomaleic anhydride 58 to give pyridazinedione derivative 81 in 67% yield
(Scheme 2.14).
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Scheme 2.14: Reagents and Conditions: (i) Tert-butyl bromoacetate, Cs2CO3, DMF, rt,
16 h; (ii) TFA, CH2Cl2, rt, 30 min; (iii) Anhydride 58, AcOH, rt, 16 h then reflux, 2 h.
In order to improve water solubility of the final construct, mono-protected PEG4-based
diamine linker 83 was first prepared by slow addition of Boc anhydride to diamine 82
(Scheme 2.15).173
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Scheme 2.15: Reagents and Conditions: (i) Boc2O, dioxane, rt, 24 h.
Amine 83 was then attached to acid 81 via EDC-mediated coupling to give Boc-protected
PD 84 in 44% yield (Scheme 2.16).
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Scheme 2.16: Reagents and Conditions: (i) EDC·HCl, NEt3, CH2Cl2, rt, 4 h.
To attach the strained alkyne part of the construct, Boc-protected PD 84 was first
deprotected to yield a free primary amine which was then reacted with acid 74 using
HBTU as coupling agent. Unfortunately these reaction conditions only returned traces of
the desired product, Solastra PD 85. As deprotected 84 as well as methyl ester 73 were
oils, it was envisaged that a highly concentrated mixture of the two in NEt3 could yield
final construct 85 but after 5 days, no reaction between the two intermediates occurred
(Scheme 2.17).174
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Scheme 2.17: Reagents and Conditions: (i) TFA, CH2Cl2, rt, 30 min; (ii) Acid 74,
HBTU, DIPEA, DMF, rt, 4 h; (iii) 73, NEt3, 30 °C, 5 days.
This lack of reactivity was attributed to the low solubility of the deprotected PD in NEt3;
it was therefore thought that attaching the PEG-amine 83 to the strained alkyne moiety
73 prior to coupling with the PD core 81 could solve the solubility issue. Gratifyingly,
nucleophilic acyl substitution with amine 83 and methyl ester 73 proceeded smoothly
to give Boc-protected intermediate 86 in 72% yield (Scheme 2.18). This reaction was
preferred to a more standard coupling between acid 74 and amine 83 as, in addition
to reducing the number of steps needed to reach the final target molecule, acid 74 was
found to be prone to decarboxylation which reduces the yield of the reaction.
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Scheme 2.18: Reagents and Conditions: (i) NEt3, 30 °C, 36 h.
Attempts to deprotect 86 were then made using TFA/CH2Cl2 mixture in various
dilutions at room temperature. However all ratios trialled returned TFA adduct 87.
Nevertheless, by lowering the temperature to −20 °C and careful monitoring of the degree
of advancement of the reaction, amine 88 could be isolated in 82% yield (Scheme 2.19).155
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Scheme 2.19: Reagents and Conditions: (i) TFA/CH2Cl2 (1 : 20 7→ 1 : 1), rt, 1 h; (ii)
TFA/CH2Cl2, −20 °C, 90min.
Finally, EDC-mediated coupling of acid 81 and amine 88 afforded Solastra PD 85
although in a low 20% yield (Scheme 2.20). This yield was partially attributed to Cl–
(from EDC·HCl) displacement of a bromine from the PD core.
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Scheme 2.20: Reagents and Conditions: (i) EDC·HCl, NEt3, CH2Cl2, rt, 4 h.
Although the synthesis of this alkyne/strained alkyne pyridazinedione with improved
water-solubility was successfully demonstrated it was decided to improve upon the route
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to Solastra PDs 79 as the last steps involving MFCO derivatives 73, 86 and 88 were
challenging and often low yielding, resulting in the synthesis proceeding in only 7%
overall yield.
2.5.2 BCN-Astra PD
In view of the issues stated above, a new route was devised to construct an alkyne/strained
alkyne PD moiety. To do this, it was decided to switch from Schultz/Pigge’s MFCO
strained alkyne 90 to van Delft’s bicyclononynes (BCNs).175 BCN 89 has the lowest
calculated logP value amongst the other popular cyclooctynes in the literature and is
therefore preferred if low lipophilicity is required (Figure 2.1).
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BCN (1.4) MFCO (2.1) DIFO (1.6) ADIBO (3.4) DIBO (3.9)
89 90 91 92 93
Figure 2.1: Structure of popular cyclooctynes and their calculated c logP for R = H
(numbers in parenthesis).
Furthermore, BCNs have been shown to react with azides with better kinetics when
compared to MFCOs (kBCN = 0.29m−1 · s−1 and kMFCO ' 1.5× 10−3m−1 · s−1
respectively).175 The addition of a BCN handle also opens the door to other click
reactions orthogonal to alkynes as they have been shown to react rapidly with tetrazines
and nitrones in aqueous media (k ' 500m−1 · s−1 and k ' 1.67m−1 · s−1 respectively)
to form stable adducts (Figure 2.2).175–177 In contrast, MFCOs 90 and DIBOs 93 have
been shown to be poor dienophiles when reacted with tetrazines.178,179
Acid 81 was therefore coupled to commercially available BCN−PEG−NH2 97 resulting
in new alkyne-strained alkyne pyridazinedione 98 as the sole isomer, with improved
water solubility, and in an improved 25% overall yield (Scheme 2.21).
With 5 dibromo PDs successfully synthesised (Azal PD 61, Pazal PD 69, MFCO-Astra
PD 79, Solastra PD 85 and BCN-Astra PD 98, vide infra, Figure 2.3, page 51) and
ready to be used for conjugation onto proteins with disulfide bonds, it was decided to
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Figure 2.2: Click reactions with BCN and azide (SPAAC), nitrone (SPANC) and
tetrazine (SPATC).
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Scheme 2.21: Reagents and Conditions: (i) HATU, DIPEA, DMF, rt, 16 h.
also investigate single cysteine modification. To this effect, mono bromo PD derivatives
had to be prepared.
2.6 Synthesis of monobromo Azide-Alkyne Pyridazine-
dione (mBr-Azal PD)
With precursor 56 in hand, it was decided to synthesise the monobromo analogue of Azal
PD 61. Deprotection of hydrazine derivative 56 followed by reaction with bromomaleic
anhydride 99 gave mBr-Azal PD 100 in 60% yield (Scheme 2.22).
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Scheme 2.22: Reagents and Conditions: (i) TFA, CH2Cl2, rt, 30 min;
(ii) Bromomaleic anhydride 99, AcOH, reflux, 16 h.
2.7 Synthesis of diethyl PD (Diet PD)
In order to optimise the conditions for the conjugation to proteins on both single cysteines
and disulfides, monobromo and dibromo PDs where reactive handles are replaced with
unreactive alkyl groups were prepared.52 Synthesis of monobromo diethyl PD 103
(mBr-Diet PD) and dibromo diethyl PD 104 (Diet PD) were achieved in high yield by
the initial condensation of maleic anhydride 57 with diethylhydrazine 101 followed by
sequential dibromination/elimination steps (Scheme 2.23).
OO O (i)
72%
(ii), (iii)
92%
NN
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Et Et
NN
OO
Et Et (iv), (v)
91%
NN
OO
Et Et
Br Br Br
HN NH
Et Et
+
101 57 102 103 104
Scheme 2.23: Reagents and Conditions: (i) AcOH, reflux, 16 h; (ii) Br2, CH2Cl2, rt, 16 h;
(iii) Et3N, CH2Cl2, rt, 16 h; (iv) Br2, CH2Cl2, 50 °C, 72 h; (v) Et3N, CH2Cl2, rt, 16 h.
Alternatively, mBr-Diet PD 103 and Diet PD 104 were prepared using the mild method
involving carbamates (vide supra, section 2.2, page 36).170 Monobromo maleimide 105 was
reacted with methyl chloroformate to give carbamate 106 in > 99% yield (Scheme 2.24).
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Scheme 2.24: Reagents and Conditions: (i) N -Methylmorpholine, methylchloroformate,
THF, rt, 20 min.
Both monobromo- and dibromo-PD precursors 106 and 60 were then reacted with
diethylhydrazine 101 to give mBr-Diet PD 103 and Diet PD 104 in 64% and 57% yield,
respectively (Scheme 2.25).
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Scheme 2.25: Reagents and Conditions: (i) CH2Cl2, rt, 16 h.
2.8 Synthesis of mono-functionalised PD
Finally, in order to optimise the conditions for the click reactions on proteins, PDs where
one of the “clickable” handles (azide, alkyne or strained alkyne moiety) is replaced by an
unreactive group were prepared.
2.8.1 Synthesis of mono-functionalised PD precursor
It was envisaged that a common PD precursor would facilitate the syntheses of mono-
functionalised PDs. It was then postulated that a PD with an unreactive methyl group
on one nitrogen and, on the other, an acid handle that could be further coupled to amines,
was a suitable common precursor. Using previously developed routes, its synthesis was
attempted. Unfortunately, monoalkylation of Boc-protected hydrazine 54 with methyl-
or ethylhalide resulted in a mixture of starting material 54, mono- and bisalkylated
hydrazine (109, 110 and 111, 112 respectively) which would greatly reduce the overall
yield of the synthesis (Scheme 2.26). Thus, an alternative route towards Methyl-Acid
PD 116 (Meta PD) was needed.
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Scheme 2.26: Reagents and Conditions: (i) Cs2CO3, DMF, rt, 16 h.
The synthesis started from inexpensive methylhydrazine 113 which was fully Boc-
protected to give hydrazine 114 in > 99% yield. Following a procedure by Stafford et al.,
114 was then selectively mono-deprotected by mild cleavage of Boc group catalysed
by Mg(ClO4)2 to yield 109.180,181 The resulting hydrazine 109 was then alkylated to
give tert-butyl ester 115 in 87% yield over three steps. Finally, 115 was deprotected
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and condensed with dibromomaleic anhydride 58 to afford Meta PD 116 in 73% yield
(Scheme 2.27).
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Scheme 2.27: Reagents and Conditions: (i) Boc2O, NEt3, DMAP, CH2Cl2, rt, 16 h;
(ii) Mg(ClO4)2, MeCN, 50 °C, 1 h; (iii) tert-Butyl bromoacetate, Cs2CO3, DMF, rt, 16 h;
(iv) TFA, CH2Cl2, rt, 30min; (v) Anhydride 58, AcOH, rt for 16 h, then reflux, 2 h.
As alkyne 81 could already act as an alkyne-functionalised PD, it was decided to focus
on the synthesis of PDs mono-functionalised with an azide and with a strained alkyne
handle.
2.8.2 Functionalisation of Meta PD
Following the successful high-yielding synthesis of Meta PD 116 but keeping in mind
the relatively modest yields obtained when acid 81 was coupled to amines using HBTU,
HATU or EDC as coupling agent (vide supra, section 2.5, page 42), it was envisaged that
the synthesis of isolable NHS- or PFP-activated ester would improve the overall yield of
the coupling.
To this end, activation of acid 116 was first attempted using DCC/NHS and TSTU
activation; but this returned a mixture of products with no trace of the expected NHS-
activated ester 117 (Scheme 2.28). However, DCC/Pentafluorophenol activation resulted
in complete conversion to PFP-ester 118 by NMR analysis of the crude mixture post-
workup of the reaction. As the crude of the reaction was contaminated with DCCU, it
was purified by column chromatography. Unfortunately, 118 partially degraded on the
silica and was isolated in only 34% yield (Scheme 2.28).
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Scheme 2.28: Reagents and Conditions: (i) TSTU, NEt3, DMF, rt, 5 h; (ii) DCC,
NHS, CH2Cl2, rt, 16 h; (iii) DCC, pentafluorophenol, dioxane, rt, 16 h.
Commercially available amine 119 was then reacted with 118 to give Azide-Methyl PD
120 (Azime PD) in 81% yield (Scheme 2.29).
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Scheme 2.29: Reagents and Conditions: (i) NEt3, CH2Cl2, rt, 16 h.
Owing to the instability of PFP-ester 118 upon purification and the overall low 28%
yield for the coupling with amine 119, it was decided to attempt a PyBOP-mediated
direct coupling between commercially available BCN−PEG−NH2 97 (vide supra, section
2.5.2, page 45) and acid 116. These new reaction conditions afforded BCN-based
Methyl-Strained Alkyne PD 121 (BCN-Mestra PD) in 54% yield (Scheme 2.30).
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Scheme 2.30: Reagents and Conditions: (i) PyBOP, DIPEA, CH2Cl2, rt, 16 h.
2.9 Conclusion
A library of monobromo- and dibromo-PD-based compounds with 0 – 2 clickable handles
have been prepared in low to good overall yields (Figure 2.3 and Appendix B). The
syntheses of dually “clickable” PDs have been optimised to generate constructs with
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improved water solubility through the use of short PEG chains, which may prove essential
when attempting conjugation onto proteins. A novel route has been developed for the
preparation of mono-functionalised PDs to be used for optimisation of click reactions
with alkynes, azides and strained alkynes. Finally, monobromo- and dibromo-PDs with
two unreactive ethyl groups on the nitrogens in lieu of clickable handles were prepared
to optimise the reaction conditions used for attachment of PDs to proteins.
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Figure 2.3: PDs synthesised with (a) two “clickable” handles; (b) one “clickable”
handle; (c) no reactive handle.
Chapter 3
Antibody, Antibody Fragment
and Protein Modification
3.1 Introduction
3.1.1 Trastuzumab
The HER receptors are proteins that are embedded in the cell membrane and communicate
molecular signals from outside the cell to inside the cell, and turn genes on and off. They
are known to stimulate cell proliferation. In some cancers, notably certain types of breast
cancer, HER2 is over-expressed and causes cancer cells to reproduce uncontrollably.182
In order to inhibit tumor growth due to HER2 over-expression, mAbs specifically directed
towards HER2 extracellular domains have been developed. One of the most potent is
the murine antibody MAb 4D5. However, its immunogenicity in human has limited its
use greatly. Thus, humanised recombinant monoclonal antibodies such as trastuzumab
(Herceptin™) were developed.
Trastuzumab interferes with the HER2/neu receptor (also known as ErbB2) and its
affinity towards this receptor is three times the affinity of MAb 4D5. Its mechanism of
action is known (Figure 3.1).183 It has been suggested that trastuzumab induces some of
its effect by downregulation of HER2/neu, leading to disruption of receptor dimerisation
and signalling.184 In brief summary, trastuzumab binds to domain IV of the extracellular
segment of the HER2/neu receptor and inhibits its ectodomain cleavage.185,186 Cells
52
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treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there
is reduced proliferation. In addition, trastuzumab suppresses angiogenesis (the process
through which new blood vessels form from pre-existing vessels) both by induction of
antiangiogenic factors and repression of proangiogenic factors. A more detailed mechanism
of action of trastuzumab may be found in a report by Hudis.183
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Figure 3.1: Mechanism of action of trastuzumab (reproduced from Hudis).183
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Trastuzumab is mainly used in the treatment of certain breast cancers but it is also being
studied for the treatment of other cancers such as gastric cancer187 and uterine papillary
serous carcinomas that also overexpress HER2/neu.188 An ADC based on trastuzumab,
trastuzumab emtansine (trade name Kadcyla™) has already been developed and recently
approved by the FDA (vide supra, section 1.4, page 11). Kadcyla™ is used to treat
patients with HER2-positive metastatic breast cancer which represents at least 20% of
breast cancers (breast cancer is the second leading cause of cancer-related death among
women). This treatment extends median overall survival by 5.8 months when compared
with standard lapatinib + capecitabine treatment.189 This, along with other results in
the field, makes this antibody a suitable construct model for the study.
3.1.2 Fab fragments
Amongst all the antibody fragments, Fabs are the most thoroughly explored; knowledge
and experience was generated during the development of 3 FDA-approved therapeutics
(Table 3.1), 6 agents in active clinical development, and 20 discontinued programs, which
collectively account for 49% of 54 identified antibody fragments that have entered the
clinical pipeline.70
Generic
(brand) names Description
Indication of 1st
approval
Year of 1st
approval
Sponsor
Abciximab
(Reopro)
Anti-GPIIb/IIIa
chimeric Fab
Clot prevention
in angioplasty 1994 Centocor
Ranibizumab
(Lucentis)
Anti-VEGF-A
humanised Fab
Macular
degeneration 2006 Genentech
Certolizumab
pegol (Cimzia)
Anti-TNFα
pegylated
humanised Fab
Moderate to
severe Crohn
disease
2008 UCB
Table 3.1: Monoclonal antibody fragments approved in the US.
Fab fragments of antibodies retain the targeting specificity of full antibodies but can
be produced more economically. Indeed, there are significant differences between
biomanufacturing fragments and full-sized antibodies, e.g. the smaller size of fragments
permits cheaper, faster production in microbial systems. In addition, Fab fragments
possess other advantages over full antibodies, such as improved tissue penetration.
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However, Fab fragments are significantly less stable in vivo than full antibodies and as a
consequence have relatively short circulating half-lives. Strategies have been developed,
such as PEGylation, to extend the half-life of fragments and reduce immunogenicity.64–67
3.2 Digestion of antibodies
The shortest method to produce Fab fragments is to enzymatically digest their
corresponding full antibody. For such a reaction, the protease of choice is papain.
Indeed, when IgG molecules are incubated with papain in the presence of a reducing
agent (papain is inactive in its oxidised form), the hinge region is split. This produces
three fragments of similar size: two Fab fragments and one Fc fragment190 that can be
easily separated via protein A purification. Fab fragments from two different antibodies,
rituximab and trastuzumab, were prepared via enzymatic digestion.
3.2.1 Rituximab
The Fab fragment of rituximab 123 (Fabrit) was prepared from rituximab 122 using
a thiol-free protocol where papain is reduced beforehand with DTT or cysteine. Pre-
activated papain, washed from the reducing agent, at an enzyme/IgG ratio of 1/40
(wt/wt) was used to generate Fabrit in an average 70% yield (determined by UV-Vis)
after protein A purification (Scheme 3.1).
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Scheme 3.1: Fabrit preparation by papain digestion and protein A purification.
Reagents and Conditions: (i) Papain, phosphate buffer pH 6.8, 37 °C, 16 h.
The fragments obtained were analysed by SDS-PAGE and by LCMS to reveal highly
pure Fabrit 123 as the sole product (Figure 3.2).
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(a) (b)
(c)
Figure 3.2: (a) SDS-PAGE of digested rituximab via a thiol-free protocol. Lane 1 –
rituximab 122; 2 – Fabrit 123; 3 – Fcrit 124; (b) Non-deconvoluted and (c) deconvoluted
LCMS data for Fabrit 123.
3.2.2 Trastuzumab
The preparation of homogeneous Fab fragments of trastuzumab 127 (FabHer) proved to
be more challenging; several enzymes and conditions had to be tried to yield FabHer 127
as a single species post-purification using standard techniques.
3.2.2.1 Direct method
In accordance with the report by K. L. Bennett et al.,191 trastuzumab was reacted with
various amounts of immobilised papain ranging from 1/40 to 1/10 (enzyme/IgG ratio,
wt/wt) in the presence and in the absence of thiol (vide supra, section 3.2.1, page 55).
At all tested ratios, the thiol-free protocol yielded a mixture of undigested trastuzumab
19, FcHer 126, and FabHer 127 (Figure 3.3 – lane 2). Attempts were made to purify the
mixture using protein A but unfortunately FabHer 127 also binds to protein A and thus
could not be isolated from the mixture (Figure 3.3 – lane 1).
In the presence of a reducing agent and at a high concentration of enzyme (1/10,
enzyme/IgG ratio, wt/wt), the digestion went to completion. Gratifyingly, it was found
that, when left for an extended period of time, reduced papain also digested FcHer into
low-molecular-weight proteolytic contaminants thus allowing for the purification of FabHer
by diafiltration without the use of protein A. The purified protein was then analysed by
SDS-PAGE to reveal FabHer free of other fragments. Unfortunately, analysis by LCMS
revealed a mixture of FabHer products with a mass difference of 367 Da consistent with
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Figure 3.3: Failed digest of trastuzumab 19. Lane 1 –mixture post-purification by
protein A; 2 – incomplete digest of trastuzumab 19.
the cleavage of the first three amino acids of the VH region, thus most likely reducing
the binding affinity of the fragment (Figure 3.4).192
(a)
(b)
Figure 3.4: (a) non-deconvoluted and (b) deconvoluted LCMS data for attempted
preparation of a trastuzumab Fab using the protocol outlined by K. L. Bennett et al.191
As no homogeneous FabHer 127 could be obtained via a direct approach, other conditions
had to be found. On the one hand, these conditions had to be milder to avoid over-
digestion of FabHer 127 but, on the other hand, they had to be harsher than the thiol-free
protocol that did not reach completion; a two-step method was developed.192
Chapter 3. Antibody, Antibody Fragment and Protein Modification 58
3.2.2.2 Two-step method
The two-step method developed consists of pre-digestion of trastuzumab 19 with pepsin
to give F(ab’)2 125, followed by thiol-free digestion with papain. Indeed, pepsin pre-
digestion to F(ab’)2 125 also cleaves the Fc in numerous small peptides that can be
removed easily by diafiltration. This reduces the steric hindrance around the hinge region
of the antibody (Figure 1.2) and allows the subsequent milder thiol-free papain digestion
to reach completion within 10 h (Scheme 3.2).
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Scheme 3.2: FabHer preparation by pepsin digestion followed by papain digestion.
Reagents and Conditions: (i) Pepsin, acetate buffer pH 3.1, 37 °C, 5 h; (ii) Papain,
phosphate buffer pH 6.8, 37 °C, 16 h.
Gratifyingly, analysis of the digest by SDS-PAGE and LCMS revealed formation of a
single Fab fragment 127 with an intact VH region in an average 65% yield (Figure 3.5).
(a) (b)
(c)
Figure 3.5: (a) SDS-PAGE of digested trastuzumab via the two-step protocol developed.
Lane 1 – ladder; 2 – FabHer 127; (b) Non-deconvoluted and (c) deconvoluted LCMS data
for the novel preparation of a FabHer 127.192
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3.2.2.3 Conclusion
Direct, “classical” methods involving digestion with papain followed by purification
with protein A or diafiltration failed to generate clean and homogeneous Fab fragments.
However, a two-step method involving pre-digestion of trastuzumab with pepsin to
give F(ab’)2 125, followed by digestion with papain and diafiltration to remove small
proteolytic fragments resulted in clean and homogeneous FabHer 127.
3.3 Modification of antibodies
The general strategy developed for the modification of mAbs and Fabs and the generation
of constructs that can be functionalised using a “double click” strategy can be divided
into two distinct steps (Figure 3.6).
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Figure 3.6: General strategy for IgG1 and Fab functionalisation.
When modifying mAbs, the four disulfides of a commercially available IgG1 are chemically
reduced, leading to eight free thiols. These can be re-bridged by addition to four
pyridazinedione-based reagents to give a conjugate with four bridging PDs, each bearing
a set of orthogonal handles to be used for dual modification.
Fab fragments contains a single solvent accessible disulfide bond that can be reduced
chemically and lead to two free cysteines. These residues can then be reacted in the
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presence of the developed pyridazinedione-based reagents to give a dually “clickable”
conjugate with two orthogonal handles. These two groups can then be independently
reacted in a sequential manner.
3.3.1 Trastuzumab
3.3.1.1 Reduction study
In order to avoid the use of excess reducing agent, a reduction study was carried out
with trastuzumab 19. Two reducing agents (DTT and TCEP) in phosphate and borate
buffer, at two different pHs (6.8 and 8), and at 37 °C were evaluated for the reduction
of the disulfide bonds of 19. For analysis purposes, the reaction was then stopped by
addition of an excess of maleimide (Scheme 3.3).119
SS SS
S S
S S
Trastuzumab
(i)
SS SS
S S
S S
Reduced 
Trastuzumab
19 128
Scheme 3.3: Reduction of trastuzumab 19.
Reagents and Conditions: (i) TCEP or DTT for 90min then maleimide, BBS pH 8.0 or
PBS pH 6.8 – 8.0, 37 °C.
SDS-PAGE analysis revealed that 8 equivalents of TCEP in borate buffer pH 8.0 with
1mm EDTA at 37 °C were sufficient to reduce the 4 disulfide bonds in 90min, thus
revealing the heavy chains (ca. 50 kDa) and the light chains (ca. 25 kDa) of the antibody
(Figure 3.7).119,155
After removal of the excess TCEP by diafiltration, re-bridging conditions had to be
optimised.
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Figure 3.7: (a) SDS-PAGE of trastuzumab reduction by TCEP in borate buffer pH
8.0 at 37 °C for 90min.119 Lane 1 – trastuzumab 19; 2 – 2 eq. of TCEP; 3 – 3 eq.; 4 – 4
eq.; 5 – 5 eq.; 6 – 6 eq.; 7 – 7 eq.; 8 – 8 eq.; (b) Non-deconvoluted and (c) deconvoluted
LCMS data for trastuzumab 19 reduced with 8 eq. of TCEP.
3.3.1.2 Conjugation study
Using di-bromo Diet PD (Diet PD) 104 as a model, it was shown that 10 equivalents of
pyridazinedione-based reagents were sufficient to react with the 8 accessible sulfhydryls
of reduced antibody 128 within 1 h at 37 °C (Scheme 3.4).
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Scheme 3.4: Modification of reduced trastuzumab 128 with Diet PD 104.
Reagents and Conditions: (i) Diet PD 104, BBS pH 8.0, 37 °C, 1 h.
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Unfortunately, SDS-PAGE analysis revealed that a mixture of two products had been
obtained by sequentially reacting TCEP then Diet PD 104 with trastuzumab 19. The
high molecular weight species was attributed to the correctly bridged antibody whereas
the ca. 80 kDa species was hypothesised to be result of a mis-bridging of the hinge
region, where the two cysteines of the heavy chain are only separated by two amino acids,
resulting in a “half-antibody” (Figure 3.8).
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Figure 3.8: SDS-PAGE of a Diet-modified trastuzumab by sequential protocol. Lane
1 – re-bridged trastuzumab 129 and 130; 2 – reduced trastuzumab 128.
To confirm this hypothesis, a mixture of 129 and 130 was enzymatically digested by
pepsin (vide supra, section 3.2.2.2, page 58) to yield a mixture of FabHer-Diet 131
and F(ab)’Her-Diet 132 which were characterised by LCMS (Scheme 3.5 and vide infra,
appendix A.3.1.6, page 150).
Her-Diet
(i)
Mis-bridged 
Her-Diet
+ +
FabHer-Diet F(ab)'Her-Diet
129 130
131 132
Scheme 3.5: Pepsin digestion of mis-bridged Her-Diet 130.
Reagents and Conditions: (i) Pepsin, acetate buffer pH 3.1, 37 °C, 5 h.
As the hinge region of IgG1s has been shown to be essential for certain effector functions
of antibodies, it was decided to investigate further the issue of mis-bridging leading to
“half-antibody”.108
It was first envisaged that an in situ protocol where the reducing agent (i.e. TCEP)
is slowly added in the presence of an excess of bridging reagent (e.g. Diet PD 104)
would alleviate the mis-bridging: the PD would rapidly trap an opened disulfide of the
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hinge region before it can react with the adjacent one. As TCEP is known to react
with dibromomaleimides, a class of heterocyles close to PDs (vide supra, section 2.1,
page 36), before attempting such a protocol, it was first needed to check the absence of
cross-reactivity between PDs and this reducing agent.193,194 Gratifyingly, when Diet PD
104 was mixed with TCEP in a buffered solution at pH 8.0, no reaction was observed
after 4 h at 37 °C (Scheme 3.6).
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Scheme 3.6: Reagents and Conditions: (i) TCEP, MeCN/BBS pH 8.0, 37 °C, 4 h.
Thus, to avoid half-antibody formation, in situ protocols were trialled. TCEP was added
to a solution of trastuzumab 19 in BBS pH 8.0 containing 50 or 100 eq. of Diet PD
104 at two different rates, 0.5 eq./h and 0.5 eq./30 min over 16 h and 8 h respectively.
The mixture was kept at 37 °C under mild agitation and samples were flash frozen for
SDS-PAGE analysis every hour. The results obtained are summarised in Figure 3.9.
(a) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 (b) 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 3.9: In situ protocol with slow addition of TCEP at 37 °C in borate buffer pH
8.0. (a) SDS-PAGE of reaction with 50 eq. of Diet PD 104. Lane 1 – 7: 0.5 eq./h after
4, 6, 8, 10, 12, 14 and 16 h respectively; Lane 8 – 14: 1 eq./h after 2, 3, 4, 5, 6, 7 and
8 h respectively; (b) SDS-PAGE of reaction with 100 eq. of Diet PD 104. Lane 1 – 7:
0.5 eq./h after 4, 6, 8, 10, 12, 14 and 16 h respectively; Lane 8 – 14: 1 eq./h after 2, 3, 4,
5, 6, 7 and 8 h respectively.
In view of these rather disappointing results, it seemed that the rate of addition of
reducing agent had no influence over the correct bridging of Diet PD 104. After addition
of 8 eq. all conditions tested showed similar amounts of “half-antibody” 130 (Figure 3.9,
lanes 7 and 14) when compared with the sequential protocol (Figure 3.8, lane 1). These
results also showed that, at 37 °C, TCEP reduces the four disulfide bonds altogether as,
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even with low amounts of reducing agent, “half-antibody” 130 was observed (Figure 3.9,
lanes 3 and 10). Another strategy had to be devised to tackle this limitation.
As the addition rate did not have an impact on the bridging, it was then envisaged that
lowering the temperature of the reaction would limit the reduction rate of TCEP while
maintaining a high concentration of PD would allow for rapid trapping of an opened
disulfide of the hinge region before the adjacent one is opened. It would also reduce
thermal motion therefore allowing the antibody to remain close to its original templated
structure where the cysteines residues are at a distance where they can be correctly
linked together.
Thus, to avoid half-antibody formation, in situ protocols at low temperature were trialled.
TCEP (8 eq.) was added to a solution of trastuzumab 19 in BBS pH 8.0 containing
50 eq. of Diet PD 104 and the mixture was kept at 4 °C for 16 h. Encouragingly, analysis
by SDS-PAGE revealed very limited formation of the undesired “half-antibody” 130
(Figure 3.10a, lane 2). This protocol was then further optimised and it was found that
pre-lowering the temperature to 4 °C before addition of TCEP allowed for complete
correct re-bridging of trastuzumab 19 and afforded exclusive formation of 129 by SDS-
PAGE (Figure 3.10b, lane 2). After removal of the excess unbound small molecules
by diafiltration, no further purification was required and a yield in excess of 95% was
obtained.
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Figure 3.10: SDS-PAGE of a trastuzumab 19 re-bridged by in situ protocol at 4 °C in
borate buffer pH 8.0. (a) Without pre-lowering of the temperature. Lane 1 – reduced
trastuzumab 128; 2 – re-bridged trastuzumab 129 and 130; 3 – trastuzumab 19; (b) With
pre-lowering of the temperature. Lane 1 – trastuzumab 19; 2 – re-bridged trastuzumab
129; 3 – reduced trastuzumab 128.
Having optimised the conjugation reaction with model compound Diet PD 104, it was
then decided to try these conditions with more relevant “clickable” PDs (vide supra,
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Figure 2.3, page 51). Gratifyingly, the optimised conditions translated well with more
complex PDs and “clickable” Her-PDs were obtained in 90 – 99% yields (Scheme 3.7).
Analysis by SDS-PAGE revealed that these optimised conditions resulted in very limited
amount of incorrect bridging in the hinge region (Figure 3.11).
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Scheme 3.7: Modification of trastuzumab 19 with “clickable” PDs.
Reagents and Conditions: (i) PD, TCEP, BBS pH 8.0, 4 °C, 16 h.
Figure 3.11: Typical SDS-PAGE of PD-modified trastuzumab by low temperature in
situ protocol. Lane 1 –Her-Solastra 134b; 2 –Her-Mestra 134d; 3 –Her-BCN-Astra 134c.
The main limitation of this approach lies in the competing Staudinger reduction when
azide containing molecules are used. On the other hand, in addition to yielding correctly
re-bridged antibody conjugates, this in situ protocol is close to being ideal and more
general in that, contrary to the sequential protocol developed, as well as those which
have been previously described, it does not rely on the fact that the reduced form of
the protein is stable.195–197 Indeed, it is well established that peptides and proteins that
contain disulfide bonds can start to unfold or scramble upon opening of their bridge.
Furthermore, protein complexes that are only connected by disulfide bonds would fall
apart if a sequential reduction/re-bridging protocol is used. Thus, by minimising the
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time a disulfide exists in its reduced form, the developed protocol has the potential to
alleviate these issues.
3.3.2 Rituximab
In order to evaluate the compatibility of the method developed with other antibodies,
similar conjugation reactions were carried out with rituximab 122. Analysis by SDS-
PAGE, UV-Vis and Ellman’s test revealed a very similar profile of re-bridging and PAR
for both antibodies. The main difference appeared to be the amount of TCEP needed to
reduced rituximab. It was found that 20 eq. were enough to effect complete reduction of
the 4 disulfide bonds (Figure 3.12).194
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Figure 3.12: SDS-PAGE of rituximab 122 and rituximab conjugates showing profiles
similar to trastuzumab 19. (a) SDS-PAGE of rituximab reduction by TCEP in borate
buffer pH 8.0 at 37 °C for 60min.119 Lane 1 – rituximab 122; 2 – 2 eq. of TCEP; 3 – 4 eq.;
4 – 8 eq.; 5 – 15 eq.; 6 – 30 eq.; 7 – 50 eq.; 8 – 80 eq.; (b) SDS-PAGE of a Diet-modified
rituximab by sequential protocol. Lane 1 –Reaction mixture; (c) SDS-PAGE of a Diet-
modified rituximab by low temperature in situ protocol. Lane 1 –Reaction mixture.
Although it gives a qualitative idea of the efficiency of the bridging, analysis using
SDS-PAGE combined with Ellman’s test could not quantitatively indicate the number of
PD per antibody. A more accurate method to access this value on a full antibody was
therefore developed.
3.3.3 PD per antibody ratio
It was found that pyridazinediones absorb light around a λmax ' 345 nm. Using di-cysteine
Diet PD 135 as a model (Figure 3.13), a standard UV-Vis curve was obtained. From
this curve, using the Beer–Lambert law, it was possible to calculate a molar extinction
coefficient value at λmax = 345 nm (ε345) for the pyridazinedione-based reagents used.
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Figure 3.13: Protected di-cysteine derivative of Diet PD used for UV-Vis standard curve.
As shown in Figure 3.14, PD 135 also absorbs light at 280 nm, and the relation with its
absorbance A345 at λmax = 345 nm is given by:
APD280 = 0.28A345
Taking into account this correction, the PD/antibody ratio (PAR) for a conjugate is
given by:
PAR = A345/ε345(A280 −APD280)/ε280
= A345/ε345(A280 − 0.28A345)/ε280
with Aλ the absorbance of the conjugate at the wavelength λ, ε345 ' 9100m−1·cm−1 and
ε280 = 215 380m−1·cm−1 for trastuzumab 19.
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Figure 3.14: UV-Vis spectrum of di-cysteine Diet PD 135.
As suggested by the SDS-PAGE analysis and by Ellman’s test, using this formula the
average calculated PAR for conjugates 134a–d was ca. 4. This is consistent with the
insertion of PDs into each of the disulfide bonds of trastuzumab 19 (Figure 3.15).
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Figure 3.15: UV-Vis spectrum of Her-Solastra 134b.
3.4 Modification of Fab fragments
3.4.1 Trastuzumab
3.4.1.1 Reduction study
As for the optimisation with a full antibody, a reduction study was carried out with
FabHer 127. Two reducing agents (DTT and TCEP) in phosphate and borate buffer, at
two pH and 8, and at 37 °C were evaluated for the reduction of the disulfide bond of
FabHer 127 (Scheme 3.8).
S S S S
(i)
FabHer Reduced FabHer
127 136
Scheme 3.8: Reduction of FabHer 127.
Reagents and Conditions: (i) TCEP or DTT, 90min, BBS or PB pH 8.0, 37 °C.
SDS-PAGE together with LCMS analysis revealed that 3 equivalents of TCEP in borate
buffer pH 8.0 with 1mm EDTA at 37 °C were sufficient to reduce the disulfide bond in
90min, thus revealing the free truncated heavy chains (observed mass 23 449Da) and
light chains (observed mass 24 209Da) of reduced FabHer 136 (Figure 3.16).155,192
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Figure 3.16: (a) SDS-PAGE of FabHer 127 reduction by TCEP in borate buffer pH
8.0 at 37 °C for 90min. Lane 1 –FabHer 127; 2 – reduction with 3 eq. of TCEP;
(b) Non-deconvoluted and (c) deconvoluted LCMS data for reduced FabHer 136.
3.4.1.2 Conjugation study
After removal of the excess TCEP by diafiltration, a small screening of conditions, using
Diet PD 104 as a model, showed that 5 equivalents of pyridazinedione-based reagent were
sufficient to re-bridge FabHer 127 within 1 h at 37 °C to afford the desired FabHer-Diet
131 covalently inserted (Scheme 3.9).
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Scheme 3.9: Modification of reduced FabHer 136 with Diet PD 104.
Reagents and Conditions: (i) Diet PD 104, BBS pH 8.0, 37 °C, 1 h.
The insertion of the PD moiety was confirmed by SDS-PAGE, LCMS and UV-Vis analysis
(Figure 3.17). The conjugate was obtained in high purity in > 95% yield.
Having optimised the conjugation reaction with model compound Diet PD 104, it was
then decided to try these conditions with more relevant “clickable” PDs (vide supra,
Figure 2.3, page 51).
FabHer was therefore reduced to reduced FabHer 136 and re-bridged using the optimised
conditions developed. The excess of unbound small molecules was removed by diafiltration
to give “clickable” FabHer-Azal 137a, FabHer-Pazal 137b, FabHer-Alkac 137d, FabHer-
Astra 137c, FabHer-Solastra 137e, FabHer-BCN-Astra 137f and FabHer-BCN-Mestra
20000 25000 30000 35000 40000 45000 50000 55000 60000
Chapter 3. Antibody, Antibody Fragment and Protein Modification 70
(a)
25
30
40
50
60
80
100
150
250
1 (b)  
m/z
800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500 1550 1600 1650 1700 1750 1800 1850 1900 1950
%
0
100 13671329
1293
1259
1227
1196
1167
1407
1450
1495
1451
1544
1595
1650
1709
(c)
mass
%
0
100
47455.00
47917.00
Figure 3.17: (a) SDS-PAGE of FabHer-Diet 131. Lane 1 –FabHer-Diet 131;
(b) Non-deconvoluted and (c) deconvoluted LCMS data for FabHer-Diet 131.
137g (Scheme 3.10), from PDs 61, 69, 81, 79, 85, 98 and 121 respectively (vide supra,
Figure 2.3, page 51).
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Scheme 3.10: Modification of FabHer with PDs 61, 69, 81, 79, 85, 98 and 121.
Reagents and Conditions: (i) TCEP, BBS pH 8.0, 37 °C, 1.5 h; (ii) PD, BBS pH 8.0,
37 °C, 1 h.
Pleasingly, the optimised conditions translated well with more complex PDs. Analysis
by LCMS, UV-Vis and SDS-PAGE confirmed that “clickable” FabHer-PDs 137 were
obtained in 90 – 99% yields in high purity without the need for lengthy purification or
separation (Figure 3.18 and Appendix A.3).
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Figure 3.18: Typical SDS-PAGE and LCMS data for FabHer-PD 137.
(a) SDS-PAGE of FabHer-Solastra 137e. Lane 1 –FabHer-Solastra 137e;
(b) Non-deconvoluted and (c) deconvoluted LCMS data for FabHer-Solastra 137e.
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3.4.2 Rituximab
In order to show the compatibility of the method with Fab fragments from other antibodies,
Fabrit 123 was modified following the same procedure with Diet PD 104. SDS-PAGE and
LCMS analysis revealed clean and complete conversion to the corresponding conjugate
(Figure 3.19).
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Figure 3.19: (a) SDS-PAGE of Fabrit-Diet 183. Lane 1 –Fabrit 123; 2 –Fabrit-Diet
183; (b) Non-deconvoluted and (c) deconvoluted LCMS data for Fabrit-Diet 183.
3.5 Conjugation with monobromo PDs
As free cysteines are extremely rare in proteins35 and since the thiol side chain has the
highest nucleophilicity of all proteinogenic groups at physiological conditions,25 it is a very
popular target for the selective and site-specific modification of proteins.198 Moreover,
with the possibility of facile cysteine introduction by site-directed mutagenesis, this is a
leading approach. The most popular strategy for labelling the thiol moiety of cysteine
residues is their alkylation with maleimides to form thioether-succinimides.38–40,198
As PDs offer a distinct reaction profile when compared with other standard cysteine-
reactive reagents (vide supra, section 1.2.2, page 4), modification of single-cysteine-
containing proteins was investigated.
Cysteine modification with mBr-Diet PD 103 has been previously described.52 It was
used as a model compound to modify a single cysteine mutant (L111C) of the SH2
domain of the Grb2 adapter protein 138 (Scheme 3.11).51
To make this approach modular and to further exemplify the use of monobromo PDs
on other proteins and with PDs with reactive handles, conjugation on a single cysteine
47351 
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Scheme 3.11: Conjugation to Grb2L111C described by Chudasama et al.52
Reagents and Conditions: (i) mBr-Diet PD 103, PBS pH 8.0, 37 °C, 16 h.
mutant (S147C) of GFP was investigated.199 Initially, single cysteine mutant GFPS147C
140 was incubated with mBr-Diet PD 103 in sodium phosphate buffer (pH 8.0) for 1 h
at 37 °C (Scheme 3.12).
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Scheme 3.12: Modification of GFPS147C 140 with mBr-Diet PD 103.
Reagents and Conditions: (i) mBr-Diet PD 103, PBS pH 8.0, 37 °C, 1 h.
As expected, LCMS analysis confirmed that this proceeded with complete conversion
and afforded GFP-derivative 141 (Figure 3.20).
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Figure 3.20: (a) Non-deconvoluted and (b) deconvoluted LCMS data for GFP-Diet
derivative 141.
Following these encouraging results with model compound mBr-Diet PD 103, it was
decided to expand the scope of this conjugation method and to appraise the protocol
with “clickable” mBr-Azal PD 100 (vide supra, Figure 2.3, page 51). Thus, GFPS147C
29503 
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140 was incubated with 10 equivalents of mBr-Azal PD 100 in PBS pH 8 with 5% DMF
for 1 h at 37 °C (Scheme 3.13).
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Scheme 3.13: Modification of GFPS147C 140 with mBr-Azal PD 100.
Reagents and Conditions: (i) mBr-Azal PD 100, PBS pH 8.0, DMF, 37 °C, 1 h.
Gratifyingly, SDS-PAGE and LCMS analysis confirmed that this proceeded with complete
conversion and afforded GFP-Azal 142 (Figure 3.21).
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Figure 3.21: (a) SDS-PAGE of GFP-Azal 142. Lane 1 –GFPS147C 140; 2 –GFP-Azal
142; (b) Non-deconvoluted and (c) deconvoluted LCMS data for GFP-Azal 142.
3.6 Conclusion
Methods for the successful attachment of PDs to either single cysteines or disulfide bonds
have been developed. They have been optimised with model compounds Diet PD 104 and
mBr-Diet PD 103 to give PD-conjugates in high yields, in high purity and in excellent
homogeneity. The reaction conditions used are mild, rapid and limit greatly disulfide
scrambling when used in challenging multi-disulfides systems such as IgG1s.
Following the optimised protocols, conjugates have then been successfully prepared by
attaching monobromo and dibromo-PDs (vide supra, Figure 2.3, page 51) to antibodies
19, 122, antibody fragments 127, 123 and a single cysteine mutant of GFP 140. These
conjugates are readily “clickable” and can be functionalised with various modalities.
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Chapter 4
Functionalisation of the
PD-modified Conjugates
4.1 Introduction
The term “theranostic” is defined as a biological entity (e.g. bioconjugate) that combines
the modalities of therapy and diagnostic imaging.200,201 Instead of using two separate
conjugates for two related objectives, theranostics combine these features into one
platform. As the payloads will reach the target simultaneously, this has the potential to
alleviate undesirable differences that exist between distinct therapeutic and imaging agents
(e.g. biodistribution, selectivity).202–204 There are plentiful opportunities in multimodal
imaging and theranostics, which can be made available through a dual-click approach by
attachment of a fluorophore and a radiolabel or cytotoxic drug, respectively.200,205,206
Furthermore, this method allows for the construction of novel ADC fragment-based
products. In terms of therapeutics, antibody fragments offer potential advantages over
full antibodies (e.g. fragments are smaller and offer greater tissue penetration; many lack
the antibody Fc region and can therefore be expressed in bacterial cell lines as there is no
requirement for post-translational glycosylation).61,207–209 However, antibody fragments
below the ca. 60 – 70 kDa size cut-off for glomerular filtration lack the stability afforded
by the antibody Fc region; therefore, they often have a lifetime in blood serum below
what is required to elicit a beneficial therapeutic effect without intensive and frequent
therapy.209–214
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It was envisaged that the technology developed in this project would allow antibody
fragment-based therapeutics to be far more accessible by delivering long lifetime antibody
fragment–drug conjugates (FDC). This could be achieved by the attachment of an
antibody fragment to: (i) a suitable toxic drug; and (ii) a blood serum-stabilising
functionality (e.g. PEG, albumin or albumin-binding functionality) to increase lifetime
in vivo, using the dual-click approach. It would generate an ideal “ADC” that would
benefit from all the advantages of antibody fragments with an increased half-life and
stability. Moreover, as the chemistry allows for the controlled stoichiometric addition of
each moiety, it would allow for the construction of well-characterised products.
4.2 “Clickable” molecules for functionalisation of PD-
Conjugates
In order to optimise the conditions for the functionalisation of the “clickable” proteins
prepared, suitable “clickable” components on which to evaluate the technology needed to
be selected. In addition to being biologically relevant, these components should ideally
be commercially available or easily prepared and water-soluble; they should also enable
facile reading of their loading by a means other than LCMS which is often challenging
on full antibody or with polymers. Moreover, their molecular weights should cover a
broad spectrum (i.e. from small molecule size to protein size: below 1 kDa to more than
10 kDa) to best explore the scope of the click conjugation.
Anti-cancer drug doxorubicin (Dox 143) has been previously used as a cytotoxic model
payload; it has a relatively distinctive absorbance maximum at 495 nm which facilitates
determination of drug-to-antibody ratios (DAR) by UV-Vis absorption.192 As such, Dox
was chosen as the cytotoxic platform (Figure 4.1).
To appraise the effectiveness of the dual-click approach on a full antibody scaffold,
where accurate mass spectrometry analysis is limited, a second light absorbing moiety
that absorbs at a wavelength sufficiently distinct to Dox’s was needed to enable facile
analysis by UV-Vis of the loading of each cargo. To this end, a commercially available,
clickable, water-soluble, cyanine-based fluorophore with a maximum absorbance at 646 nm
(sulfo-Cy5 145) was selected (Figure 4.1).
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Finally, to expand the scope of the dual-click approach to high molecular weight payloads,
a commercially available life extension module comprised of a 20 kDa water-soluble PEG
chain functionalised on one end with an azide and, on the other, with an unreactive
methyl group was selected (Figure 4.1). In addition to enabling facile analysis by SDS-
PAGE, the choice of the 20 kDa PEG 144 was motivated by the fact that its effects
on half-life are well-characterised in vivo. Indeed, attachment of such PEGs can endow
proteins with many desirable attributes, such as improved circulating half-life in vivo and
also enhanced water-solubility, reduced immunogenicity, enhanced proteolytic resistance
and improved thermal and mechanical stability without significantly compromising the
penetration ability of a Fab fragment.64,215–218
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Figure 4.1: Molecules used to appraise the dual-click approach.
4.2.1 Synthesis of “clickable” doxorubicin
As Dox 143 did not have a commercially available “clickable” analogue, it had to be
prepared. The derivative should ideally be water-soluble; thus, it was decided to prepare
acid PEG4−N3 146 to incorporate an azide handle and to increase water-solubility of
the final “clickable” molecule.
Azide 64 was converted to acid 146 which was then reacted with Dox 143 using HBTU as
coupling agent. This afforded “clickable” Dox 147 in good overall yield (Scheme 4.1).155
4.2.2 Synthesis of water-soluble tetrazines
Some of the tetrazines with the fastest kinetics can undergo rapid 1,4 additions with
nucleophiles such as H2O and are therefore not suitable for conjugation on proteins.219
To alleviate this issue, a variety of water-compatible tetrazines with reduced reactivities
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Scheme 4.1: Reagents and Conditions: (i) Tert-butyl bromoacetate, NaOH,
toluene/H2O, rt, 16 h; (ii) Dox 143, HBTU, DIPEA, DMF, rt, 3 h.
have been developed. While being still highly reactive towards bicyclononynes (BCNs)
89,176,177 pyrimidinyl-substituted tetrazine 150 has been shown to remain stable in
aqueous buffer for extended period of time.220,221 Nevertheless, it is not soluble in water
above 0.2mm.222 To explore further this bioorthogonal reaction with BCNs, derivatives
with increased solubility were prepared.
Tetrazine 150 was synthesised following a procedure described by Chen et al.220 Hydrazine,
4-cyanobenzoic acid and 2-pyrimidinecarbonitrile where reacted to give a dihydrotetrazine
which was oxidised by NaNO2 to yield pyrimidinyl-substituted tetrazine 150 in 8% yield
(Scheme 4.2). This low yield can be explained by the challenging separation of the
statistical mixture of symmetrical and unsymmetrical by-products formed during the
reaction (vide infra, Appendix A.2, page 112).220
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Scheme 4.2: Reagents and Conditions: (i) Hydrazine hydrate, EtOH, reflux, 2 h;
(ii) NaNO2, AcOH, 10 °C, 10 min.
Acid 150 was then activated with NHS and reacted with diamine PEGs of various lengths
(NH2−PEG4−NH2 82, NH2−PEG18−NH2 184 and NH2−PEG38−NH2 185) to yield
tetrazines 152a–c in 41%, 71% and 26% yield respectively (Scheme 4.3).
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Scheme 4.3: Reagents and Conditions: (i) NHS, EDC, pyridine, DMSO, 40 °C, 3 h;
(ii) 82, 184 or 185, pyridine, DMSO, rt, 24 h.
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With this small library of “clickable” reagents available, copper(I)-catalysed Azide–Alkyne
Cycloaddition (CuAAC), Strain-Promoted Azide–Alkyne Cycloaddition (SPAAC) and
Strain-Promoted Alkyne–Tetrazine Cycloaddition (SPATC) protocols were developed
and optimised for the generation of dually functionalised constructs.
4.3 Copper-free functionalisation
4.3.1 SPATC — Tetrazines
Using FabHer-BCN-Mestra 137g as the “clickable” protein model and tetrazine 152a as
the tetrazine model, SPATC conditions were optimised. It was found that incubation for
1 h at room temperature of 5 equivalents of tetrazine 152a was sufficient to convert 137g
to clicked FabHer 153 in near quantitative yield and in high purity (Scheme 4.4). The
buffer used and pH (6.2 – 8.0) were found to have no measurable impact on the reaction.
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Scheme 4.4: Modification of FabHer-BCN-Mestra 137g with tetrazine 152a.
Reagents and Conditions: (i) Tetrazine 152a, DMSO, PBS pH 7.0, rt, 1 h.
Unfortunately, upon repeating this reaction after storage of the stock solution of BCN-
Mestra PD 121 kept at −20 °C in DMSO for a week, only a partial conversion to 153
was observed. An additional fragment which mass corresponds to FabHer-BCN-Mestra
137g + ca. 32 was observed by LCMS, which indicates degradation of the BCN residue
overtime upon storage (Scheme 4.5).
This side product has been previously observed and it was suggested that over time, the
small amount of molecular oxygen present in the stock solution would react with the
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Scheme 4.5: Modification of degraded FabHer-BCN-Mestra 137g with tetrazine 152a.
Reagents and Conditions: (i) Tetrazine 152a, DMSO, PBS pH 7.0, rt, 1 h.
strained alkyne to give the corresponding cyclooctanedione.223–225 Although an LC-MS
analysis with increased resolution would be needed to confirm this hypothesis, this could
explain the lack of reactivity with a highly reactive tetrazine.
4.3.2 SPAAC — Cyclooctynes
4.3.2.1 Bicyclo[6.1.0]nonyne (BCN)
FabHer-BCN-Mestra 137g was also used as the “clickable” protein model with azide
NH2−PEG4−N3 119 as the azide model. Similarly, conditions for SPAAC were optimised.
It was found that incubation for 3 h at room temperature of 5 equivalents of azide 119
was sufficient to convert 137g to clicked FabHer 155 in near quantitative yield and
in high purity. Here again, the buffer used and pH (6.2 – 8.0) were found to have no
measurable impact on the reaction. Unfortunately, and as expected, the same degradation
pathway was observed and a mixture of products was obtained when the stock solution
of BCN-Mestra PD 121 was not prepared freshly before use (Scheme 4.6).
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Scheme 4.6: Modification of degraded FabHer-BCN-Mestra 137g with azide 119.
Reagents and Conditions: (i) Azide 119, DMSO, PBS pH 7.0, rt, 3 h.
4.3.2.2 Monofluorosubstituted Cyclooctyne (MFCO)
In view of the limitations of BCN-base PDs and in spite of the slower kinetics associated
with MFCOs, it was decided to focus on Solastra PD 85 as the bridging platform. It
was hypothesised that the lower reativity of 85 would limit its degradation in organic
solvent and therefore allow for more consistent results between repeats.
Thus, click reactions on the strained alkyne 137e were also conducted in various buffers,
at different pHs, and at various temperatures using model azide 119. In the presence of 5
equivalents of “clickable” molecule, the conversion of FabHer-Solastra 137e was complete
in 6 h at room temperature (Scheme 4.7). The pHs and buffers tested (PBS pH 6.8 and
BBS pH 8) did not have a measurable impact on the outcome or the rate of the reaction.
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Scheme 4.7: Modification of FabHer-Solastra 137e with azide 119.
Reagents and Conditions: (i) Azide 119, DMF, PBS pH 7.0, rt, 1 h.
Gratifyingly, PD 85 was stable in DMF at −20 °C over an extended period of time.
Indeed, repeating the reaction with the same stock solution of bridging molecule two
months later resulted in the same outcome (Figure 4.2).
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Figure 4.2: (a) Non-deconvoluted and (b) deconvoluted LCMS data for FabHer-Solastra-
PEG4 137e after 2 months of storage of 85 in DMF.
4.4 Copper-catalysed functionalisation
Two ligands (TCEP and THPTA) in acetate, phosphate and borate buffers, at different
pHs (5 – 8.5) and at various temperatures (4 °C, 21 °C or 37 °C) were evaluated for the
CuAAC of the model PEG4-azide 119 on alkyne FabHer-Alkac 137d. It was found that
500 µm of THPTA (ca. 10 eq.), 100 µm of CuSO4 (ca. 2 eq.), and 5mm sodium ascorbate
were sufficient for the reaction to reach completion at room temperature within 1 h when
at least 5 equivalents of “clickable” molecule were used (Scheme 4.8). When TCEP was
used as a ligand or when no ligand was used, no reaction was observed. The pH did
not have a measurable impact on the outcome or the rate of the reaction and the only
requirement for the buffer was the strict absence of EDTA; indeed, EDTA would inhibit
the reaction by complexing copper.
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Scheme 4.8: Modification of FabHer-Alkac 137d with azide 119.
Reagents and Conditions: (i) Azide 119, CuSO4, THPTA, sodium ascorbate, PBS pH
7.0, rt, 1 h.
Alternatively, a protocol where Cu(I)Br was used instead of generating the Cu(I) source
from CuSO4/sodium ascorbate, was developed for proteins where the Cu(II)-based
protocol failed to result in full conversion (vide infra, section 5.4.4, page 94).
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4.5 Dually functionalised proteins — Proof of concept
With both the conditions for CuAAC and SPAAC in hand, it was decided to prepare a
dually functionalised FabHer. As modification via Azal PD 61, Pazal PD 69 and Solastra
PD 85 (vide supra, Figure 2.3, page 51) proved to be equally facile, at this juncture it
was decided to proceed with Solastra PD 85 only owing to the commercial availability of
a large library of modalities bearing an azide handle.
Thus, starting from FabHer-Solastra 137e, PEG4-azide 119 and sulfo-Cy5 145 were
sequentially clicked onto the conjugate using SPAAC to give FabHer-Solastra-PEG4 156
quantitatively, followed by CuAAC with sulfo-Cy5 145 resulting in dually modified FabHer-
Solastra-PEG4-Cy5 158. The reaction was followed by LCMS and complete and clean
conversion of FabHer-Solastra 137e to dually functionalised FabHer-Solastra-PEG4-Cy5
158 was observed (Scheme 4.9).
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Scheme 4.9: Dual functionalisation of Fab-pyridazinedione conjugate 137c.
Reagents and Conditions: SPAAC (i) Azide 64, BBS pH 8.0, rt, 6 h; CuAAC (ii) Cy5
derivative 145, CuSO4, THPTA, sodium ascorbate, PB pH 7.0, rt, 1 h.
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4.5.1 Antibody Fragment–Drug Conjugate (FDC)
A dually modified Fab with both a half-life extension moiety and a cytotoxic agent
is a highly valuable target (vide supra, sections 1.4, page 11 and 4.1, page 74); the
construction of such a conjugate was therefore of interest. As such, a clinically relevant
FDC preparation was attempted.
FabHer-Solastra 137e was sequentially modified with PEG20k 144 by SPAAC followed by
CuAAC with doxorubicin derivative 147. Gratifyingly, the final conjugate was analysed
by UV-Vis and SDS-PAGE and revealed clean conversion to the desired product FabHer-
Solastra-PEG20k-Dox 159 (Figure 4.3). This further demonstrates the flexibility of this
chemistry to allow for the facile attachment of large constructs such as a PEG20k 144
moiety.
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Figure 4.3: SDS-PAGE analysis of FabHer-PEG20k-Dox 159. Lane 1 – Ladder; 2 – FDC;
3 –FabHer.
4.5.2 Antibody–drug conjugate — Theranostics
A theranostic based on a dually modified antibody with both a fluorophore and a cytotoxic
agent is also a highly valuable target (vide supra, section 4.1, page 74). As a proof of
concept, the preparation of a theranostic based on doxorubicin and Cy5 was attempted.
Her-Solastra 134b was sequentially modified with doxorubicin derivative 147 by SPAAC
followed by CuAAC with sulfo-Cy5 145. As the four components of the reaction (i.e.
the antibody, the PD moiety, doxorubicin and sulfo-Cy5) have a maximum of absorption
at four distinct wavelengths (λmax = 280, 340, 495 and 646 nm respectively), the reaction
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could easily be followed by UV-Vis and the loading of each payload could be measured
at every step of the protocol (vide infra, appendix A.1.8, page 108). Gratifyingly, the
analysis by UV-Vis and SDS-PAGE of the final conjugate revealed clean conversion to the
desired product Her-Solastra-Dox-Cy5 161. UV-Vis also revealed a drug loading of ca. 4
per antibody and a fluorophore loading of ca. 4 per antibody consistent with modification
of the four disulfides of the antibody with complete conversion of the “clickable” handles
to their corresponding module (Scheme 4.10).
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Scheme 4.10: Dual functionalisation of Her-Solastra 134b with 147 and 145.
Reagents and Conditions: SPAAC (i) Doxorubicin derivative 147, BBS pH 8.0, rt, 6 h;
CuAAC (ii) Cy5 derivative 145, CuSO4, THPTA, ascorbate, PB pH 7.0, rt, 1 h.
4.6 Conclusion
Both Copper(I)-catalyzed Azide–Alkyne Cycloaddition (CuAAC) and Strain-Promoted
Cycloaddition protocols were developed and optimised for the generation of dually
functionalised constructs based on native antibody and antibody fragment. By clicking
the reactive handles on the PD conjugate with a series of “clickable” PEG-azide (e.g.
PEG4 64 and PEG20k 144), fluorophores and/or cytotoxic construct (e.g. doxorubicin-
azide 147), functionalised proteins were prepared in a selective, rapid and efficient manner.
As the functionalisation via this dual-click approach is distal from the antigen-binding
site of the proteins modified, it was envisaged that the impact on the activity would be
minimal, therefore allowing for a plethora of applications.
Her-Solastra Her-Solastra-Dox
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Activity and Stability of
PD-Conjugates
5.1 Introduction
The most popular strategy for labelling the thiol moiety of cysteine residues is by alkylation
with maleimides to form thioether-succinimides.38–40,198 However, it has recently come
to light that such an appendage is suboptimal, owing to issues of hydrolysis and thiol
exchange with reactive thiols in the blood (e.g. albumin).112–114 Indeed, the succinimide
169 obtained upon reaction can revert back to maleimide and free thiol 168 via a
retro-Michael pathway (Figure 5.1).
Hydrolysis
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Figure 5.1: Albumin reaction with maleimide.
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The lack of control over these reactions poses thorny reliability issues when it comes to
the development of therapeutically relevant conjugates as the construct may not reach
the target intact or as expected. This has major implications for therapeutics that employ
a maleimide motif to functionalise a protein thiol for in vivo applications. For example,
in ADCs, the use of maleimides to attach cytotoxic drugs to an antibody is not ideal as
thiol exchange onto human serum albumin in the blood can result in lowered activity
and/or off-target toxicity.113,226,227 Although recent advances have been made in this
area through the use of hydrolysed maleimides and succinimides,113–117 a strong drive to
develop novel reagents for reliable, chemoselective, stable and irreversible thiol labelling
remains, particularly for the construction of ADCs.228,229
Indeed, the ADC is exposed to different conditions whilst circulating in the blood.
The mode of action at cellular or molecular level is complex, with each step adding an
additional layer of difficulty. Thus, several factors, activity and stability-related, are key
when designing an ADC:230
• Circulation. The ADC must behave like a naked antibody when circulating in
the plasma. In particular, the linker must be stable in the bloodstream to limit
damage to healthy tissue. Decomposition or decay would release the cytotoxin
before being delivered to the target site and result in off-site toxicity.
• Antigen Binding. It is necessary that the conjugated antibody retains high
immunoaffinity. Ideally, attaching the cytotoxic compound to the antibody should
not disturb its binding specificity.
• Internalisation. A sufficient intracellular concentration of the drug must be
achieved. This is challenging because antigen targets on cell surfaces are often
present in limited numbers and the internalisation process for antigen-antibody
complexes is frequently inefficient.
• Cytotoxicity. The inherent potency of the released drug must be sufficient to kill
the tumor cell, even at low concentration. To achieve significant cytotoxicity, use of
very potent drugs with subnanomolar IC50 (as free drug) becomes necessary. It has
been shown that compounds found to be too toxic when tested as a stand-alone
chemotherapy agent are suitable candidates for ADC payloads. These toxins can
be 100 to 1000 times more cytotoxic than traditional anticancer agents.
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It has also been shown that for most ADCs, overall efficacy is hindered by linker
instability79,231–234 and compositional heterogeneity.89,91,232–234 In this context, the
selectivity, stability and activity of the PD-based conjugates were investigated.
5.2 Selectivity
To demonstrate the selectivity towards thiols of PDs on a small molecule model,
monobromo Diet PD 103 and dibromo Diet PD 104 were incubated with lysine. After
72 h of incubation at 20 °C in a THF/BBS pH 8.0 mixture with a stoichiometric amount of
the amino acid, the reaction was analysed and no trace of addition product was observed
thus confirming the exquisite selectivity of PDs towards thiols over amines (Scheme 5.1)
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Scheme 5.1: Reagents and Conditions: (i) l-lysine, THF/BBS pH 8.0, 20 °C, 72 h.
5.3 Stability of dibromo PD-based conjugates
5.3.1 Hydrolytic stability in buffered solutions
FabHer-Diet 131 was used as a model to assess the hydrolytic stability of the PD
constructs. It was buffer-exchanged into solution with pHs of 3.1 and 9.0 and the
conjugate was incubated at 37 °C for 24 h. To assess its hydrolytic stability over an
extended period of time, FabHer-Diet 131 was also incubated in PBS at 4 °C for 8 months.
Gratifyingly, LCMS and SDS-PAGE analysis revealed that the conjugate had exceptional
hydrolytic stability as no trace of hydrolysis was observed for the range of conditions
tested (Figure 5.2).
Similarly, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 were subjected to the
forcing conditions described above for FabHer-Diet 131. SDS-PAGE analysis revealed
that the conjugates showed no degradation for the range of conditions tested (Figure 5.3).
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Figure 5.2: (a) SDS-PAGE of FabHer-Diet 131. Lane 1 –FabHer-Diet 131; 2 –After 8
months of storage at 4 °C in PBS; 3 –After 24 h at 37 °C in buffer pH 3.1; 4 –After 24 h
at 37 °C in buffer pH 9.0; (b) Deconvoluted LCMS data for lane 2; (c) Deconvoluted
LCMS data for lane 3; (d) Deconvoluted LCMS data for lane 4.
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Figure 5.3: (a) SDS-PAGE analysis of FabHer-PEG20k-Dox 159. Lane 1 – after two
months of storage at 4 °C in PBS; 2 –After 24 h at 37 °C in buffer pH 3.1; 3 –After 24 h
at 37 °C in buffer pH 9.0; (b) SDS-PAGE analysis of Her-Solastra-Dox-Cy5 161. Lane
1 – after two months of storage at 4 °C in PBS; 2 –After 24 h at 37 °C in buffer pH 3.1;
3 –After 24 h at 37 °C in buffer pH 9.0.
5.3.2 Stability towards thiol exchange
Dibromopyridazinediones were also tested for potential thiol exchange with glutathione
(GSH), a small molecule present at an average concentration of 5 µm in blood plasma
and of 1 – 10mm in the cytoplasm of mammalian cells.235
To demonstrate stability in blood plasma, FabHer-Diet 131 was buffer exchanged into a
simulated body fluid solution (SBF)236 by repeated diafiltration into fresh buffer. Then,
human serum albumin (HSA) (final concentration 600 µm) and GSH (final concentration
20µm) were added. The solution was incubated at 37 °C for 7 days. The reaction was
monitored by SDS-PAGE (Figure 5.4) and the analysis revealed no trace of reaction of
47822
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conjugate 131 with GSH (expected resulting mass ca. 23 kDa) or with HSA (expected
resulting mass ca. 90 kDa).
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Figure 5.4: SDS-PAGE gel following incubation of FabHer-Diet 131 in blood plasma
mimicking conditions for 0, 1, 2, 3, 5 and 7 days (lanes 1 – 6 respectively).
Similarly, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 were incubated in a
SBF for 7 days. SDS-PAGE analysis revealed that the conjugates showed no trace of
unwanted reaction with GSH or HSA (Figure 5.5).
(a)
250
130
100
70
55
35
25
1 2 3 4 5
HSA-HSA
HSA
no HSA-FabHer
no GSH-FabHer
chain
Conjugate
no HSA-FabHer
chain
(b)
250
130
100
70
55
35
25
1 2 3 4 5
HSA-HSA
HSA
no GSH-Her
fragment
Her-conjugate
no GSH-Her
fragment
no HSA-Her
fragment
Figure 5.5: (a) SDS-PAGE gel following incubation of FabHer-PEG20k-Dox 159 in
blood plasma mimicking conditions for 0, 1, 3, 5 and 7 days (lanes 1 – 5 respectively);
(b) Her-Solastra-Dox-Cy5 161 in blood plasma mimicking conditions for 0, 1, 3, 5 and 7
days (lanes 1 – 5 respectively).
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Interestingly, when FabHer-Diet 131 was incubated at 37 °C in the presence of a
intracellular relevant concentration of thiol e.g. 1mm GSH, LCMS analysis showed
no trace of GSH-exchange after 4 h but when incubated for a further 12 h, FabHer-Diet
131 reverted back to unmodified FabHer 127. This feature can potentially be used to
form the core of novel prodrug systems where the drug in only released when internalised
inside a diseased cell.52,57
5.4 From reversible to irreversible cysteine modification
During the course of developing bromopyridazinediones for reversible cysteine conjugation
(vide supra, section 5.3.2, page 88), the prospect of pyridazinediones (PDs) as irreversible
cysteine functionalisation reagents was explored. Previously, Chudasama et al. showed
that if one of the nitrogen atoms on the PD core is unsubstituted, the molecule does not
react with thiols at physiological pH (or higher).52 It was postulated that this lack of
reactivity is a consequence of such a structure existing as its enol-like tautomer, which is
likely to be significantly deprotonated under physiological pH (or higher). Indeed, the
reported pKa of 1-methyl-3,6-(1H,2H )-pyridazinedione is ca. 5.7 in H2O and the calculated
pKa of its thioether analogue, 1-methyl-4-(methylthio)-3,6-(1H,2H )-pyridazinedione is ca.
5.9.237–239 Thiol reactivity will therefore be greatly reduced as the electrophilicity of the
resulting PD-core moiety will be tuned down considerably. As such, the development of a
strategy that would enable the generation of a mono-alkylated PD species post-conjugation
to a cysteine thiol to afford a thiol-stable construct was set about (Figure 5.6).
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Figure 5.6: General strategy towards irreversible cysteine modification.
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5.4.1 Strategy
The appraisal of this strategy began with the reaction of model protein GFPS147C 140
with PDs 102 and 173 to confirm observations by Chudasama et al. when using protein
Grb2L111C 138 (Scheme 5.2).52,199 These results were consistent with previously reported
work and confirmed that a mono-alkylated PD is unreactive to thiols (or other nucleophilic
functional groups on amino acid side-chains).
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Scheme 5.2: Incubation of GFPS147C 140 with PD 102 and monoalkylated PD 173.
Reagents and Conditions: (i) PBS pH 8.0, 37 °C, 1 h; (ii) PBS pH 8.0, 37 °C, 72 h.
These initial studies paved the way to appraise the use of a novel strategy to develop
irreversible pyridazinedione conjugates (Figure 5.6). To achieve this goal, a selective
method for cleavage of R2 from the PD core was needed. Although many strategies could
have been applied, it was decided, at this juncture, to take the opportunity to develop a
novel, mild and simple method based on an azide trigger.
The desire to use an azide-based cleavable handle originates from the bioorthogonality
of the azide functional group. Taking inspiration from the well-documented work on
p-aminobenzyloxycarbonyl (PABC) linkers,240 a p-azidobenzyl cleavage strategy was
developed (Scheme 5.3).
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Scheme 5.3: Use of a p-azidobenzyl cleavage strategy to generate a PD-based thiol-
stable conjugate.
5.4.2 Small molecule study
Initially the p-azidobenzyl cleavage strategy was evaluated in a small molecule study
through the use of cysteine derivative 175. The stability of cysteine derivative 175 was
first appraised. It was prepared in high yield by reacting N -(tert-butoxycarbonyl)-l-
cysteine methyl ester 186 with mBr-Azal PD 100 in the presence of NEt3. Cysteine
derivative 175 was then incubated with 15 equivalents of 1-hexanethiol in THF/PBS
buffer (pH 7.4) which led to thiol exchange and yielded PD derivative 176 in 71% yield
(Scheme 5.4).
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Scheme 5.4: Reagents and Conditions: (i) Thiol 186, CH2Cl2, rt, 2 h; (ii) 1-Hexanethiol,
THF/PBS at pH 7.4, rt, 72 h.
The cleavage strategy was then assessed by treating PD 175 with TCEP. Gratifyingly,
this led to clean conversion to derivative 177, thus providing proof of concept for this
novel cleavage strategy. Moreover, incubation of derivative 177 with 15 equivalents of
1-hexanethiol in THF/PBS buffer (pH 7.4) did not lead to thiol exchange (Scheme 5.5).
This provided support for the hypothesis of a mono-alkylatedPD being thiol unreactive
under physiological pH or higher (vide supra, Scheme 5.2, page 91).
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Scheme 5.5: Reagents and Conditions: (i) TCEP, DMF, rt, 2 h; (ii) 1-Hexanethiol,
THF/PBS at pH 7.4, rt, 72 h.
5.4.3 Protein study
Following these encouraging results on a small molecule study, the strategy was appraised
on model protein GFPS147C 140. Initially, GFPS147C 140 was incubated with mBr-Azal
PD 100 in PBS (pH 8.0) for 1 h at 37 °C. This proceeded with complete conversion and
afforded GFP-Azal 178 (Scheme 5.6). Next, the TCEP cleavage strategy was applied by
incubating this derivative with 10 equivalents of TCEP in PBS pH 8.0. Satisfyingly, clean
conversion to conjugate 179 was observed, which is consistent with the small molecule
study results (Scheme 5.6 and Figure 5.7).
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Scheme 5.6: Appraisal of cleavage strategy on GFP-Azal 178.
Reagents and Conditions: (i) TCEP, PBS pH 8.0, 37 °C, 1.5 h; (ii) GSH, PBS at pH 7.4,
37 °C, 72 h.
Having established that this cleavage strategy is applicable on a protein, the thiol
stability of GFP-Azal 178 and conjugate 179 was then compared by incubation with
GSH (0.5mm) for 72 h in PBS pH 7.4 and at 37 °C. Gratifyingly, GFP-derivative 179
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was completely stable under the reaction conditions, whereas derivative 178 showed
complete thiol exchange with glutathione (Scheme 5.6).
It is also noteworthy that analysis by LCMS revealed that no hydrolysis occurred under
these conditions, which is consistent with previous observations on the PD core being
hydrolytically stable (Figure 5.7). This therefore validated the cleavage strategy on a
model protein scaffold.
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Figure 5.7: (a) Deconvoluted LCMS data for GFP-Azal 178;
(b) Deconvoluted LCMS data for alkyne 179.
5.4.4 Functionalisation
The use of an alkyne handle, which is retained post p-azidobenzyl cleavage, allows for the
resulting construct to be readily functionalised by CuAAC. Thus, protein scaffold 179
was functionalised by the use of click chemistry. The optimised conditions previously
developed were trialled using benzyl azide as the model azide (vide supra, section 4.4,
page 81). The most promising conditions were the use of Cu(I)Br as copper source with
THPTA as ligand. These conditions gave complete conversion of starting material alkyne
179 to triazole conjugate 180a. Moreover, these conditions allowed for clean reaction of
the alkyne derivative with dansyl azide 162 and sulfo-Cy5 145 to afford 180b and 180c,
respectively (Scheme 5.7 and Figure 5.8). This strategy also highlights the versatility of
the PD platform with a facile shift from reversible to irreversible constructs achieved
under mild conditions.
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Scheme 5.7: Functionalisation of alkyne 179.
Reagents and Conditions: (i) Cu(I)Br/MeCN, THPTA, PBS pH 8.0, 37 °C, 4 h.
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Figure 5.8: (a) Deconvoluted LCMS data for benzyl derivative 180a;
(b) Deconvoluted LCMS data for dansyl derivative 180b;
(c) Deconvoluted LCMS data for Cy5 derivative 180c.
5.5 Activity
5.5.1 Binding affinity: ELISA
The impact on antibody/antigen binding of conjugating PDs to FabHer 127 was first
appraised on model FabHer-Diet 131. It was rationalised that, as the interchain disulfide
is distal from the antigen-binding site of the Fab fragment, this impact should be minimal
(vide supra, Figure 1.2, page 10). To appraise it, the binding profile of FabHer-Diet 131
around the reported value of dissociation constant (KD ' 5 nm) was evaluated against
unmodified FabHer 127 using ELISA.241 Encouragingly, comparable antigen binding was
observed across the two constructs with KD values for FabHer 127 and FabHer-Diet 131 of
5.2± 0.5 nm and 6.1± 0.6 nm, respectively; even though a broader range of concentration
could be trialled to measure the KD of the constructs prepared with better accuracy, this
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gives good indication that the conjugation does not affect the affinity of the modified
fragment (Figure 5.9).
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Figure 5.9: ELISA analysis of FabHer 127 and FabHer-Diet 131 binding to the HER2.
The impact of the dual-click sequence on both dually modified fragment FabHer-
Solastra-PEG20k-Dox 159 and full antibody Her-Solastra-Dox-Cy5 161 was then
evaluated (Figure 5.10). As expected, no significant difference was observed between
the respective binding activities across the four constructs with measured KD of
7.9± 0.8 nm and 8.2± 0.8 nm for FabHer 127 and FabHer-Solastra-PEG20k-Dox 159
respectively, and 6.3± 0.7 nm and 7.7± 0.7 nm for trastuzumab 19 and Her-Solastra-Dox-
Cy5 161 respectively; this again indicates that neither the conjugation nor the dual
functionalisation affect the affinity of the PD-modified conjugates.
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Figure 5.10: ELISA analysis of FabHer 127, FabHer-Solastra-PEG20k-Dox 159,
trastuzumab 19 and Her-Solastra-Dox-Cy5 161 binding to the HER2.
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5.5.2 Internalisation study
The effect of the conjugation chemistry on the internalising properties of trastuzumab
19 and FabHer 127 was next appraised. For this purpose, FabHer-Solastra 137e and
Her-Solastra 134b were directly conjugated to an azide derivative of AlexaFluor488 via
SPAAC to form FabHer-Solastra-AlexaFluor488 181 and Her-Solastra-AlexaFluor488
182 respectively (Figure 5.11).
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Figure 5.11: (a) SDS-PAGE of Her-Solastra-AlexaFluor488 182. Lane 1 –Her-Solastra-
AlexaFluor488 182; (b) Non-deconvoluted and (c) deconvoluted LCMS data for FabHer-
Solastra-AlexaFluor488 181.
These two constructs were then incubated with breast cancer cell lines BT-474 (HER2-
positive) and MDA-MB-468 (HER2-negative). Initially, incubation was performed at 4 °C,
a temperature allowing binding but not internalisation; analysis by confocal microscopy
revealed that Her-Solastra-AlexaFluor488 182 and FabHer-Solastra-AlexaFluor488 181
bound to BT-474 cells (Figure 5.12a) but not to MDA-MB-468 cells (Figure 5.12b),
indicating the specificity of these constructs to HER2-positive cell lines. Internalisation of
the bound antibodies occurred when the temperature was increased to 37 °C; incubation
under these conditions for 1 h resulted in cytoplasmic localisation of the labelled constructs
in BT-474 cells (Figure 5.12a), thus indicating that the chemistry employed does not
interfere with the internalising properties of trastuzumab 19 or FabHer 127.
48871
20000 25000 30000 35000 40000 45000 50000 55000
24436
Chapter 5. Activity and Stability of PD-Conjugates 98
(a) Nuclei Conjugate Actin Merge
Untreated
4 °C
37 °C
4 °C
37 °C
181
181
182
182
(b)
Untreated
4 °C
4 °C
181
182
Figure 5.12: Internalisation analysis by confocal microscopy.
(a) BT474 treated with 181 and 182; (b) MDA-MB-468 treated with 181 and 182.
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5.5.3 Cytotoxicity assay
Finally, the selectivity and cytotoxicity of constructs FabHer-Solastra-PEG20k-Dox 159
and Her-Solastra-Dox-Cy5 161 in in vitro studies, using the same HER2-positive and
negative cell lines in the microscopy studies (i.e. BT-474 and MDA-MB-468), were
evaluated. Initially, the sensitivity of both cell lines to doxorubicin was appraised to
assess their suitability in a cytotoxicity assay. A comparable reduction in cell viability was
observed for both cell lines at similar concentrations of the toxic payload (IC50 = 39nm
and 10 nm for BT-474 and MDA-MB-468 respectively), thus paving the way for toxicity
studies with doxorubicin conjugates FabHer-Solastra-PEG20k-Dox 159 and Her-Solastra-
Dox-Cy5 161 (Figure 5.13).
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Figure 5.13: Inhibition of cell proliferation in cancer cell lines with different levels of
HER2 expression, i.e. BT-474 (HER2-positive) and MDA-MB-468 (HER2-negative),
with doxorubicin 143.
Gratifyingly, BT-474 cell viability was reduced significantly when incubated with the
conjugates (IC50 = 2.8 µm and 2.1 µm for conjugates FabHer-Solastra-PEG20k-Dox 159
and Her-Solastra-Dox-Cy5 161 respectively), especially when compared to the controls of
native trastuzumab 19 and FabHer 127 where the reduction in cell survival was minimal
at high concentrations (Figure 5.14).
Additionally, highlighting the targeted delivery aspect of the work, no toxicity was
observed in analogous studies with MDA-MB-468 cells incubated with either conjugate
FabHer-Solastra-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 (Figure 5.15). This is
consistent with the observations by confocal microscopy, i.e. trastuzumab and FabHer
conjugates 182 and 181 do not appear to bind to these cells, and hence doxorubicin
could not be internalised and thereby cause a toxic effect.
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Figure 5.14: Inhibition of cell proliferation in cancer cell lines with high levels of HER2
expression with conjugates 159 and 161 (at similar concentration in doxorubicin) in
comparison with trastuzumab 19 and FabHer 127.
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Figure 5.15: Inhibition of cell proliferation in cancer cell lines with low levels of HER2
expression with conjugates 159 and 161 (at similar concentration in doxorubicin) in
comparison with trastuzumab 19 and FabHer 127.
These results clearly highlight the selectivity of conjugates 159 and 161 over doxorubicin
alone, and indicate that the toxic drug in conjugates 159 and 161 is delivered by an
HER2-dependent internalisation mechanism.
5.6 Conclusion
By assessing the selectivity, activity and stability of the conjugates in a broad range of
conditions, it was demonstrated that PD reagents and conjugates show:
• a unique and exquisite chemoselectivity towards reaction with cysteines in the
presence of all other amino acids, even under forcing conditions;
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• complete retention of binding and internalisation activity, even post-conjugation to
a large construct;
• exceptional resistance to hydrolysis at various extreme pHs and temperatures;
• tunable reactivity towards exogenous thiols: from stable in blood to irreversible in
cytoplasm.
Chapter 6
Conclusion
6.1 Summary
A series of novel pyridazinedione-based reagents with various orthogonal handles have
been synthesised in 3 – 5 scalable steps.
These molecules have shown exquisite selectivity towards cysteine thiols with no side
reactions observed even at high temperature and/or after a prolonged period of time.
The adducts generated are hydrolytically stable and have been dually functionalised,
selectively using two “click reactions” to generate a range of constructs (vide supra,
Figure 2.3, page 51).
By the introduction of PD molecules bearing orthogonal “clickable” handles into the
native disulfide bonds of antibodies, it was possible to demonstrate:
• the opportunity to synthesise multifunctionalised Fab fragments in a rapid and
facile manner;
• the complete retention of binding activity post-conjugation and functionalisation;
• the potential of the method to generate a novel Fab-based ADC candidate with
extended half-life;
• a new approach to a multifunctionalised, homogeneous full antibody to open the
door to next-generation full antibody-based drug conjugate therapeutics;
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• selective internalisation into HER2 positive cells with conjugates 181 and 182
of trastuzumab and FabHer that were directly conjugated to AlexaFluor488 via a
PD-linker;
• selective cell killing over doxorubicin alone on appropriate HER2 cell lines.
By the introduction of PD molecules into a protein with an engineered cysteine, a novel
p-azidobenzyl cleavage strategy was developed and demonstrated on both a small molecule
system and on a model protein. This resulted in a route to thiol-stable conjugates with
clear advantages over conventional conjugation chemistries (e.g. maleimides).
6.2 Future outlook
Having demonstrated the facile conjugation of PDs across various platforms and the rapid
and clean dual functionalisation of the resulting conjugates with a range of biologically
relevant molecules, an exciting next step would be to use PDs to generate clinically
relevant protein–protein conjugates. For example, this would enable the generation of
bispecific antibodies armed with cytotoxic drugs or bispecific T-cell engagers (BiTEs)
with extended half-life in vivo. One could also envisage the reconstruction of a full
antibody where a tailored Fc and two different Fabs could be attached together in a
stepwise fashion using click reactions.
Another interesting next step would be the attachment on the same targeting entity of
two drugs that operate by an orthogonal mechanism of action, which is a concept that is
gathering increasing momentum.242–245
Owing to the plethora of fields where thiol functionalisation needs to be robust and
reliable (e.g. in antibody–drug conjugates) it is believed that this work will find use in a
variety of domains where irreversible/reversible protein modification is needed.
The modular “plug-and-play” approach enabled by PDs has broader applications in
fields outside the scope of antibody modification (for example, dual warhead antibiotics,
folic acid conjugates, tetrablock polymersomes);243–246 then, one can envisage numerous
applications for such a linker technology (e.g. multi-labelling of protein conjugates,
cleavable fluorophores, radiolabels and quantum dots for imaging) with the possibility
of combining two different functions. Hence, this will potentially be a highly versatile
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platform (Figure 6.1) which could open the door to a valuable and novel range of
conjugates.
Figure 6.1: Potential applications of PD-conjugates.
Appendix A
Experimental
A.1 General experimental
A.1.1 Chemicals
All reagents were purchased from Sigma Aldrich, Alfa Aesar, Acros, Synaffix, Lumiprobe
and Avocado and used as received unless otherwise stated. Trastuzumab was purchased
from UCLH pharmacy.
A.1.2 Solvents
Solvents were used as received unless otherwise stated. Petrol refers to petroleum ether
(b.p. 40 – 60 °C).
A.1.3 Chromatography
Reaction progress was monitored by analytical TLC using Merck aluminium coated plates
covered with a 0.2mm layer of silica gel 60 F254. Product spots were visualised by UV
irradiation at 254 nm and subsequent staining with potassium permanganate solution,
followed by heating. Column chromatography was carried out with silica gel (33 – 70 µm)
supplied by VWR.
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A.1.4 Spectroscopy
1H NMR spectra were recorded at 300 MHz, 400 MHz, 500 MHz and 600 MHz and
13C NMR at 75 MHz, 100 MHz, 125 MHz and 150 MHz on Bruker AMX300, AMX400,
AMX500 and AMX600 at 25 °C as described below. The chemical shifts (δ) for 1H
and 13C are quoted relative to residual signals of the solvent on the parts per million
(ppm) scale. NMR peaks are reported as singlet (s), doublet (d), triplet (t), quartet
(q), quint. (quintet), m (multiplet), br (broad), dd (doublet of doublet). Coupling
constants (J values) are reported in Hertz (Hz) and are reported as JH-H couplings unless
otherwise stated. Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR
Spectrometer operating in ATR mode. Mass spectra were obtained at UCL on either a
VG70-SE (FAB), Thermo Finnigan MAT900Xp (EI and CI) or Waters LCT Premier XE
(ES) mass spectrometer.
A.1.5 Miscellaneous
Unless stated otherwise, all reaction mixtures were stirred magnetically. Melting points
were measured with a Gallenkamp apparatus and are uncorrected. Compound 65 was
synthesised following literature procedure and all data were consistent with literature
data.171 All reactions involving moisture sensitive techniques were performed under an
atmosphere of dry argon via standard vacuum line techniques and glassware was flame
dried and allowed to cool under reduced pressure. Within this text, room temperature is
defined as between 19 – 22 °C. Reactions described as being performed at −78 °C were
cooled by an acetone bath with submerged solid CO2 pellets. Reactions performed at
0 °C were cooled with an ice and water bath. Concentration in vacuo refers to distillation
on a Büchi rotary evaporator, and where appropriate under high vacuum.
A.1.6 General remarks on conjugation experiments
Conjugation experiments were carried out in standard polypropylene micro test tubes
3810X at atmospheric pressure with mixing at room temperature unless otherwise stated.
All buffer solutions were prepared with double-deionised water and filter-sterilised. BBS
was 25mm sodium borate, 25mm NaCl and 0.5mm EDTA at pH 8.0 unless stated
otherwise. PBS was 140mm NaCl and 12mm phosphates at pH 7.4. Ultrapure DMF
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was purchased from Sigma-Aldrich and kept under dry and inert conditions. Solutions
of TCEP 20mm were prepared in BBS. Ultrafiltration was carried out in vivaspin
500 polyethersulfone (PES) membrane concentrators with a molecular weight cut-off
(MWCO) of 10 kDa or 30 kDa. Centrifugation was carried out on an eppendorf 5415R
fixed angle rotor centrifuge operating at 14 000 rcf at room temperature. Purification by
size exclusion chromatography (SEC) was carried out on an ÄKTA Purifier HPLC system
(GE Healthcare), equipped with a HiLoad Superdex 75 16/60 column (GE Healthcare)
equilibrated in PBS, running at a flow rate of 0.5 mL/min. Detection was by absorption at
280 nm. Trastuzumab was obtained in its clinical formulation (lyophilised). The powder
was dissolved in 10mL sterile water and the buffer exchanged completely for digest buffer
(50mm phosphate, 1mm EDTA, pH 6.8) via ultrafiltration (MWCO 50 kDa, Sartorius).
The concentration after the exchange was determined by UV-Vis absorbance and adjusted
to 23 µm and was stored in flash frozen aliquots at −18 °C or −80 °C. For experiments,
aliquots were thawed, buffer swapped into the buffer of choice and concentration was
corrected to 23 µm.
A.1.7 Protein mass spectroscopy
LC-MS was performed on protein samples using one Thermo Scientific uPLC connected
to MSQ Plus Single Quad Detector (SQD) with the following parameters. Column:
Hypersil Gold C4 1.9 µm, 2.1 µm× 50 µm. Wavelength: 254 nm. Mobile Phase: 99:1
Water (0.1% formic acid): MeCN (0.1% formic acid) to 1:9 Water (0.1% formic acid):
MeCN (0.1% formic acid) gradient over 4 min. Flow Rate: 0.3 mL/min. MS Mode: ES+.
Scan Range: m/z = 100 – 2000. Scan time: 1.5 s. Data obtained in continuum mode.
The electrospray source of the MS was operated with a capillary voltage of 3.5 kV and a
cone voltage of 50V. Nitrogen was used as the nebulizer and desolvation gas at a total
flow of 600L/h. Total mass spectra for protein samples were reconstructed from the ion
series using the pre-installed ProMass software using default settings for large proteins
in m/z range 500 – 2000.
Alternatively, LC-MS was performed on protein samples using a Waters Acquity uPLC
connected to Waters Acquity Single Quad Detector (SQD) with the following parameters.
Column: Hypersil Gold C4, 1.9 µm, 2.1 µm× 50µm. Wavelength: 254 nm. Mobile Phase:
95:5 Water (0.1% Formic Acid): MeCN (0.1% Formic Acid) Gradient over 4 min (to
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5:95 Water (0.1% Formic Acid): MeCN (0.1% Formic Acid). Flow Rate: 0.6 mL/min.
MS Mode: ES+. Scan Range: m/z = 250 – 2000. Scan time: 0.25 s. Data obtained
in continuum mode. The electrospray source of the MS was operated with a capillary
voltage of 3.5 kV and a cone voltage of 50V. Nitrogen was used as the nebulizer and
desolvation gas at a total flow of 600L/h. Ion series were generated by integration of
the total ion chromatogram (TIC) over the appropriate range. Total mass spectra for
protein samples were reconstructed from the ion series using the MaxEnt 1 algorithm
pre-installed on MassLynx software.
It is noteworthy to mention that the accuracy of the LC-MS was highly dependent upon
the instrument used, its state at the time of the experiment (e.g. unclean column affecting
signal-to-noise ratio) as well as the algorithm used to deconvolute.
A.1.8 UV-Vis spectroscopy
UV-Vis spectra were recorded on a Varian Cary 100 Bio UV/Visible spectrophotometer,
operating at room temperature. Sample buffer was used as blank for baseline correction.
Calculation of the molecule over antibody ratio, r, follows the formula below with
ε280 = 215 380m−1 · cm−1 for trastuzumab derivatives, ε280 = 68 590m−1 · cm−1 for
FabHer derivatives, ε345 = 9100m−1 · cm−1 for PDs, ε495 = 8030m−1 · cm−1 for Dox
derivatives, ε646 = 271 000m−1 · cm−1 and 0.724, 0.28, and 0.13 as a correction factor
(CF) for Dox derivatives, PDs, and sulfo-Cy5 derivatives respectively for the absorbance
at 280 nm.
r = Aλ/ελ
(A280 −∑λCFλ ×Aλ) /ε280
With Aλ the absorbance at wavelength λ, and ελ the extinction coefficient of the molecule
of interest.
A.1.9 SDS-PAGE
Non-reducing glycine-SDS-PAGE at 12% acrylamide (16% for GFP conjugates) gels
were performed following standard lab procedures. A 4% stacking gel was used and a
broad-range MW marker (10 – 250 kDa, BioLabs) was co-run to estimate protein weights.
Samples (3 – 5 µL at ca. 20µm) were mixed with loading buffer (1 – 2 µL, composition
for 6×SDS: 1 g SDS, 1mL glycerol, 6mL 0.5m Tris buffer pH 6.8, 2mg R 250 dye) and
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heated at 75 °C for 2min. The gel was run at constant current (30 – 35mA) for 40 min
(150V for 60 min for GFP conjugates) in 1×SDS running buffer. All gels were stained
with Coomassie dye. Gel photographs were taken with a Wiko-Stairway device.
A.1.10 Enzyme-linked immunosorbent assay (ELISA)
Binding affinity to HER2 receptor was determined by ELISA. A 96-well plate was coated
for 1 h at room temperature with HER2 (Human HER2/ErbB2 Protein (His Tag) from
Sino Biological) (100 µL of a 0.25µg·mL−1 solution in PBS), including coating one row of
wells with PBS only for negative controls. Next, the coating solutions were removed and
each well washed with PBS twice. Then, the wells were coated with a 1% BSA solution in
PBS (200 µL) overnight at 4 °C. Next, the wells were washed with 0.1% Tween 20 in PBS
twice and with PBS three times. Solutions of trastuzumab 19, FabHer 127 and relevant
FabHer-PD and Her-PD conjugates in PBS were prepared with the following dilution
series: 100 nm, 30 nm, 10 nm, 3.3 nm, 1.1 nm, 0.37 nm, and 0.12 nm. Wells were coated
with the dilution series solutions in triplicate, including a PBS only at 30 nm in the
absence of HER2 as negative controls, and incubated for 2 h at room temperature. Then,
the solutions were removed and the wells washed with 0.1% Tween 20 in PBS twice and
with PBS three times. Detection antibody (100 µL of anti-human IgG, Fab-specific-HRP
solution, prepared by taking 4µL of a 1:5000 diluted solution and further diluting with
20mL of PBS) was then added and incubated for 1 h at room temperature. Then, the
solutions were removed and the wells washed with 0.1% Tween 20 in PBS twice and
with PBS three times. OPD solution (100 µL of 10mg/20mL OPD in phosphate-citrate
buffer with sodium perborate, prepared by dissolving 1 capsule in 100mL water) was
added to each well. After 30 s the reaction was stopped through addition of 4m HCl
(50 µL). The absorption was measured at 490 nm and corrected by subtracting average
of negative controls. The results obtained were analysed with GraphPad Prism using a
regression with variable slope (four parameters).
A.1.11 Ellman’s test
To a solution of the protein of interest (50 µL, 40 µm, 1 eq.) in phosphate buffer (100mm
sodium phosphate, 1mm EDTA, pH 8.0) was added TCEP (final concentration 400 µm,
10 eq.) and the reaction mixture incubated at 37 °C for 2 h. The excess reagents were then
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removed by repeated diafiltration into fresh buffer using VivaSpin sample concentrators
(GE Healthcare, 10 000 MWCO). The concentration of protein was then adjusted to
40µm. Following this, a solution of Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid))
in phosphate buffer (100mm sodium phosphate, 1mm EDTA, pH 8.0) (final concentration
1.6mm, 40 eq.) was added and the reaction mixture was incubated at 21 °C for 30min.
The mixture was then analysed by UV-Vis after a 10-fold dilution and the absorption at
412 nm was measured (ε412 = 14 150m−1 · cm−1).
A.1.12 Cell lines
Breast cancer cell lines BT-474 and MDA-MB-468 were purchased from ATCC. BT-474
cells were maintained at 37 °C, 5% CO2 in Hybricare Medium (ATCC) complemented
with 10% foetal calf serum (Labtech International, Ringmer, UK). MDA-MB-468 cells
were maintained at 37 °C, 5% CO2 in Dulbecco’s modified Eagle’s medium complemented
with 10% foetal calf serum and 2mm l-glutamine (PAA Laboratories, UK).
A.1.13 Internalisation analysis by confocal microscopy
Analysis by Dr Enrique Miranda Rota.
Cells on coverslips at 70% confluency were incubated with AlexaFluor488-conjugated
constructs at 10mg/mL for 1 h at 4 °C. Cells were extensively washed with PBS to remove
unbound antibodies and incubated at 37 °C in growth media. Internalisation was allowed
for 1 h, followed by extensive washing and fixation with 4% formaldehyde for 10 min at 4 °C.
Coverslips were then blocked with 5% goat serum in 0.3% Triton-X100 (Sigma). Actin was
detected with phalloidin-568 (Invitrogen) and Hoechst trihydrochloride (Invitrogen) was
used to stain cell nuclei. Coverslips were mounted on slides using ProLong Gold Antifade
(Invitrogen) and examined using Perkin Elmer Spinning Disc Confocal microscope and
Volocity Visualization software.
A.1.14 Toxicity assays
Cells were seeded in 96-well plates at 104 cells/well and allowed to attach for 24 h. Serial
dilution of trastuzumab 19, FabHer 127, Dox 143, FabHer-PEG20k-Dox 159 and Her-
Solastra-Dox-Cy5 161 were added to the cells at concentrations ranging from 40 to 0 µm
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in complete growth medium. After 96 h, cell viability was measured using the CellTiter
96 Aqueous Non-radioactive cell proliferation assay (Promega) following manufacturer’s
instructions. Cell viability was plotted as percentage of untreated cells. The results
obtained were analysed with GraphPad Prism using a regression with variable slope (four
parameters).
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A.2 Characterisations
1-Azido-4-methylbenzene 52167
N3
To a solution of p-toluidine (2.0 g, 18 mmol) in 2m HCl (28 mL) at −5 °C was added
slowly a solution of sodium nitrite (1.5 g, 22 mmol) in H2O (5 mL) over 5 min making
sure that the internal temperature did not rise above 0 °C. After completion of addition,
the reaction mixture was stirred at −5 °C for 5 min to form a diazonium salt. Then urea
(0.13 g, 2.2 mmol) was added to neutralise the diazonium salt solution. Following this,
the diazonium salt solution was added to a solution of sodium azide (2.4 g, 37mmol)
and sodium acetate (4.6 g, 56mmol) in 30 mL of H2O at 0 °C over 5 min. The mixture
was stirred for 2 h at 0 °C. The mixture was extracted into Et2O (2× 60mL), the
combined organic layers dried (MgSO4) and concentrated in vacuo to afford 1-azido-4-
methylbenzene 52 (2.3 g, 17 mmol, 94%) as a yellow oil: 1H NMR (500 MHz, CDCl3) δ
7.15 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 2.33 (s, 3H); 13C NMR (125 MHz,
CDCl3) δ 137.2 (C), 134.7 (C), 130.4 (CH), 118.9 (CH), 21.0 (CH3); IR (thin film) 2104,
1609, 1521 cm−1.
1-Azido-4-(bromomethyl)benzene 53168
N3
Br
A solution of 1-azido-4-methylbenzene 52 (0.85 g, 6.4 mmol), N -bromosuccinimide (1.5 g,
8.3mmol) and azobis(isobutyronitrile) (0.31 g, 1.9 mmol) in dry benzene (20 mL) was
heated under reflux under argon in the dark for 8 h. After this time, the mixture was
poured onto H2O (20 mL), extracted into Et2O (2× 20 mL), the combined organic layers
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography
(neat petrol) yielded 1-azido-4-(bromomethyl)benzene 53 (1.1 g, 5.1 mmol, 80%) as a
light brown solid: 1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2H), 7.00 (d, J =
8.4 Hz, 2H), 4.48 (s, 2H); 13C NMR (150 MHz, CDCl3) δ 140.3 (C), 134.6 (C), 130.7
(CH), 119.5 (CH), 33.0 (CH2); IR (solid) 2107, 1607, 1505 cm−1; LRMS (EI) 213 (100,
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[M81Br]+•), 211 (100, [M79Br]+•); HRMS (EI) calcd for C7H6N3Br [M79Br]+• 210.9740,
observed 210.9743.
Di-tert-butyl 1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 55169
HN N
BocBoc
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate (300 mg, 1.29 mmol) in a
mixture of toluene (2 mL) and 5% aq. NaOH (2mL) were added tetra-n-butylammonium
bromide (13 mg, 0.03 mmol) and propargyl bromide (461 mg, 3.87 mmol). The reaction
mixture was stirred at 20 °C for 16 h. After this time, H2O (20 mL) was added and the
mixture was extracted with ethyl acetate (3× 15 mL). The combined organic layers were
washed with brine (15 mL), dried (MgSO4), and concentrated in vacuo. Purification by
flash column chromatography (20 % EtOAc/petrol) yielded di-tert-butyl 1-(prop-2-yn-
1-yl)hydrazine-1,2-dicarboxylate 55 (437 mg, 1.62 mmol, 86%) as a white solid: m.p.
101 – 103 °C (lit. m.p.169 103.1 – 103.4 °C); 1H NMR (500 MHz, CDCl3) δ 6.47 (br. s,
0.78H), 6.18 (br. s, 0.22H,), 4.27 (s, 2H), 2.24 (t, J = 2.4 Hz, 1H), 1.48 (s, 18H); 13C
NMR (150 MHz, CDCl3) δ 155.0 (C), 82.2 (C), 81.7 (C), 79.0 (C), 77.7 (C), 72.5 (CH),
39.5 (CH2), 28.5 (CH3), 28.5 (CH3); IR (solid) 3310, 2109, 1703 cm−1.
Di-tert-butyl 1-(4-azidobenzyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate
56
N
Boc
Boc
N
N3
To a solution of di-tert-butyl 1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 55 (0.20 g,
0.70 mmol) in DMF (10 mL) were added caesium carbonate (0.48 g, 1.5 mmol) and
1-azido-4-(bromomethyl)benzene 53 (0.23 g, 1.1 mmol). The reaction mixture was stirred
at 20 °C for 16 h. After this time, the reaction mixture was diluted with H2O (20mL)
and extracted with EtOAc (3× 20 mL). The combined organic layers were washed with
brine (15 mL), dried (MgSO4), and concentrated in vacuo. Purification by flash column
chromatography (20% Et2O/petrol) yielded di-tert-butyl 1-(4-azidobenzyl)-2-(prop-2-yn-
1-yl)hydrazine-1,2-dicarboxylate 56 (0.26 g, 0.65 mmol, 93%) as a viscous dark yellow
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liquid: 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.4 Hz,
2H), 4.63 – 3.98 (m, 4H), 2.19 (t, J = 2.4 Hz, 1H), 1.47 (s, 9H), 1.30 (s, 9H); 13C NMR
(150 MHz, CDCl3) δ 154.6 (C), 154.3 (C), 139.5 (C), 133.6 (C), 131.4 (CH), 118.9 (CH),
81.7 (C), 81.6 (C), 78.5 (C), 72.9 (CH), 52.6 (CH2), 39.3 (CH2), 28.3 (CH3), 28.1 (CH3);
IR (thin film) 3257, 2110, 1705, 1600, 1507 cm−1; LRMS (CI) 424 (100, [M+Na]+), 365
(70); HRMS (CI) calcd for C20H27N5O4Na [M+Na]+ 424.1961, observed 424.1965.
3,4-Dibromo-furan-2,5-dione 58247
O
O
O
Br
Br
A mixture of maleic anhydride (1.5 g, 15 mmol), AlCl3 (28 mg, 0.21 mmol) and Br2
(1.6 mL, 4.9 g, 31 mmol) was heated at 160 °C in a sealed ampoule for 20 h. After
this time, the reaction mixture was allowed to cool to room temperature and diluted
with EtOAc (25 mL). The reaction mixture was then filtered and the solid washed
thoroughly with EtOAc (3 × 25 mL). The filtrate was then concentrated in vacuo to
afford 3,4-dibromo-furan-2,5-dione 58 as a yellow solid (3.3 g, 13 mmol, 83%): m.p.
108 – 111 °C (lit. m.p.247 113 – 114 °C); 13C NMR (MeOD, 150 MHz) δ 164.4 (C), 125.9
(C); IR (solid) 1769, 1706, 1590 cm−1.
1-(4-Azidobenzyl)-4,5-dibromo-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione 61
N
N
O
O
Br
Br
N3
To a solution of di-tert-butyl 1-(4-azidobenzyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-dicarbo-
xylate 56 (1.8 g, 4.5 mmol) in CH2Cl2 (55 mL) was added TFA (18 mL) and the reaction
mixture stirred at 20 °C for 30 min. After this time, all volatile materials were removed
in vacuo. The crude residue was added to a solution of 2,3-dibromomaleic anhydride 58
(1.4 g, 5.4 mmol) in glacial AcOH (125 mL), and the reaction mixture heated at 130 °C
for 16 h. Then the reaction mixture was concentrated in vacuo, and purification by
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flash column chromatography (15% to 50% Et2O/petrol) yielded 1-(4-azidobenzyl)-4,5-
dibromo-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-dione 61 (0.69 g, 1.6 mmol, 35%)
as a yellow solid: m.p. 79 – 81 °C; 1H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.5Hz,
2H), 7.02 (d, J = 8.5Hz, 2H), 5.46 (s, 2H), 4.75 (d, J = 2.5Hz, 2H), 2.45 (t, J = 2.5Hz,
1H); 13C NMR (125 MHz, CDCl3) δ 153.5 (C), 153.0 (C), 140.8 (C), 136.7 (C), 135.8
(C), 130.9 (C), 128.5 (CH), 120.0 (CH), 75.7 (C), 75.2 (CH), 50.3 (CH2), 37.1 (CH2); IR
(solid) 3251, 2111, 1636, 1507 cm−1; LRMS (CI) 442 (50, [M81Br81Br+H]+), 440 (100,
[M81Br79Br+H]+), 438 (50, [M79Br79Br+H]+); HRMS (CI) calcd for C14H1079Br2N5O2
[M79Br79Br+H]+ 437.9196, observed 437.9197.
Methyl 3,4-dibromo-2,5-dioxo-2,5-dihydro-1H -pyrrole-1-carboxylate 60170
N
O
O
O
OMe
Br
Br
To a solution of dibromomaleimide (1.0 g, 3.9 mmol) and N -methylmorpholine (0.43 mL,
3.9 mmol) in THF (35 mL) was added methylchloroformate (0.31 mL, 3.9 mmol) and the
reaction mixture stirred at 20 °C for 20 min. After this time, CH2Cl2 (40 mL) was added,
and the reaction mixture was washed with H2O (50 mL), dried (MgSO4) and concentrated
in vacuo to afford methyl 3,4-dibromo-2,5-dioxo-2,5-dihydro-1H -pyrrole-1-carboxylate 60
(1.2 g, 3.8 mmol, 97%) as a pink power: m.p. 114 – 116 °C; 1H NMR (500 MHz, CDCl3) δ
4.00 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.3 (C), 147.0 (C), 131.5 (C), 54.9 (CH3);
HRMS (EI) calcd for C6H3O4N79Br2 [M79Br79Br]+• 310.8423, observed 310.8427.
tert-Butyl 14-azido-3-(tert-butoxycarbonyl)-2-(prop-2-yn-1-yl)-6,9,12-trioxa-
2,3-diazatetradecan-1-oate 66
N
Boc
Boc
NOOON3
To a solution of di-tert-butyl 1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 55 (0.11 g,
0.40 mmol) in DMF (3 mL) were added caesium carbonate (0.16 g, 0.48 mmol) and 2-(2-
(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl methanesulfonate 65 (0.13 g, 0.44 mmol) and the
reaction mixture stirred at 20 °C for 16 h. After this time, the reaction mixture was diluted
with H2O (10 mL), extracted with Et2O (5×10 mL), the combined organic layers washed
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with sat. aq. LiCl (2× 10 mL), dried (MgSO4), and concentrated in vacuo. Purification
by flash column chromatography (30% EtOAc/petrol) yielded tert-butyl 14-azido-3-(tert-
butoxycarbonyl)-2-(prop-2-yn-1-yl)-6,9,12-trioxa-2,3-diazatetradecan-1-oate 66 (0.18 g,
0.38 mmol, 94%) as a yellow oil: 1H NMR (500 MHz, CDCl3) δ 4.61 – 3.41 (m, 16H)
3.38 (t, J = 5.0 Hz, 2H), 2.27 – 2.21 (m, 1H) 1.51 – 1.42 (m, 18H); 13C NMR (150 MHz,
CDCl3) (rotamers) δ 155.3 (C), 155.3 (C), 154.8 (C), 154.7 (C), 154.5 (C), 154.3 (C),
153.9 (C), 82.2 (C), 82.0 (C), 81.7 (C), 81.7 (C), 81.4 (C), 81.3 (C), 79.3 (C), 79.3 (C),
78.9 (C), 72.5 (CH), 72.3 (CH), 72.1 (CH), 70.8 (CH2), 70.8 (CH2), 70.7 (CH2), 70.5
(CH2), 70.4 (CH2), 70.3 (CH2), 70.1 (CH2), 68.6 (CH2), 68.5 (CH2), 68.4 (CH2), 50.8
(CH2), 50.7 (CH2), 50.7 (CH2), 49.8 (CH2), 49.8 (CH2), 41.3 (CH2), 41.2 (CH2), 39.7
(CH2), 39.6 (CH2), 28.3 (CH3), 28.3 (CH3), 28.3 (CH3), 28.2 (CH3), 28.1 (CH3), 28.0
(CH3), 28.0 (CH3), 27.8 (CH3); IR (thin film) 3258, 2100, 1708 cm−1; LRMS (CI) 494
(50, [M+Na]+), 272 (100); HRMS (CI) calcd for C21H37N5O7Na [M+Na]+ 494.2591,
observed 494.2582.
18,19-Dibromo-5,6,8,9,11,12,14,15-octahydro-22H -pyridazino[1,2-g][1,2,3]tri
azolo[5,1-j][1,4,14]trioxa[7,8,11]triazacyclohexadecine-17,20-dione 67
(Z)-14,15-Dibromo-11,12,13,16-tetrahydro-31H -6,9,12-trioxa-1(1,2)-pyridazina-
3(4,1)-triazolacyclotetradecaphane-13,16-dione 68
N
N
O O
O
O
O
Br
Br
N N
N
N
N
O
O
O
O
O
Br
Br N
N
N
To a solution of tert-butyl 14-azido-3-(tert-butoxycarbonyl)-2-(prop-2-yn-1-yl)-6,9,12-
trioxa-2,3-diazatetradecan-1-oate 66 (54 mg, 0.11 mmol) in CH2Cl2 (1 mL) was added
TFA (0.5 mL) and the reaction mixture stirred at 20 °C for 30 min. After this time,
all volatile materials were removed in vacuo. The crude residue was added to a
solution of 2,3-dibromomaleic anhydride 58 (30 mg, 0.11 mmol) in glacial AcOH
(2 mL), and the reaction mixture heated at 130 °C for 16 h. Then the reaction mixture
was concentrated in vacuo, and purification by flash column chromatography (0 – 2%
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MeOH/CH2Cl2) yielded 18,19-dibromo-5,6,8,9,11,12,14,15-octahydro-22H -pyridazino[1,2-
g][1,2,3]tri azolo[5,1-j][1,4,14]trioxa[7,8,11]triazacyclohexadecine-17,20-dione 67 and
(Z )-14,15-dibromo-11,12,13,16-tetrahydro-31H -6,9,12-trioxa-1(1,2)-pyridazina-3(4,1)-tri
azolacyclotetradecaphane-13,16-dione 68 as an inseparable mixture of regioisomers
(21 mg, 42 µmol, 38%) as a yellow oil: 1H NMR (500 MHz, CDCl3) (major regioisomer)
δ 7.52 (s, 1H), 5.75 (s, 2H), 4.80 (t, J = 4.6 Hz, 2H), 4.43 (t, J = 4.5 Hz, 2H), 3.88 (t,
J = 4.5 Hz, 2H), 3.77 (t, J = 4.6 Hz, 2H), 3.68 – 3.43 (m, 8H); 13C NMR (125 MHz,
CDCl3) (major regioisomer) δ 152.9 (C), 152.8 (C), 142.0 (C), 136.3 (C), 136.0 (C),
131.8 (CH), 70.6 (CH2), 70.3 (CH2), 70.2 (CH2), 69.8 (CH2), 67.9 (CH2), 53.5 (CH2),
50.8 (CH2), 49.2 (CH2).
1-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-4,5-dibromo-2-(prop-2-yn-1-
yl)-1,2-dihydropyridazine-3,6-dione 69
N
N
O
O
Br
Br O O O N3
To a solution of tert-butyl 14-azido-3-(tert-butoxycarbonyl)-2-(prop-2-yn-1-yl)-6,9,12-
trioxa-2,3-diazatetradecan-1-oate 66 (0.10 g, 0.21 mmol,) in CH2Cl2 (2 mL) was added
TFA (1 mL) and the reaction mixture stirred at 20 °C for 30 min. After this time, all
volatile materials were removed in vacuo. The crude residue was added to a solution of N -
methoxycarbonyl-dibromomaleimide 60 (73mg, 0.23mmol) and NEt3 (47mg, 0.47mmol)
in CH2Cl2 (5mL) and the reaction mixture stirred at 20 °C for 16 h. Then the reaction mix-
ture was concentrated in vacuo, and purification by flash column chromatography (0.2%
MeOH/CH2Cl2) yielded 1-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-4,5-dibromo-2-
(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-dione 69 (29mg, 0.06mmol, 27%) as a yellow
oil: 1H NMR (600 MHz, CDCl3) δ 5.15 (d, J = 2.4 Hz, 2H), 4.45 (t, J = 4.7 Hz, 2H),
3.77 (t, J = 4.7 Hz, 2H), 3.67 – 3.64 (m, 2H), 3.63 – 3.54 (m, 8H), 3.39 (t, J = 5.1 Hz,
2H), 2.38 (t, J = 2.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 152.9 (C), 152.5 (C), 136.4
(C), 135.8 (C), 76.6 (C), 74.5 (CH), 70.8 (CH2), 70.8 (CH2), 70.7 (CH2), 70.6 (CH2),
70.2 (CH2), 68.3 (CH2), 50.7 (CH2), 48.4 (CH2), 37.3 (CH2); IR (thin film) 3243, 2099,
1634, 1574 cm−1; LRMS (CI) 512 (50, [M81Br81Br+H]+), 510 (100, [M81Br79Br+H]+),
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508 (50, [M79Br79Br+H]+); HRMS (CI) calcd for C15H20O5N579Br2 [M79Br79Br+H]+
507.9831, observed 507.9835.
(Z)-Methyl 2-hydroxycyclooct-1-enecarboxylate 71172
HO CO2Me
To a solution of dimethyl carbonate (1.4 g, 16 mmol) in toluene (20 mL) was added
sodium hydride (0.88 g, 24 mmol). The resulting mixture was heated to 90 °C and a
solution of cyclooctanone 70 (1.0 g, 7.9 mmol) in toluene (5 mL) was added dropwise
over 30min. The resultant mixture was stirred at reflux for 4 h. The reaction mixture
was cooled down to 20 °C and AcOH (2 mL) was added. The resulting precipitate
was then dissolved by addition of 2m HCl (6 mL). The mixture was extracted with
toluene (3× 30mL) the combined organic layers washed with sat. aq. NaHCO3 (20 mL),
H2O (20 mL), dried (MgSO4), and concentrated in vacuo. Purification by flash column
chromatography (10% Et2O/petrol) yielded (methyl 2-oxocyclooctanecarboxylate 71
(1.4 g, 7.9 mmol, 99%) as a clear liquid: 1H NMR (500 MHz, CDCl3) (major tautomer)
δ 12.51 (s, 1H), 3.75 (s, 3H), 2.42 – 2.32 (m, 4H), 1.77 – 1.66 (m, 2H), 1.56 – 1.42 (m, 6H);
13C NMR (125 MHz, CDCl3) (major tautomer) δ 176.3 (C), 173.5 (C), 99.2 (C), 51.5
(CH3), 32.4 (CH2), 30.0 (CH2), 28.8 (CH2), 26.6 (CH2), 26.2 (CH2), 24.0 (CH2); IR (thin
film) 2960, 2940, 2860, 1740, 1700 cm−1.
Methyl 1-fluoro-2-oxocyclooctanecarboxylate 72172
O CO2MeF
To a solution of (Z)-methyl 2-hydroxycyclooct-1-enecarboxylate 71 (4.5 g, 25 mmol)
in dry MeCN (80 mL) was added Selectfluor™ (10 g, 29 mmol) at 0 °C. The resulting
mixture was stirred at 55 °C for 16 h. The reaction mixture was poured into water
(200 mL), extracted with EtOAc (3× 200 mL), washed with brine (3× 100 mL), dried
(MgSO4), and concentrated in vacuo. Purification by flash column chromatography (10%
Et2O/petrol) yielded methyl 1-fluoro-2-oxocyclooctanecarboxylate 72 (4.2 g, 21 mmol,
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86%) as a white solid: m.p. 42 – 44 °C (lit. m.p.172 42 – 45 °C); 1H NMR (500 MHz,
CDCl3) δ 3.75 (s, 3H), 2.69 – 2.46 (m, 3H), 2.22 – 2.16 (m, 1H), 1.84 – 1.79 (m, 2H),
1.69 – 1.56 (m, 3H), 1.47 – 1.33 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 208.5 (d, 2JC-F
= 22.1 Hz, C), 167.4 (d, 2JC-F = 24.9 Hz, C), 99.0 (d, JC-F = 200.6 Hz, C), 53.0 (CH3),
38.7 (CH2), 33.3 (d, 2JC-F = 22.1 Hz, CH2), 27.3 (CH2), 26.4 (CH2), 24.3 (CH2), 21.1
(CH2); IR (thin film) 2924, 2853, 1751, 1713 cm−1.
Methyl 1-fluorocyclooct-2-ynecarboxylate 73172
CO2MeF
To a solution of methyl 1-fluoro-2-oxocyclooctanecarboxylate 72 (2.0 g, 9.9 mmol) in dry
THF (200 mL) stirred at −78 °C was added a solution of KHMDS (0.91m in THF, 33mL,
30mmol) dropwise over 10 min. After the addition was complete the reaction mixture
was maintained for 30 min at −78 °C. Then a solution of Tf2NPh (3.9 g, 11mmol) in
THF (30 mL) was added dropwise over 10 min. The reaction was stirred at −78 °C for
1 h. The reaction mixture was then warmed up to 20 °C and stirred for an additional 16 h.
Methanol (15 mL) was then added and the reaction mixture was concentrated in vacuo.
Purification by flash column chromatography (0 – 20% EtOAc/petrol) yielded methyl
1-fluorocyclooct-2-ynecarboxylate 73 (1.3 g, 7.4 mmol, 75%) as a yellow oil: 1H NMR
(500 MHz, CDCl3) δ 3.83 (s, 3H), 2.41 – 2.20 (m, 4H), 2.06 – 1.85 (m, 4H), 1.77 – 1.66 (m,
1H), 1.50 – 1.42 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 168.8 (d, 2JC-F = 27.8 Hz, C),
108.5 (d, 3JC-F = 9.6 Hz, C), 91.7 (d, JC-F = 186.2Hz, C), 86.9 (d, 2JC-F = 31.7 Hz,
C), 53.4 (CH3), 46.2 (d, 2JC-F = 25.0 Hz, CH2), 33.9 (CH2), 29.2 (CH2), 25.6 (CH2),
20.7 (CH2); IR (thin film) 2930, 2854, 2222, 1751 cm−1.
1-Fluorocyclooct-2-yne-1-carboxylic acid 74172
CO2HF
To a solution of methyl 1-fluorocyclooct-2-ynecarboxylate 73 (0.15 g, 0.82 mmol) in
MeOH (2 mL) was added LiOH (69 mg, 1.6 mmol) in H2O (2 mL). The reaction
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mixture was heated at 50 °C for 10 min. Then the reaction was stirred at 20 °C for an
additional 2 h. The reaction mixture was then cooled to 0 °C and diluted with water,
acidified to pH 2 with diluted aq. HCl solution. The reaction mixture was extracted with
EtOAc (3× 10 mL), washed with brine (2× 10 mL), dried (MgSO4), and concentrated
in vacuo. Purification by flash column chromatography (50% EtOAc/petrol) yielded
1-fluorocyclooct-2-yne-1-carboxylic acid 74 (0.12 g, 0.71 mmol, 87%) as a yellow liquid:
1H NMR (300 MHz, CDCl3) δ 2.45 – 2.30 (m, 4H), 2.07 – 1.86 (m, 4H), 1.78 – 1.68 (m,
1H), 1.52 – 1.45 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 173.7 (d, 2JC-F = 29.1 Hz, C),
109.6 (d, 3JC-F = 9.9 Hz, C), 91.6 (d, JC-F = 185.8 Hz, C), 86.2 (d,2JC-F = 31.7 Hz,
C), 46.4 (d, 2JC-F = 24.6 Hz, CH2), 33.9 (CH2), 29.1 (CH2), 25.6 (CH2), 20.7 (CH2);
IR (thin film) 3474, 2932, 2850, 2220, 1732 cm−1; HRMS (ES−) calcd for C9H10FO2
[M−H]− 169.0665, observed 169.0666.
N,N’-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(1-fluoro
cyclooct-2-ynecarboxamide) 78
H
N O
O
O
F
HN
O
F
O
To a solution of 1-fluorocyclooct-2-ynecarboxylic acid 74 (0.23 g, 1.4 mmol) and DIPEA
(0.48 mL, 2.7 mmol) in DMF (10 mL) was added HBTU (0.61 g, 1.6 mmol) and the
reaction mixture stirred at 20 °C for 5 min. After this time, was added 1,11-diamino-
3,6,9-trioxaundecane (0.13 g, 0.68 mmol) and the reaction mixture stirred at 20 °C for
4 h. Then the reaction mixture was diluted with H2O (30 mL), extracted with EtOAc
(3× 15 mL), the combined organic layers were dried (MgSO4) and concentrated in vacuo.
The crude residue was purified by flash column chromatography (50% EtOAc/Et2O) to
afford N,N’-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(1-fluorocyclooct-
2-ynecarboxamide) 78 (0.18 g, 0.37 mmol, 54%) as a yellow oil: 1H NMR (600 MHz,
CDCl3) δ 7.21 (br. s, 2H), 3.62 – 3.50 (m, 12H), 3.50 – 3.35 (m, 4H), 2.35 – 2.15 (m, 8H),
2.05 – 1.74 (m, 8H), 1.64 – 1.55 (m, 2H), 1.42 – 1.30 (m, 2H); 13C NMR (150 MHz, CDCl3)
δ 169.4 (d, 2JC-F = 24.0 Hz, C), 109.6 (d, 3JC-F = 10.6 Hz, C), 93.6 (d, JC-F = 186.2 Hz,
C), 86.9 (d, 2JC-F = 31.6Hz, C), 70.1 (CH2), 70.0 (CH2), 69.8 (CH2), 46.5 (d, 2JC-F =
24.0 Hz, CH2), 39.3 (CH2), 33.8 (CH2), 28.9 (CH2), 25.6 (CH2), 20.5 (CH2); IR (thin
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film) 3414, 1672 cm−1; LRMS (ES−) 495 (60, [M-H]−), 475 (80), 455 (100); HRMS (ES−)
calcd for C26H37O5N2F2 [M-H]− 495.2671, observed 495.2668.
1-(4-((4,5-Dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-
yl)methyl)phenyl)-4-fluoro-N -(1-(1-fluorocyclooct-2-yn-1-yl)-1-oxo-5,8,11-
trioxa-2-azatridecan-13-yl)-4,5,6,7,8,9-hexahydro-1H -cycloocta[d][1,2,3]triazole-
4-carboxamide 79
H
N O
O
O
FN
N N
N
N
O
O
Br
Br
H
N
O
F
O
To a solution of N,N’-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(1-fluoro
cyclooct-2-ynecarboxamide) 78 (0.14 g, 0.28 mmol) in CH2Cl2 (5 mL) was added slowly
a solution of 1-(4-azidobenzyl)-4,5-dibromo-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-
3,6-dione 61 (50 mg, 0.11 mmol) in CH2Cl2 (3 mL) and the reaction mixture stirred
at 20 °C for 16 h. After this time, the reaction mixture was concentrated in vacuo
and the crude residue purified by flash column chromatography (1% MeOH/EtOAc)
to afford 1-(4-((4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-
yl)methyl)phenyl)-4-fluoro-N -(1-(1-fluorocyclooct-2-yn-1-yl)-1-oxo-5,8,11-trioxa-2-aza
tridecan-13-yl)-4,5,6,7,8,9-hexahydro-1H -cycloocta[d][1,2,3]triazole-4-carboxamide 79
(33 mg, 0.04 mmol, 36%) as an inseparable mixture of diastereo- and regioisomers as a
yellow oil: 1H NMR (600 MHz, CDCl3) δ 7.44 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz,
2H), 7.32 (br. s, 1H), 6.88 (br. s, 1H), 5.57 (t, J = 2.4 Hz, 2H), 4.77 (s, 2H), 3.71 – 3.51
(m, 14 H), 3.48 (t, J = 6.0 Hz, 2H), 3.02 – 2.92 (m, 1H), 2.92 – 2.84 (m, 1H), 2.73 – 2.58
(m, 1H), 2.48 (t, J = 2.4 Hz, 1H), 2.44 – 2.22 (m, 5H), 2.02 – 1.39 (m, 12H); 13C NMR
(150MHz, CDCl3) δ 170.9 (d, 2JC-F = 24.5 Hz, C), 168.6 (d, 2JC-F = 24.0 Hz, C), 153.5
(C), 153.0 (C), 143.1 (d, 2JC-F = 23.9 Hz, C), 136.7 (C), 136.4 (C), 136.2 (d, 3JC-F =
4.6 Hz, C), 135.4 (d, 3JC-F = 4.6 Hz, C), 128.2 (CH), 127.0 (CH), 126.9 (CH), 109.4 (d,
3JC-F = 10.5 Hz, C), 95.2 (C), 95.2 (C), 94.5 (d, JC-F = 186.7 Hz, C), 93.9 (C), 93.9 (C),
93.4 (C), 87.4 (d, 2JC-F = 31.5 Hz, C), 75.6 (C), 75.4 (CH), 70.7 (CH2), 70.6 (CH2), 70.6
(CH2), 70.5 (CH2), 70.4 (CH2), 70.4 (CH2), 69.7 (CH2), 69.5 (CH2), 50.2 (CH2), 46.5 (d,
2JC-F = 24.5 Hz, CH2), 39.4 (CH2), 39.3 (CH2), 37.4 (CH2), 34.0 (CH2), 33.3 (CH2), 33.1
(CH2), 29.0 (CH2), 26.5 (CH2), 25.8 (CH2), 24.0 (CH2), 22.3 (CH2), 22.3 (CH2), 21.8
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(CH2), 21.2 (CH2), 20.7 (CH2), 20.7 (CH2); IR (thin film) 3440, 2107, 1677, 1647, 1574,
1518 cm−1; LRMS (ES+) 960 (50, [M81Br81Br+Na]+), 958 (100, [M81Br79Br+Na]+),
956 (50, [M79Br79Br+Na]+); HRMS (ES+) calcd for C40H48O7N779Br2F2 [M79Br2+H]+
934.1989, observed 934.1950.
Di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate 80
N N
Boc Boc
O
O
To a solution of di-tert-butyl 1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 55 (0.50 g,
1.9 mmol) in DMF (15 mL) were added caesium carbonate (0.72 mg, 2.2 mmol) and
tert-butyl bromoacetate (0.54 g, 2.8 mmol) and the reaction mixture stirred at 20 °C for
16 h. After this time, the reaction mixture was diluted with H2O (50 mL), extracted with
EtOAc (4× 50 mL), the combined organic layers washed with sat. aq. LiCl (2× 30 mL),
dried (MgSO4), and concentrated in vacuo. Purification by flash column chromatography
(10% EtOAc/petrol) yielded di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-
yl)hydrazine-1,2-dicarboxylate 80 (0.71 g, 1.9 mmol, 97%) as a colourless oil: 1H NMR
(600 MHz, CDCl3) δ 4.58 – 4.35 (m, 2H), 4.16 – 4.01 (m, 1H), 3.67 – 3.64 (m, 1H), 2.18
(t, J = 2.3 Hz, 1H), 1.53 – 1.41 (m, 27H); 13C NMR (150 MHz, CDCl3) (major rotamer)
δ 168.1 (C), 166.3 (C), 153.9 (C), 83.0 (C), 81.9 (C), 81.8 (C), 79.4 (C), 71.9 (CH),
53.5 (CH2), 40.1 (CH2), 28.3 (CH3), 28.3 (CH3), 28.1 (CH3); IR (thin film) 3265, 2108,
1714 cm−1; LRMS (CI) 385 (55, [M+H]+), 329 (65), 273 (100); HRMS (CI) calcd for
C19H33O6N2 [M+H]+ 385.2333, observed 385.2319.
2-(4,5-Dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-yl)
acetic acid 81
N NHO
O
OO
Br Br
To a solution of di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-yl)hydrazine-
1,2-dicarboxylate 80 (0.50 g, 1.3 mmol) in CH2Cl2 (10 mL) was added TFA (10mL)
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and the reaction mixture stirred at 20 °C for 2 h. After this time, all volatile materials
were removed in vacuo. The crude residue was added to a solution of 2,3-dibromomaleic
anhydride 58 (0.40 g, 1.6 mmol) in glacial AcOH (40 mL), and the reaction mixture was
stirred at 20 °C for 16 h then heated at 130 °C for 2 h. Then the reaction mixture
was concentrated in vacuo, and purification by flash column chromatography (3%
MeOH/CH2Cl2 with 1% AcOH) yielded 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-
2,3-dihydropyridazin-1(6H )-yl)acetic acid 81 (0.32 g, 0.87mmol, 67%) as a white solid:
m.p. 108 – 110 °C; 1H NMR (600 MHz, MeOD) δ 4.95 (s, 2H), 4.91 (s, 2H), 2.98 (s,
1H); 13C NMR (150 MHz, CDCl3) δ 170.1 (C), 155.6 (C), 154.3 (C), 137.1 (C), 136.8
(C), 77.2 (C), 76.2 (CH), 50.3 (CH2), 38.7 (CH2); IR (solid) 3444, 3287, 2109, 1729,
1631 cm−1; LRMS (CI) 369 (50, [M81Br81Br+H]+), 367 (100, [M81Br79Br+H]+), 365 (50,
[M79Br79Br+H]+); HRMS (CI) calcd for C9H7N2O479Br2 [M79Br79Br+H]+ 364.8767,
observed 364.8762.
Tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate 83173
H2N O NHBoc3
To a solution of 4,7,10-trioxa-1,13-tridecanediamine 82 (5.0 g, 23 mmol) in dioxane
(100mL) was added di-tert-butyl dicarbonate (0.85 g, 3.9 mmol) dropwise over 3 h. The
reaction mixture was then stirred at 20 °C for 16 h and then poured into water (100 mL),
extracted with CH2Cl2 (3 × 100 mL). The organic layer was then washed with brine
(3× 100 mL), dried (MgSO4) and concentrated in vacuo to yield tert-butyl(3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propyl)carbamate 83 (6.7 g, 21 mmol, 90 %) as a clear oil:
1H NMR (500 MHz, CDCl3) δ 5.12 (br. s, 1H), 3.62 – 3.49 (m, 12H), 3.21 – 3.18 (m, 2H),
2.78 – 2.75 (t, J = 6.7 Hz, 2H), 1.75 – 1.66 (m, 4H), 1.40 (s, 9H); 13C NMR (125 MHz,
CDCl3) δ 156.1 (C), 78.9 (C), 70.7 (CH2), 70.6 (CH2), 70.3 (CH2), 70.2 (CH2), 69.6
(CH2), 69.5 (CH2), 39.7 (CH2), 38.6 (CH2), 33.5 (CH2), 29.7 (CH2), 28.5 (CH3); LRMS
(CI) 321 (50, [M+H]+), 220 (100, [M-C5H8O2]+).
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Tert-butyl (1-(cyclooct-2-yn-1-yl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)
carbamate 86
F O
N
H
O NHBoc3
To a solution of methyl 1-fluorocyclooct-2-ynecarboxylate 73 (1.0 g, 5.0 mmol) in NEt3
(6mL) was added tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate
(4.8 g, 15 mmol). The reaction mixture was stirred at 20 °C for 48 h. After this time, all
volatile materials were removed in vacuo. Purification by flash column chromatography
(0% to 50% EtOAc/petrol) yielded tert-butyl (1-(cyclooct-2-yn-1-yl)-1-oxo-6,9,12-trioxa-
2-azapentadecan-15-yl)carbamate 86 (1.7 g, 3.6 mmol, 72%) as a yellow oil: 1H NMR
(600MHz, CDCl3) δ 7.00 (br. s, 1H), 4.98 (br. s, 1H), 3.62 – 3.58 (m, 4H), 3.58 – 3.52
(m, 6H), 3.49 (t, J = 6.0 Hz, 2H), 3.37 (q, J = 6.0 Hz, 2H), 3.18 (q, J = 5.5 Hz,
2H), 2.43 – 2.16 (m, 4H), 2.07 – 1.98 (m, 1H), 1.98 – 1.87 (m, 2H), 1.86 – 1.66 (m, 5H),
1.66 – 1.58 (m, 1H), 1.44 – 1.33 (m, 10H); 13C NMR (150 MHz, CDCl3) δ 168.1 (d, 2JC-F
= 24.1 Hz, C), 155.9 (C), 108.8 (d, 3JC-F = 10.5 Hz, C), 94.3 (d, JC-F = 186.4 Hz, C),
87.4 (d, 2JC-F = 31.6Hz, C), 78.7 (C), 70.5 (CH2), 70.4 (CH2), 70.3 (CH2), 70.1 (CH2),
70.1 (CH2), 69.5 (CH2), 46.2 (d, 2JC-F = 24.1 Hz, CH2), 38.5 (CH2), 38.1 (CH2), 33.8
(CH2), 29.5 (CH2), 28.8 (CH2), 28.6 (CH2), 28.3 (CH3), 25.6 (CH2), 20.5 (CH2); IR
(thin film) 3345, 2927, 2864, 2228, 1685, 1679 cm−1; LRMS (CI) 473 (25, [M+H]+), 373
(100, [M-C5H8O2]+); HRMS (CI) calcd for C24H42FO6N2 [M+H]+ 473.3027, observed
473.3023.
Tert-butyl (1-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-
1(2H )-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate 84
N
N
N
H
O
O
O
Br
Br
O NHBoc3
To a solution of 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-
yl)acetic acid 81 (93mg, 0.26mmol) in CH2Cl2 (5mL) were added EDC·HCl (54mg,
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0.28mmol) and NEt3 (28 mg, 0.28 mmol). The resulting solution was stirred at 20 °C
for 5min. After this time, tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)
carbamate 83 (90mg, 0.28mmol) was added and the resulting solution was stirred at
20 °C for 4 h. Then, the reaction mixture was diluted with H2O (15 mL), extracted
with EtOAc (3 × 15 mL), the combined organic layers were dried (MgSO4) and
concentrated in vacuo. The crude residue was purified by flash column chromatography
(5% MeOH/CH2Cl2) to afford tert-butyl (1-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-
3,6-dihydropyridazin-1(2H )-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate 84
(77mg, 0.11mmol, 44%) as a yellowish oil: 1H NMR (500 MHz, CDCl3) δ 7.07 (s, 1H),
5.00 (d, J = 2.5 Hz, 2H), 4.95 (t, J = 5.7 Hz, 1H), 4.87 (s, 2H), 3.68 – 3.63 (m, 4H),
3.62 – 3.56 (m, 6H), 3.52 (t, J = 6.0 Hz, 2H), 3.39 (q, J = 6.0 Hz, 2H), 3.19 (q, J =
6.4 Hz, 2H), 2.44 (t, J = 2.5 Hz, 1H), 1.84 – 1.69 (m, 4H), 1.48 – 1.36 (m, 9H); 13C NMR
(125 MHz, CDCl3) δ 165.2 (C), 156.2 (C), 153.5 (C), 152.4 (C), 136.3 (C), 135.8 (C),
79.1 (C), 76.3 (C), 74.8 (CH), 70.5 (CH2), 70.4 (CH2), 70.2 (CH2), 69.9 (CH2), 69.5
(CH2), 50.4 (CH2), 38.5 (CH2), 37.2 (CH2), 29.8 (CH2), 28.5 (CH3). 89 N -(1-(4,5-
Dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-yl)-2-oxo-
7,10,13-trioxa-3-azahexadecan-16-yl)-1-fluorocyclooct-2-ynecarboxamide 85
F O
N
H
O N
H3
O
N
N
O
O
Br
Br
To a solution of tert-butyl (1-(cyclooct-2-yn-1-yl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-
yl)carbamate 86 (50mg, 0.11mmol) in CH2Cl2 (3mL) was added TFA (1.5mL) dropwise
at −20 °C and the reaction mixture stirred at −20 °C for 2 h. After this time, all volatile
materials were removed in vacuo. The crude residue was then dissolved in CH2Cl2 (2mL)
and was added to a solution of 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropy-
ridazin-1(6H )-yl)acetic acid 81 (39 mg, 0.11 mmol), EDC·HCl (22mg, 0.12mmol), and
NEt3 (24 mg, 0.23 mmol) in CH2Cl2 (3 mL). The resulting solution was stirred at 20 °C
for 4 h. Then the reaction mixture was diluted with H2O (15 mL), extracted with EtOAc
(3× 15 mL), the combined organic layers were dried (MgSO4) and concentrated in vacuo.
The crude residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to
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afford N -(1-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-yl)-2-
oxo-7,10,13-trioxa-3-azahexadecan-16-yl)-1-fluorocyclooct-2-ynecarboxamide 85 (16mg,
0.02mmol, 20%) as a yellowish oil: 1H NMR (600 MHz, MeOD) δ 7.10 (br. s, 1H),
7.00 (br. s, 1H), 5.01 (d, J = 2.4 Hz, 2H), 4.88 (s, 2H), 3.69 – 3.64 (m, 4H), 3.63 – 3.55
(m, 8H), 3.40 (q, J = 5.8 Hz, 4H), 2.44 (t, J = 2.4 Hz, 1H), 2.42 – 2.20 (m, 4H), 2.11 –
2.03 (m, 1H), 2.02 – 1.89 (m, 2H), 1.89 – 1.75 (m, 6H), 1.49 – 1.39 (m, 1H); 13C NMR
(150MHz, CDCl3) δ 168.5 (d, 2JC-F = 24.1 Hz, C), 165.3 (C), 153.6 (C), 152.4 (C),
136.4 (C), 135.9 (C), 109.4 (d, 3JC-F = 10.6 Hz, C), 94.6 (d, JC-F = 186.4 Hz, C),
87.5 (d, 2JC-F = 31.6 Hz, C), 76.3 (C), 74.9 (CH), 70.5 (CH2), 70.5 (CH2), 70.4 (CH2),
70.1 (CH2), 70.1 (CH2), 69.9 (CH2), 50.5 (CH2), 46.5 (d, 2JC-F = 24.5 Hz, CH2), 38.8
(CH2), 38.2 (CH2), 37.3 (CH2), 34.0 (CH2), 29.0 (CH2), 28.9 (CH2), 28.5 (CH2), 25.8
(CH2), 20.7 (CH2); IR (thin film) 3301, 2927, 2867, 2123, 1646 cm−1; LRMS (ES+) 723
(50, [M81Br81Br+H]+), 721 (100, [M81Br79Br+H]+), 719 (50, [M79Br79Br+H]+); HRMS
(ES+) calcd for C28H38O7N 794 Br2F [M79Br2+H]+ 719.1091, observed 719.1084.
((1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-(2-(4,5-dibromo-3,6-
dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-1(2H )-yl)acetamido)ethoxy)
ethoxy)ethyl)carbamate 98
H O
NH
O
O
H
NH
O
2
NN
OO
BrBr
To a solution of 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H )-
yl)acetic acid 81 (38 mg, 0.10 mmol), HATU (44 mg, 0.12 mmol), and DIPEA (15 mg,
0.12 mmol) in DMF (2 mL). The resulting solution was stirred at 20 °C for 16 h. Then
the reaction mixture was diluted with H2O (15 mL), extracted with EtOAc (3× 15 mL),
the combined organic layers were dried (MgSO4) and concentrated in vacuo. The
crude residue was purified by flash column chromatography (neat EtOAc) to afford
((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-(2-(4,5-dibromo-3,6-dioxo-2-(prop-
2-yn-1-yl)-3,6-dihydropyridazin-1(2H )-yl)acetamido)ethoxy)ethoxy)ethyl)carbamate 98
(30 mg, 46µmol, 44%) as a yellowish oil: 1H NMR (600 MHz, CDCl3) δ 8.32 (br. s,
0.5H), 6.90 (br. s, 0.5H), 5.94 (br. s, 0.5H), 5.29 (br. s, 0.5H), 5.05 – 4.91 (m, 4H),
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4.14 – 4.10 (m, 2H), 3.70 – 3.54 (m, 8H), 3.50 – 3.44 (m, 2H), 3.40 – 3.30 (m, 2H), 2.45 (s,
1H), 2.31 – 2.17 (m, 6H), 1.61 – 1.51 (m, 2H), 1.41 – 1.24 (m, 1H), 1.01 – 0.85 (m, 2H);
13C NMR (150 MHz, CDCl3) (major rotamer) δ 165.6 (C), 157.0 (C), 153.6 (C), 152.4
(C), 136.5 (C), 135.8 (C), 98.9 (C), 76.2 (C), 75.0 (CH), 70.7 (CH2), 70.5 (CH2), 70.3
(CH2), 69.4 (CH2), 63.0 (CH2), 50.6 (CH2), 40.9 (CH2), 39.8 (CH2), 38.7 (CH3), 37.4
(CH2), 29.1 (CH), 21.5 (CH2), 20.2 (CH), 17.8 (CH2); IR (thin film) 3304, 2916, 2111,
1680, 1644 cm−1; LRMS (ES+) 675 (50, [M81Br81Br+H]+), 673 (100, [M81Br79Br+H]+),
671 (50, [M79Br79Br+H]+); HRMS (ES+) calcd for C26H33N4O779Br2 [M79Br79Br+H]+
671.0716, observed 671.0740.
N -Doxorubicin-14-azido-3,6,9,12-tetraoxatetradecan-1-amide 147
O
O
O
O
OH
OH OH
OH O
O OH
N
H
O
O O 3
N3
To a solution of 14-azido-3,6,9,12-tetraoxatetradecan-1-oic acid (4.4 mg, 16µmol) and
DIPEA (6.2 µL, 35µmol) in DMF (1mL) was added HBTU (6.7 mg, 18 µmol) and the
reaction mixture stirred at 20 °C for 5 min. After this time, doxorubicin 143 (9.3 mg,
16 µmol) was added and the reaction mixture stirred at 20 °C for 3 h. Then the reaction
mixture was diluted with H2O (10 mL) and CH2Cl2 (10 mL), extracted with CH2Cl2
(3× 15 mL), the combined organic layers washed with sat. aq. LiCl (2× 10 mL) and
acetate buffer pH 5.0, dried (MgSO4) and concentrated in vacuo. The crude residue
was purified by flash column chromatography (5% MeOH/EtOAc) to afford 14-azido-N -
((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-
10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H -pyran-4-
yl)-3,6,9,12-tetraoxatetradecan-1-amide 147 (9.0 mg, 11 µmol, 70%) as a red solid: m.p.
61 – 64 °C; 1H NMR (600 MHz, MeOD) δ 13.84 (1H, s), 13.05 (1H, s), 7.79 (1H, d, J
= 7.5 Hz), 7.75 (1H, apt. t, J = 7.9 Hz), 7.48 (1H, d, J = 8.3 Hz), 5.38 – 5.42 (1H,
m), 5.03 – 5.07 (1H, m), 4.74 (2H, d, J = 5.3 Hz), 4.29 (1H, q, J = 6.4 Hz), 4.18 – 4.23
(1H, m), 3.99 (3H, s), 3.58 – 3.70 (17H, m), 3.35 (2H, t, J = 5.3 Hz), 3.01 (1H, d, J =
18.4Hz), 2.84 (1H, d, J = 18.4 Hz), 2.35 (1H, d, J = 14.3 Hz), 2.11 – 2.17 (1H, m), 2.00
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(1H, m), 1.77 (1H, dd, J = 13.2, 4.5 Hz), 1.26 (3H, d, J = 6.8 Hz); 13C NMR (150 MHz,
MeOD) δ 214.8 (C), 187.9 (C), 187.6 (C), 172.0 (C), 162.4 (C), 157.3 (C), 156.1 (C),
137.2 (CH), 136.2 (C), 135.7 (C), 135.1 (C), 121.4 (C), 120.5 (CH), 120.2 (CH), 112.3
(C), 112.1 (C), 102.1 (CH), 77.3 (C), 71.9 (CH2), 71.6 (CH2), 71.5 (CH2), 71.5 (CH2),
71.3 (CH2), 71.2 (CH2), 71.1 (CH), 71.0 (CH2), 69.8 (CH), 68.6 (CH), 65.7 (CH2), 57.1
(CH3), 51.7 (CH2), 46.7 (CH), 37.3 (CH2), 34.0 (CH2), 30.7 (CH2), 17.3 (CH3); IR
(solid) 3405, 3341, 2917, 2100, 1650, 1615, 1578 cm−1; LRMS (ES+) 825 (100, [M+Na]+);
HRMS (ES+) calcd. for C37H46N4O16Na [M+Na]+ 825.2808, observed 825.2807.
4-(6-(Pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 150220
N
N
N N
NN O
OH
To a solution of 2-pyrimidinecarbonitrile 148 (3.6 g, 34 mmol) in 20 mL ethanol were
added 4-cyanobenzoic acid 149 (5.0 g, 34 mmol) and hydrazine monohydrate (8.5 g,
8.3 mL, 0.17 mol). Then the solution was stirred and heated under reflux for 16 h. After
cooling to 20 °C, the solid was collected by filtration and washed with acetone (2× 50 mL).
To the remaining solid was added acetic acid (100 mL) followed by an aqueous solution
of NaNO2 (3.5 g, 51 mmol) at 5 °C and the reaction mixture stirred at 20 °C for 2 h. The
purple colored tetrazine was collected and washed with water (3× 20 mL). The solid
was added into nearly boiled DMF and kept at this temperature for another 5 min. The
DMF solution was filtered whilst it was hot. The filtrate was collected and dried in vacuo
to yield 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 150 (0.80 g, 2.7 mmol,
8%) as a purple solid: 1H NMR (600 MHz, DMSO-d6) δ 13.35 (br. s, 1H), 9.21 (d, J =
4.9 Hz, 2H), 8.71 (d, J = 8.4 Hz, 2H), 8.25 (d, J = 8.4 Hz, 2H), 7.85 (t, J = 4.9 Hz,
1H); 13C NMR (150 MHz, DMSO-d6) δ 166.8 (C), 163.2 (C), 163.0 (C), 159.1 (C), 158.6
(CH), 135.4 (C), 130.3 (CH), 128.4 (CH), 127.9 (C), 123.1 (CH); LRMS (ES−) 279 (100,
[M−H]−).
Appendix A. Experimental 129
2,5-Dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoate
151248
N
N
N N
NN O
O N
O
O
To a solution of 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid 150 (0.10 g,
0.36 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (83 mg,
0.43 mmol) in DMSO/pyridine (19:1, 5 mL) was added N -hydroxysuccinimide (62 mg,
0.54 mmol) and the reaction mixture was stirred at 40 °C for 3 h. Then, the reaction
mixture was diluted with H2O (50mL), extracted with CH2Cl2 (1×30 mL), washed with
brine (3× 20 mL), the combined organic layers were dried (MgSO4) and concentrated in
vacuo. The crude residue was then redissolved in CH2Cl2 (7 mL) and precipitated with
Et2O (50 mL). The precipitate was collected by filtration, washed with Et2O (50 mL)
and dried in vacuo to yield 2,5-dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-
3-yl)benzoate 151 (0.12 g, 32 mmol, 88%) as a red solid: 1H NMR (600 MHz, DMSO-d6)
δ 9.22 (d, J = 4.9 Hz, 2H), 8.85 (d, J = 8.2 Hz, 2H), 8.43 (d, J = 8.2 Hz, 2H), 7.86 (t,
J = 4.9 Hz, 1H), 2.94 (s, 4H); 13C NMR (150 MHz, DMSO-d6) δ 170.3 (C), 163.0 (C),
161.4 (C), 159.1 (C), 158.6 (CH), 137.8 (C), 131.1 (CH), 129.1 (CH), 127.9 (C), 123.2
(CH), 25.6 (CH2); LRMS (ES+) 400 (100, [M+Na]+).
N,N ’-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-diyl))bis(4-(6-
(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzamide) 152a
N
N
N N
NN O
HN
O
N N
NN
N
N
O
O
NH2
To a solution of 4,7,10-trioxa-1,13-tridecanediamine 82 (26 mg, 0.12 mmol) in
DMSO/pyridine (19:1, 5 mL) was added 2,5-dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzoate 151 (80 mg, 24 mmol) and the reaction mixture was stirred
at 20 °C for 16 h. Then, the reaction mixture was diluted with H2O (50mL), extracted
with CH2Cl2 (1×30mL), washed with brine (3× 20 mL), the combined organic layers were
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography
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(5% MeOH/CH2Cl2) yielded N,N ’-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-
diyl))bis(4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzamide) 152a (37 mg, 0.05 mmol,
41%) as a purple solid: 1H NMR (600 MHz, CDCl3) δ 9.13 (d, J = 4.9 Hz, 4H), 8.78
(d, J = 8.4 Hz, 4H), 8.09 (d, J = 8.4 Hz, 4H), 7.59 (t, J = 4.9 Hz, 2H), 7.50 (br. s,
2H), 3.75 – 3.58 (m, 16H), 1.96 – 1.88 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 166.3
(C), 164.2 (C), 163.3 (C), 159.5 (C), 158.6 (CH), 139.2 (C), 133.7 (CH), 129.0 (CH),
128.2 (CH), 122.7 (CH), 71.0 (CH2), 70.5 (CH2), 70.3 (CH2), 39.4 (CH2), 28.9 (CH2);
IR (solid) 3292, 2962, 1632, 1561, 1539 cm−1; LRMS (ES+) 767 (100, [M+Na]+); HRMS
(ES+) calcd. for C36H37N14O5 [M+H]+ 745.3071, observed 745.3074.
N,N’-(3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-Nonadecaoxa
nonapentacontane-1,59-diyl)bis(4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)
benzamide) 152b
N
N
N N
NN O
HN
O
N N
NN
N
N
NH
O
O
18
To a solution of O,O’-bis(2-aminoethyl)octadecaethylene glycol (0.11 g, 0.12 mmol) in
DMSO/pyridine (19:1, 5 mL) was added 2,5-dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzoate 151 (80 mg, 24 mmol) and the reaction mixture was stirred
at 20 °C for 16 h. Then, the reaction mixture was diluted with H2O (50mL), extracted
with CH2Cl2 (1×30mL), washed with brine (3× 20 mL), the combined organic layers were
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography
(5% MeOH/CH2Cl2) yielded N,N’-(3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-
nonadecaoxanonapentacontane-1,59-diyl)bis(4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)
benzamide) 152b (82 mg, 0.04 mmol, 26%) as a purple solid: 1H NMR (600 MHz,
CDCl3) δ 9.15 (d, J = 4.9 Hz, 4H), 8.80 (d, J = 8.3 Hz, 4H), 8.11 (d, J = 8.3 Hz, 4H),
7.61 (t, J = 4.9 Hz, 2H), 7.37 (br. s, 2H), 3.79 – 3.49 (m, 80H); 13C NMR (150 MHz,
CDCl3) δ 166.6 (C), 164.2 (C), 163.3 (C), 159.5 (C), 158.6 (CH), 139.0 (C), 133.8 (CH),
129.0 (CH), 128.4 (CH), 122.8 (CH), 70.6 (CH2), 70.6 (CH2), 70.4 (CH2), 69.9 (CH2),
40.3 (CH2); IR (solid) 3484, 2868, 1650, 1546 cm−1; LRMS (ES+) 1444 (100, [M+Na]+);
HRMS (ES+) calcd. for C66H97N14O21 [M+H]+ 1421.6953 observed 1421.6955.
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N,N’-(4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,
76,79,82,85,88,91,94,97-Dotriacontaoxahectane-1,100-diyl)bis(4-(6-(pyrimidin-
2-yl)-1,2,4,5-tetrazin-3-yl)benzamide) 152c
N
N
N N
NN O
HN
O
N N
NN
N
N
O
O
NH31
To a solution of O,O’-bis(3-aminopropyl)polyethylene glycol 1500 (0.18 g, 0.12 mmol) in
DMSO/pyridine (19:1, 5 mL) was added 2,5-dioxopyrrolidin-1-yl 6-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzoate 151 (80 mg, 24 mmol) and the reaction mixture was stirred
at 20 °C for 16 h. Then, the reaction mixture was diluted with H2O (50mL), extracted
with CH2Cl2 (1×30mL), washed with brine (3× 20 mL), the combined organic layers were
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography
(5% MeOH/CH2Cl2) yielded N,N’-(4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,
55,58,61,64,67,70,73,76,79,82,85,88,91,94,97-dotriacontaoxahectane-1,100-diyl)bis(4-(6-
(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzamide) 152c (0.19 g, 0.09 mmol, 71%) as a
purple solid: 1H NMR (600 MHz, CDCl3) δ 9.11 (d, J = 4.9 Hz, 4H), 8.76 (d, J = 8.3 Hz,
4H), 8.04 (d, J = 8.3 Hz, 4H), 7.58 (t, J = 4.9 Hz, 2H), 7.50 (br. s, 2H), 3.76 – 3.48 (m,
130H), 1.90 (quint., J = 5.7 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 166.1 (C), 164.1
(C), 163.2 (C), 159.5 (C), 158.5 (CH), 139.2 (C), 133.6 (CH), 128.8 (CH), 128.2 (CH),
122.7 (CH), 70.8 (CH2), 70.6 (CH2), 70.5 (CH2), 70.3 (CH2), 39.3 (CH2), 28.7 (CH2);
IR (solid) 2921, 1656, 1562 cm−1; LRMS (MALDI) 2024±44 (100, [M]).
1,2-Diethyl-1,2-dihydro-pyridazine-3,6-dione 10252
NN
OO
Et Et
To a solution of maleic anhydride 57 (98 mg, 1.0 mmol) in glacial AcOH (3 mL) was
added N,N’-diethylhydrazine·2HCl (0.16 g, 1.0 mmol) and the reaction mixture heated
at 130 °C for 16 h. The solvent was removed in vacuo and the crude residue purified
by column chromatography (50% EtOAc/petrol to neat EtOAc) to give 1,2-diethyl-1,2-
dihydro-pyridazine-3,6-dione 102 (0.12 g, 0.72 mmol, 72%) as a white solid: 1H NMR
(600 MHz, CDCl3) δ 6.85 (s, 2H), 4.11 (q, J = 7.0 Hz, 4H), 1.25 (t, J = 7.0 Hz, 6H); 13C
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NMR (150 MHz, CDCl3) δ 157.6 (C), 134.7 (CH), 40.2 (CH2), 13.3 (CH3); IR (solid)
2984, 1636, 1590 cm−1; LRMS (CI) 169 (100, [M+H]+); HRMS (CI) calcd for C8H13N2O2
[M+H]+ 169.0977, observed 169.0980.
4-Bromo-1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 10352
NN
OO
Et Et
Br
To a solution of 1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 102 (0.17 g, 1.0 mmol) in
CH2Cl2 (3 mL) was added Br2 (1.6 g, 0.51 mL, 10 mmol) and the reaction mixture
stirred at 20 °C for 16 h. The solvent and excess Br2 were removed in vacuo and then
NEt3 (0.41 g, 0.56mL, 4.0 mmol) and CH2Cl2 (3 mL) were added and the reaction
mixture stirred at 20 °C for 16 h. The solvent was removed in vacuo and the crude
residue purified by column chromatography (50% EtOAc/petrol to neat EtOAc) to give
4-bromo-1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 103 (0.23 g, 0.92 mmol, 92%) as
a yellow solid: m.p. 80 – 82 °C; 1H NMR (600 MHz, CDCl3) δ 7.31 (s, 1H), 4.14 (q, J
= 7.0 Hz, 2H), 4.07 (q, J = 7.0 Hz, 2H), 1.26 (t, J = 7.0 Hz, 3H), 1.22 (t, J = 7.0 Hz,
3H); 13C NMR (150 MHz, CDCl3) δ 156.2 (C), 154.3 (C), 136.0 (CH), 133.7 (C), 41.9
(CH2), 40.7 (CH2), 13.3 (CH3), 13.3 (CH3); IR (solid) 3058, 2979, 2938, 1631, 1595 cm−1;
LRMS (CI) 249 (100, [M81Br+H]+), 247 (100, [M79Br +H]+); HRMS (CI) calcd for
C8H12BrN2O2 [M81Br+H]+ 249.0082, observed 249.0086.
4,5-Dibromo-1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 10452
NN
OO
Et Et
Br Br
To a solution of 4-bromo-1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 103 (0.25 mg,
1.0mmol) in CH2Cl2 (3 mL) was added Br2 (1.6 g, 0.51 mL, 10 mmol) and the reaction
mixture stirred at 50 °C for 72 h. The solvent and excess Br2 were removed in vacuo
and then NEt3 (0.41 g, 0.56mL, 4.0mmol) and CH2Cl2 (3 mL) were added and the
reaction mixture stirred at 20 °C for 16 h. The solvent was removed in vacuo and the
crude residue purified by column chromatography (50% EtOAc/petrol to neat EtOAc)
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to give 4,5-dibromo-1,2-diethyl-1,2-dihydro-pyridazine-3,6-dione 104 (0.30 g, 0.91 mmol,
91%) as a yellow solid: m.p. 112 – 114 °C 1H NMR (600 MHz, CDCl3) δ 4.17 (q, J =
7.0 Hz, 4H), 1.28 (t, J = 7.0 Hz, 6H); 1C NMR (150 MHz, CDCl3) δ 153.3 (C), 136.1
(C), 42.4 (CH2), 13.2 (CH3); IR (solid) 2979, 2937, 1630, 1574 cm−1; LRMS (EI) 328 (50,
[M81Br81Br]+•), 326 (100, [M81Br79Br]+•), 324 (50, [M79Br79Br]+•); HRMS (EI) calcd
for C8H10Br2N2O2 [M79Br79Br]+• 323.9104, observed 323.9097.
Tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate 114181
N N
Boc
Boc Boc
To a solution of methylhydrazine 113 (1.0 g, 1.1mL 22mmol), NEt3 (4.3 g, 6.0mL,
43mmol) and DMAP (0.26 g, 2.2mmol) in CH2Cl2 (75mL) was added Boc2O (19 g,
87mmol) and the reaction mixture stirred at 20 °C for 72 h. Then the reaction mixture
was diluted with H2O (80mL), extracted with EtOAc (3 × 60 mL), the combined
organic layers were dried (MgSO4) and concentrated in vacuo. The crude residue was
purified by flash column chromatography (20% EtOAc/petrol) to afford tri-tert-butyl
2-methylhydrazine-1,1,2-tricarboxylate 114 (7.4 g, 22mmol, 99%) as a yellowish oil: 1H
NMR (600 MHz, CDCl3) (major rotamer) δ 3.05 (s, 3H), 1.51 – 1.43 (m, 27H); 13C NMR
(150 MHz, CDCl3) (major rotamer) δ 154.0 (C), 150.1 (C) 83.4 (C), 81.4 (C), 35.7 (CH3),
28.3 (CH3), 28.1 (CH3); LRMS (ES+) 369 (100, [M+Na]+).
Di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate 109180
N NH
Boc Boc
To a solution of tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate 114 (2.0 g,
5.8mmol), in dry MeCN (15mL) was added Mg(ClO4)2 (0.27 g, 1.2mmol) and the
reaction mixture stirred at 20 °C for 1 h. Then the reaction mixture was diluted with 10%
aq. citric acid (20mL) and Et2O (15mL), extracted with Et2O (3×20 mL), the combined
organic layers were dried (MgSO4) and concentrated in vacuo. The crude residue was
purified by flash column chromatography (15% EtOAc/petrol) to afford di-tert-butyl
1-methylhydrazine-1,2-dicarboxylate 109 (1.3 g, 5.2mmol, 89%) as a white solid: m.p.
54 – 55 °C (lit. m.p.180 55 – 56 °C); 1H NMR (600 MHz, CDCl3) (major rotamer) δ 6.40
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(br. s, 1H), 3.11 (s, 3H), 1.48 – 1.45 (m, 18H); 13C NMR (150 MHz, CDCl3) (major
rotamer) δ 155.9 (C), 155.1 (C) 81.3 (C), 81.1 (C), 37.6 (CH3), 28.3 (CH3), 28.1 (CH3);
IR (solid) 3316, 2978, 2932, 1701 cm−1; LRMS (ES+) 269 (100, [M+Na]+); HRMS (ES+)
calcd. for C11H22N2O4Na [M+Na]+ 269.1477, observed 269.1476.
Di-tert-butyl 1-(2-(t-butoxy)-2-oxoethyl)-2-methylhydrazine-1,2-dicarboxylate
115
N N
Boc Boc
O
O
To a solution of di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate 109 (0.94 g, 3.8mmol)
in DMF (20mL) were added caesium carbonate (1.9 g, 5.7mmol) and tert-butyl
bromoacetate (1.1 g, 0.84mL, 5.7mmol) and the reaction mixture stirred at 20 °C for 16 h.
After this time, the reaction mixture was diluted with H2O (50mL), extracted with Et2O
(4× 50 mL), the combined organic layers washed with sat. aq. LiCl (2× 30 mL), dried
(MgSO4), and concentrated in vacuo. Purification by flash column chromatography (10%
Et2O/petrol) yielded di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-methylhydrazine-1,2-
dicarboxylate 115 (1.3 g, 3.7mmol, 98%) as a colourless oil: 1H NMR (600 MHz, CDCl3)
δ 4.73 – 4.04 (m, 2H), 3.68 – 3.10 (m, 3H), 1.54 – 1.39 (m, 27H); 13C NMR (150 MHz,
CDCl3) (major rotamer) δ 169.2 (C), 155.2 (C), 81.9 (C), 81.6 (C), 81.1 (C), 52.7
(CH2), 36.8 (CH3), 28.4 (CH3), 28.3 (CH3), 28.2 (CH3); IR (thin film) 2978, 1748 cm−1;
LRMS (ES+) 361 (100, [M+H]+); HRMS (ES+) calcd for C17H33O6N2 [M+H]+ 361.2339,
observed 361.2333.
2-(4,5-Dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetic
acid 116
N NHO
O
OO
Br Br
To a solution of di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-methylhydrazine-1,2-
dicarboxylate 115 (1.0 g, 2.8mmol) in CH2Cl2 (10 mL) was added TFA (10 mL) and
the reaction mixture stirred at 20 °C for 2 h. After this time, all volatile materials were
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removed in vacuo. The crude residue was added to a solution of 2,3-dibromomaleic
anhydride 58 (0.75 g, 2.8mmol) in glacial AcOH (40mL), and the reaction mixture stirred
at 20 °C for 16 h heated at 130 °C for 16 h. Then the reaction mixture was concentrated
in vacuo, and purification by flash column chromatography (3% MeOH/CH2Cl2 with 1%
AcOH) yielded 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetic
acid 116 (0.65 g, 1.9mmol, 73%) as a white solid: m.p. 210 – 214 °C; 1H NMR (600 MHz,
MeOD) δ 4.96 (s, 2H), 3.62 (s, 3H); 13C NMR (150 MHz, MeOD) δ 170.2 (C), 154.8
(C), 154.0 (C), 137.4 (C), 135.7 (C), 49.5 (CH2), 35.0 (CH3); IR (solid) 3023, 2969, 1731,
1662 cm−1; LRMS (ES−) 338 (50, [M81Br81Br-H]−), 340 (100, [M81Br79Br-H]−), 342 (50,
[M79Br79Br-H]−); HRMS (ES−) calcd for C7H5N2O479Br2 [M79Br79Br-H]− 337.8538,
observed 337.8540.
Perfluorophenyl 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1
(2H )-yl)acetate 118
NN O
O
O O
BrBr
F
F F
F
F
To a solution of 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetic
acid 116 (50 mg, 0.15 mmol) in dioxane (5 mL) were added DCC (33 mg, 0.16 mmol)
and pentafluorophenol (32 mg, 0.18 mmol). The resulting solution was stirred at 20 °C for
16 h. Then the reaction mixture was diluted with H2O (15 mL), extracted with EtOAc
(3× 15 mL), the combined organic layers were washed with sat. aq. sodium bicarbonate
(3×10 mL), dried (MgSO4) and concentrated in vacuo. The crude residue was purified by
flash column chromatography (0 – 2% EtOAc/CH2Cl2) to afford perfluorophenyl 2-(4,5-
dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetate 118 (25 mg, 50 µmol,
34%) as a yellowish oil: 1H NMR (500 MHz, CDCl3) δ 5.23 (s, 2H), 3.67 (s, 3H); 13C
NMR (125 MHz, CDCl3) δ 163.1 (C), 153.6 (C), 152.8 (C), 137.6 (C), 134.6 (C), 47.6
(CH2), 34.8 (CH3).
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N -(2-(2-(2-Azidoethoxy)ethoxy)ethyl)-2-(4,5-dibromo-2-methyl-3,6-dioxo-3,
6-dihydropyridazin-1(2H )-yl)acetamide 120
OON
H
O
N
N
O
O
Br
Br
N3
To a solution of perfluorophenyl 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-
1(2H )-yl)acetate 118 (19 mg, 37µmol) in CH2Cl2 (0.5 mL) were added 2-(2-(2-
azidoethoxy)ethoxy)ethan-1-amine 119 (9.0 mg, 41µmol), and NEt3 (5.6 mg, 5.8 µL,
55 µmol). The resulting solution was stirred at 20 °C for 16 h. Then the reaction mixture
was diluted with H2O (5 mL), extracted with EtOAc (3× 10 mL), the combined organic
layers were washed with sat. aq. sodium bicarbonate (3× 5 mL), dried (MgSO4) and
concentrated in vacuo. The crude residue was purified by flash column chromatography
(0 – 5% MeOH/CH2Cl2) to afford N -(2-(2-(2-azidoethoxy)ethoxy)ethyl)-2-(4,5-dibromo-2-
methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetamide 120 (15 mg, 30 µmol, 81%) as
a yellowish oil: 1H NMR (500 MHz, CDCl3) δ 6.84 (t, J = 5.6 Hz, 1H), 4.73 (s, 2H), 3.72 –
3.61 (m, 14H), 3.60 – 3.56 (m, 2H), 3.48 (td, J = 5.6, 4.6 Hz, 2H), 3.41 (t, J = 4.6 Hz,
2H), 1.74 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 165.4 (C), 152.5 (C), 152.2 (C), 137.0
(C), 134.7 (C), 70.7 (CH2), 70.5 (CH2), 70.4 (CH2), 70.0 (CH2), 69.4 (CH2), 50.8 (CH2),
39.8 (CH2), 35.0 (CH3); IR (thin film) 3247, 2965, 2101, 1688, 1634 cm−1; LRMS (ES+)
501 (50, [M81Br81Br+H]+), 499 (100, [M81Br79Br+H]+), 497 (50, [M79Br79Br+H]+);
HRMS (ES+) calcd for C13H19N6O579Br2 [M79Br79Br+H]+ 496.9784, observed 496.9790.
((1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-(2-(4,5-dibromo-2-
methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetamido)ethoxy)ethoxy)
ethyl)carbamate 121
H O
NH
O
O
H
NH
O
2
NN
OO
BrBr
To a solution of 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetic
acid 116 (86 mg, 0.25 mmol), PyBOP (0.14 g, 0.28 mmol), and DIPEA (36 mg,
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0.28 mmol) in CH2Cl2 (5 mL). The resulting solution was stirred at 20 °C for 16 h.
Then the reaction mixture was diluted with H2O (15 mL), extracted with EtOAc
(3 × 15 mL), the combined organic layers were dried (MgSO4) and concentrated in
vacuo. The crude residue was purified by flash column chromatography (neat EtOAc) to
afford ((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-(2-(4,5-dibromo-2-methyl-
3,6-dioxo-3,6-dihydropyridazin-1(2H )-yl)acetamido)ethoxy)ethoxy)ethyl)carbamate 121
(87 mg, 0.14 mmol, 54%) as a yellowish oil: 1H NMR (600 MHz, CDCl3) δ 8.34 (br. s,
0.5H), 7.00 (br. s, 0.5H), 5.96 (br. s, 0.5H), 5.29 (br. s, 0.5H), 4.85 – 4.73 (m, 2H), 4.12
(d, J = 8.2 Hz, 2H), 3.76 – 3.50 (m, 11H), 3.50 – 3.43 (m, 2H), 3.40 – 3.30 (m, 2H), 2.31 –
2.17 (m, 6H), 1.61 – 1.51 (m, 2H), 1.41 – 1.24 (m, 1H), 1.01 – 0.85 (m, 2H); 13C NMR
(150 MHz, CDCl3) (major rotamer) δ 165.6 (C), 157.8 (C), 153.4 (C), 152.5 (C), 137.0
(C), 134.8 (C), 98.9 (C), 70.8 (CH2), 70.6 (CH2), 70.5 (CH2), 70.3 (CH2), 70.2 (CH2),
70.0 (CH2), 69.6 (CH2), 69.4 (CH2), 63.0 (CH2), 50.9 (CH2), 40.9 (CH2), 39.7 (CH3),
35.0 (CH2), 29.1 (CH), 21.5 (CH2), 20.2 (CH), 17.8 (CH2); IR (thin film) 3338, 2925,
1685, 1633 cm−1; LRMS (ES+) 651 (50, [M81Br81Br+H]+), 649 (100, [M81Br79Br+H]+),
647 (50, [M79Br79Br+H]+); HRMS (ES+) calcd for C24H33N4O779Br2 [M79Br79Br+H]+
647.0716, observed 647.0713.
2-(4-Azidobenzyl)-4-bromo-1-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione 100
Br
N
N
O
O
N3
To a solution of di-tert-butyl 1-(4-azidobenzyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate 56 (0.24 mg, 0.59 mmol) in CH2Cl2 (9 mL) was added TFA (3 mL) and
the reaction mixture stirred at 20 °C for 2 h. After this time, all volatile material was
removed in vacuo using toluene to form an azeotrope. The crude residue was added to a
solution of bromomaleic anhydride (0.13 g, 0.71 mmol) in glacial AcOH (15 mL), and the
reaction mixture heated at 130 °C for 16 h. Then the reaction mixture was concentrated
in vacuo, and purification by flash column chromatography (20% EtOAc/petrol) yielded
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an inseparable mixture of regioisomers 2-(4-azidobenzyl)-4-bromo-1-(prop-2-yn-1-yl)-
1,2-dihydropyridazine-3,6-dione and 1-(4-azidobenzyl)-4-bromo-2-(prop-2-yn-1-yl)-1,2-
dihydropyridazine-3,6-dione 100 (0.13 g, 0.35 mmol, 60%) as an orange oil: 1H NMR
(600 MHz, CDCl3) (major regioisomer) δ 7.42 (s, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.02
(d, J = 8.3 Hz, 2H), 5.47 (s, 2H), 4.68 (d, J = 2.5 Hz, 2H), 2.42 (t, J = 2.5 Hz, 1H);
13C NMR (150 MHz, CDCl3) (major regioisomer) δ 155.8 (C), 154.5 (C), 140.7 (C),
135.9 (CH), 134.6 (C), 131.2 (C), 128.5 (CH), 120.0 (CH), 76.1 (C), 74.7 (CH), 49.9
(CH2), 35.4 (CH2); IR (solid) 3299, 3140, 3066, 2970, 2249, 2110, 1637, 1596 cm−1;
LRMS (ES+) 384 (100, [M81Br+Na]+), 382 (100, [M79Br+Na]+); HRMS (ES+) calcd
for C14H10N5O581BrNa [M81Br+Na]+ 383.9897, observed 383.9721.
Methyl (S)-(2-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-yl)-1,2,3,6-tetrahydro
pyridazin-4-yl)-N -(tert-butoxycarbonyl)-L-cysteinate 175
S N
N
O
O
N3
BocHN
O
O
To a mixture of regioisomers 2-(4-azidobenzyl)-4-bromo-1-(prop-2-yn-1-yl)-1,2-
dihydropyridazine-3,6-dione and 1-(4-azidobenzyl)-4-bromo-2-(prop-2-yn-1-yl)-1,2-
dihydropyridazine-3,6-dione 100 (65 mg, 0.19 mmol) in CH2Cl2 (5 mL) were added
NEt3 (0.22 mg, 0.22 mmol) and N -(tert-butoxycarbonyl)-l-cysteine methyl ester (53 mg,
0.22 mmol) and the mixture was stirred at 20 °C for 2 h. The reaction mixture
was then concentrated in vacuo, and purification by flash column chromatography
(20% EtOAc/petrol) yielded an inseparable mixture of regioisomers methyl (S)-(1-
(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -(tert-
butoxycarbonyl)-l-cysteinate and methyl (S)-(2-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-
1-yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -(tert-butoxycarbonyl)-l-cysteinate 175 (86 mg,
0.17 mmol, 89%) as a yellow viscous oil: 1H NMR (600 MHz, CDCl3) (major regioisomer)
δ 7.22 (m, 2H), 7.00 (d, J = 8.4 Hz, 2H), 6.65 (s, 1H), 5.52 – 5.31 (m, 3H), 4.75 – 4.58
(m, 3H), 3.80 (s, 3H), 3.36 (m, J = 5.0 Hz, 1H), 3.24 (m, J = 5.0 Hz, 1H), 2.38 (t, J
= 2.5 Hz, 1H), 1.44 (s, 9H); 13C NMR (150 MHz, CDCl3) (major regioisomer) δ 170.5
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(C), 156.4 (C), 155.1 (C), 149.9 (C), 140.5 (C), 131.3 (C), 128.5 (CH), 122.8 (CH), 119.9
(CH), 80.9 (C), 76.2 (C), 74.4 (CH), 53.3 (CH3), 52.0 (CH), 48.1 (CH2), 35.6 (CH2),
33.3 (CH2), 28.4 (CH3); IR (film) 3289, 2974, 2241, 2109, 1744, 1710, 1628 cm−1; LRMS
(ES+) 537 (100, [M+Na]+); HRMS (ES+) calcd for C23H26N6O6SNa [M+Na]+ 537.1532,
observed 537.1533.
Methyl N -(tert-butoxycarbonyl)-(S)-(3-hydroxy-6-oxo-1-(prop-2-yn-1-yl)-1,
6-dihydropyridazin-4-yl)-L-cysteinate 177
S N
N
O
OH
BocHN
O
O
To a an mixture of regioisomers methyl (S)-(1-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-
yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -(tert-butoxycarbonyl)-l-cysteinate and methyl
(S)-(2-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -
(tert-butoxycarbonyl)-l-cysteinate 175 (20 mg, 44 µmol) in DMF (2 mL) was added
TCEP·HCl (13 mg, 53 µmol) and the mixture was stirred at 20 °C for 2 h. The reaction
mixture was then concentrated in vacuo, and purification by flash column chromatography
(5% MeOH/CH2Cl2) yielded methyl N -(tert-butoxycarbonyl)-(S)-(3-hydroxy-6-oxo-1-
(prop-2-yn-1-yl)-1,6-dihydropyridazin-4-yl)-l-cysteinate 177 (14 mg, 36 µmol, 82%) as a
yellow oil: 1H NMR (600 MHz, CDCl3) (major regioisomer) δ 6.80 (s, 1H), 5.42 (d, J =
7.4 Hz, 1H), 4.81 – 4.74 (m, 2H), 4.71 – 4.66 (m, 1H), 3.80 (s, 3H), 3.42 – 3.28 (m, 2H),
2.32 (t, J = 2.5 Hz, 1H), 1.45 (s, 9H); 13C NMR (150 MHz, CDCl3) (major regioisomer)
δ 170.5 (C), 156.0 (C), 155.3 (C), 152.0 (C), 147.9 (C), 115.4 (CH), 81.0 (C), 73.1 (CH),
53.2 (CH3), 52.4 (CH), 40.3 (CH2), 33.0 (CH2), 28.4 (CH3); IR (film) 3295, 2960, 2922,
2851, 2109, 1743, 1708, 1637 cm−1; LRMS (ES+) 406 (100, [M+Na]+); HRMS (ES+)
calcd for C16H18N3O6SNa [M+Na]+ 406.1049, observed 406.1049.
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2-(4-Azidobenzyl)-4-(hexylthio)-1-(prop-2-yn-1-yl)-1,2-dihydropyridazine-
3,6-dione 176
S N
N
O
O
N3
5
To a an mixture of regioisomers methyl (S)-(1-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-
yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -(tert-butoxycarbonyl)-l-cysteinate and methyl
(S)-(2-(4-azidobenzyl)-3,6-dioxo-1-(prop-2-yn-1-yl)-1,2,3,6-tetrahydropyridazin-4-yl)-N -
(tert-butoxycarbonyl)-l-cysteinate 175 (86 mg, 0.17 mmol) in THF/PBS at pH 7.4 (1:1,
2 mL) was added hexane thiol (0.30 g, 2.6 mmol) and the mixture was stirred at 20 °C
for 72 h. The reaction mixture was then concentrated in vacuo, and purification by
flash column chromatography (20% EtOAc/petrol) yielded an inseparable mixture of
regioisomers 2-(4-azidobenzyl)-4-(hexylthio)-1-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione and 1-(4-azidobenzyl)-4-(hexylthio)-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione (47 mg, 0.12 mmol, 71%) as a colourless oil: 1H NMR (600 MHz, CDCl3) (major
regioisomer) δ 7.26 – 7.19 (m, 2H), 7.04 – 6.98 (m, 2H), 6.58 (s, 1H), 5.42 (s, 2H), 4.71
(d, J = 2.5 Hz, 2H), 2.80 (t, J = 7.4 Hz, 2H), 2.41 (t, J = 2.5 Hz, 1H), 1.79 – 1.70 (m,
2H), 1.52 – 1.44 (m, 2H), 1.37 – 1.30 (m, 4H), 0.94 – 0.88 (m, 3H); 13C NMR (150 MHz,
CDCl3) (major regioisomer) δ 157.0 (C), 155.7 (C), 150.7 (C), 140.3 (C), 131.9 (C), 128.3
(CH), 121.8 (CH), 119.9 (CH), 76.3 (C), 74.5 (CH), 48.1 (CH2), 35.5 (CH2), 31.4 (CH2),
31.0 (CH2), 28.8 (CH2), 27.3 (CH2), 22.6 (CH2), 14.1 (CH3); IR (film) 3245, 2955, 2928,
2856, 2243, 2108, 1680, 1631 cm−1; LRMS (ES+) 398 (100, [M+H]+); HRMS (ES+)
calcd for C20H24N5O2S [M+H]+ 398.1651, observed 398.1654.
N -(2-Azidoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide 162249
N
S NH
O
O
N3
To a solution of dansyl chloride (0.27 g, 1.0 mmol) in CH2Cl2 (10 mL) were added 2-
bromoethylamine hydrobromide (0.21 g, 1.0 mmol) and NEt3 (0.28 mL, 2.0 mmol).
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The reaction mixture was stirred at 20 °C for 4 h. After this time, all volatile
material was removed in vacuo. The crude residue was then added to a solution
of NaN3 (0.16 g, 2.5 mmol) in MeCN (10 mL), and the reaction mixture heated
at 90 °C for 16 h. Then, the reaction mixture was concentrated in vacuo, and
purification by flash column chromatography (50% Et2O/petrol) yielded N -(2-azidoethyl)-
5-(dimethylamino)naphthalene-1-sulfonamide 162 as a light green oil (0.19 g, 0.59 mmol
59%): 1H NMR (600 MHz, CDCl3) δ 8.57 (d, J = 8.5 Hz, 1H), 8.28 – 8.23 (m, 2H), 7.60
(dd, J = 8.5, 7.3 Hz, 1H), 7.53 (dd, J = 8.5, 7.3 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H),
4.99 (t, J = 6.4 Hz, 1H), 3.34 – 3.28 (m, 2H), 3.09 – 3.02 (m, 2H), 2.90 (s, 6H); 13C NMR
(150 MHz, CDCl3) δ 152.2 (C),134.5 (C), 130.9 (CH), 130.0 (C), 129.8 (CH), 129.6 (C),
128.8 (CH), 123.3 (CH), 118.6 (CH), 115.5 (CH), 51.0 (CH2), 45.6 (CH3), 42.5 (CH2);
HRMS (ES+) calcd for C14H18N5O2S [M+H]+ 320.1181, observed 320.1184.
N -methoxycarbonyl-3-bromomaleimide 106170
N
O
O
Br O
O
To a solution of 3-bromomaleimide (0.20 g, 1.1 mmol) and N -methylmorpholine (0.13 mL,
1.1 mmol) in THF (10 mL) was added methylchloroformate (88 µL, 1.1 mmol) and the
reaction mixture was stirred for 30 min at 20 °C. After this time, the reaction mixture was
diluted with CH2Cl2 (20 mL), the organic phase was washed with H2O, dried (MgSO4),
and concentrated in vacuo to yield N -methoxycarbonyl-3-bromomaleimide 106 (0.27 g,
1.1 mmol, 100%) as a pale pink solid: m.p. 120 – 122 °C; 1H NMR (600 MHz, CDCl3) δ
7.04 (s, 1H), 4.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 163.5 (C), 160.9 (C), 147.6
(C), 133.3 (C), 133.1 (CH), 54.7 (CH3); IR (solid) 1808, 1763, 1724, 1603, 1438, 1320,
1263, 1070 cm−1.
Di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate 110
N
H
NO
O
O
O
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 54 (7.0 g, 30 mmol) and
caesium carbonate (4.0 g, 12 mmol) in DMF (50 mL) was added bromoethane (0.64mL,
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6.0 mmol) and the reaction mixture stirred at 20 °C for 16 h. After this time, the
reaction mixture was diluted with EtOAc (75 mL) and washed with H2O (3× 40 mL)
and brine (3 × 30 mL). The organic phase was then concentrated in vacuo, and cold
hexane was added to the crude residue to precipitate out and recover the excess di-
tert-butyl hydrazine-1,2-dicarboxylate 54 as a white solid through recrystallisation and
filtration. The filtrate was then concentrated further in vacuo, and purification by flash
column chromatography (5 – 15% EtOAc/petrol) yielded di-tert-butyl 1-ethylhydrazine-
1,2-dicarboxylate 110 (0.64 g, 2.5 mmol, 41%) as a white crystalline solid: m.p. 54 – 57 °C;
1H NMR (600 MHz, CDCl3) δ 6.15 (br. s, 1H), 3.49 (m, 2H), 1.48 – 1.45 (m, 18H), 1.14
(t, J = 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 155.3 (C), 81.2 (C), 81.0 (C),
45.8 (CH2), 44.1 (CH2), 28.4 (CH3), 28.3 (CH3), 12.7 (CH3); IR (solid) 3313, 2978,
2934, 1706 cm−1; LRMS (ES+) 261 (100, [M+H]+); HRMS (ES+) calcd for C12H24N2O4
[M+H]+ 261.1814, observed 261.1813.
Di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate 112
N
NO
O
O
O
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 54 (1.0 g, 4.3 mmol) and
caesium carbonate (5.6 g, 17 mmol) in DMF (20 mL) was added bromoethane (1.1 g,
10 mmol) and the reaction mixture stirred at 20 °C for 24 h. After this time, the reaction
mixture was diluted with EtOAc (50 mL) and washed with H2O (4× 20 mL) and brine
(2× 20 mL). The organic phase was then concentrated in vacuo, and purification by flash
column chromatography (50% EtOAc/petrol) yielded di-tert-butyl 1,2-diethylhydrazine-
1,2-dicarboxylate 112 (1.1 g, 3.8 mmol, 88%) as a colourless oil. 1H NMR (300 MHz,
CDCl3) δ 3.57 – 3.33 (m, 4H), 1.50 – 1.39 (m, 18H), 1.16 (t, J = 7.2 Hz, 6H); 13C
NMR (75 MHz, CDCl3) δ 155.1 (C), 80.6 (C), 46.37 (CH2), 44.37 (CH2), 28.35 (CH3),
28.27 (CH3), 13.56 (CH3), 12.95 (CH3); IR (thin film) 2980, 2927, 2881, 1698 cm−1;
LRMS (ES+) 288 (100, [M+H]+); HRMS (ES+) calcd for C16H32N2O [M+H]+ 288.2049,
observed 288.2054.
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A.3 Protein modification
A.3.1 Antibody modification
A.3.1.1 Antibody digestion
Attempted preparation of a trastuzumab Fab using the protocol described
by K. L. Bennett et al.191
In accordance with the report by K. L. Bennett et al.,191 trastuzumab 19 (6.4mg·mL−1)
in digestion buffer was reacted with a 1/10 amount (wt/wt) of immobilised papain
(250 µg·mL−1 of gel) for 20 h at 37 °C under nitrogen in a buffer containing 20mm sodium
phosphate monobasic, 10mm disodium EDTA and 80mm cysteine·HCl (pH 7.0). The
cysteine·HCl was incorporated immediately before trastuzumab digestion. After digestion,
the mixture was centrifuged at 200 g for 5 min and the supernatant was removed for
purification. The supernatant was concentrated to a volume of 200 µL using a diafiltration
column (30 kDa MWCO) to purify it from low-molecular-weight proteolytic contaminants,
and buffer exchanged into phosphate-buffered saline (PBS, pH 7.0) by passage through
diafiltration columns (30 kDa MWCO) four times with excessive PBS (pH 7.0). Finally,
the sample was analysed by LCMS and revealed a mixture of Fab products, LCMS:
observed masses: 47 309 and 47 675Da.
Preparation of trastuzumab Fab using sequential digests with pepsin and
papain
Immobilised pepsin (0.15 mL) was washed with digestion buffer (20mm sodium acetate
trihydrate, pH 3.1) four times and trastuzumab 19 (0.5 mL, 6.4mg·mL−1 in digestion
buffer) was added. The mixture was incubated for 5 h at 37 °C whilst shaking (1100 rpm).
The resin was separated from the digest using a filter column, and washed with digest
buffer (50mm phosphate, 1mm EDTA, 150mm NaCl, pH 6.8) three times. The digest
was combined with the washes and the volume adjusted to 0.5 mL. The sample was
analysed by LCMS and revealed formation of F(ab’)2 125, LCMS: observed mass:
97 303Da. After this, papain (1.0 mL, 0.25mg·mL−1) was activated with 10mm DTT
(in digest buffer: 50mm phosphate, 1mm EDTA, 150mm NaCl, pH 6.8) under an argon
atmosphere whilst shaking (1100 rpm) for 1 h at 25 °C in the dark. The resin was
washed with digest buffer (without DTT) four times and the 0.5 mL of F(ab’)2 125
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added. The mixture was incubated for 16 h at 37 °C whilst shaking (1100 rpm) in the
dark. Then the resin was separated from the digest using a filter column, and washed
with PBS (pH 7.0) three times. The digest was combined with the washes and the
buffer was exchanged completely for PBS (pH 7.4) using diafiltration columns (10 kDa
MWCO) and the volume adjusted to 0.4 mL. The digest was analysed by SDS-PAGE
and LCMS to reveal formation of a single FabHer fragment 127: observed mass 47 650Da.
The concentration of FabHer was determined by UV/VIS using a molecular extinction
coefficient of ε280 = 68 590m−1·cm−1. [Fab] = 3.3mg·mL−1 (0.40 mL, 64%).
Preparation of rituximab Fab using digest with papain
Immobilised papain (0.3 mL, 0.25mg·mL−1) was activated with 10mm DTT (in digest
buffer: 50mm phosphate, 1mm EDTA, 150mm NaCl, pH 6.8) under an argon atmosphere
whilst shaking (1100 rpm) for 1 h at 25 °C in the dark. The resin was washed with digest
buffer (without DTT) four times and rituximab 122 (3 mg in 0.5 mL of digest buffer)
was added. The mixture was incubated for 16 h at 37 °C whilst shaking (1100 rpm) in
the dark. Then the resin was separated from the digest using a filter column, and washed
with PBS (pH 7.0) three times. The digest was combined with the washes and the
buffer was exchanged completely for PBS (pH 7.4) using diafiltration columns (10 kDa
MWCO) and the volume adjusted to 1.5 mL. Then, the sample was applied to a NAb
protein A column (Thermo Scientific) and incubated at 20 °C under constant agitation
for 1 h. The Fab fraction, FabRit 123, was eluted according to manufacturers’ protocol,
the column washed three times with PBS (pH 7.4) and the Fc fraction, FcRit 124, eluted
four times with 0.2m glycine·HCl, pH 2.5, which was neutralised with 10% of the volume
of a 1m Tris, pH 8.5 solution. The FabRit 123 fraction was combined with the washes
and both FabRit and FcRit solutions were buffer exchanged into PBS using diafiltration
columns (10 kDa MWCO). The digests were analysed by SDS-PAGE and LCMS to
reveal formation of FabRit 123: observed mass 47 185Da, and glycosylated FcRit 124:
observed mass 52 922Da. The concentration of FabRit 123 was determined by UV/VIS
using a molecular extinction coefficient of ε280 = 82 905m−1·cm−1.
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A.3.1.2 General procedures
General procedure for the preparation of the FabHer-Pyridazinedione conju-
gate (FabHer-PD)
To a solution of FabHer 127 (50 µL, 30 µm, 1.4mg·mL−1, 1 eq.) in borate buffer (25mm
sodium borate, 25mm NaCl, 1mm EDTA, pH 8.0) was added TCEP (final concentration
90 µm, 3 eq.) and the reaction mixture incubated at 37 °C for 90 min. After this time,
was added a solution of pyridazinedione in DMF (final concentration 1.5mm, 5 eq.)
and the reaction mixture incubated at 37 °C for 1 h. The excess reagents were then
removed by repeated diafiltration into fresh buffer using VivaSpin sample concentrators
(GE Healthcare, 10 000 MWCO). Following this, analysis by LCMS revealed > 99%
conversion to the conjugate.
General procedure for the preparation of the Her-Pyridazinedione conjugate
(Her-PD)
To a solution of FabHer 127 (50 µL, 30 µm, 1.4mg·mL−1, 1 eq.) in borate buffer (25mm
sodium borate, 25mm NaCl, 1mm EDTA, pH 8.0) was added TCEP (final concentration
90 µm, 3 eq.) and the reaction mixture incubated at 37 °C for 90 min. After this time,
was added a solution of pyridazinedione in DMF (final concentration 1.5mm, 5 eq.) and
the reaction mixture incubated at 37 °C for 1 h. The excess reagents were then removed
by repeated diafiltration into fresh buffer using VivaSpin sample concentrators (GE
Healthcare, 10 000 MWCO). Following this, analysis by SDS-PAGE and UV-Vis revealed
> 95% conversion to the conjugate.
General procedure for Azide–Alkyne Huisgen Cycloaddition (CuAAC)
To a solution of “clickable” FabHer-Pyridazinedione 137 (50µL, 42 µm, 2mg·mL−1) in
PB (pH 7.4) containing tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (500 µm),
CuSO4 (100 µm) was added a cargo molecule (azide or alkyne) (final concentration
100 µm, 5 eq.) and sodium ascorbate (final concentration 5mm) and the reaction mixture
incubated at 25 °C for 1 h. The excess reagents were then removed by repeated diafiltration
into fresh buffer using VivaSpin sample concentrators (GE Healthcare, 10 000 MWCO).
Following this, analysis by LCMS revealed > 95% conversion to the conjugate.
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General procedure for Strain-Promoted Azide–Alkyne Cycloaddition
(SPAAC)
To a solution of “clickable” FabHer-Pyridazinedione 137 (50µL, 21 µm, 1.0mg·mL−1) in
PBS, PB, or BBS was added a cargo molecule (azide) and the reaction mixture incubated
at 25 °C for 3 – 6 h. Following this, analysis by LCMS revealed > 95% conversion to the
conjugate. The excess reagents were then removed by repeated diafiltration into fresh
buffer using VivaSpin sample concentrators (GE Healthcare, 10 000 MWCO).
A.3.1.3 Preparation of Fab-PD constructs
Vide supra, Figure 2.3, page 51 for the structure of the PDs.
Preparation of FabHer-Diet 131
The general procedure for the preparation of a FabHer-PD conjugate was followed with
Diet PD 104 as the bridging reagent.
Observed mass: 47 822Da. Expected mass: 47 820Da.
Preparation of FabHer-AzideAlkyne-Pyridazinedione conjugate (FabHer-Azal
137a)
The general procedure for the preparation of a FabHer-PD conjugate was followed with
Azal PD 61 as the bridging reagent.
Observed mass: 47 925Da. Expected mass: 47 924Da.
Preparation of FabHer-PEGAzideAlkyne-Pyridazinedione conjugate (FabHer-
Pazal 137b)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
Pazal PD 69 as the bridging reagent.
Observed mass: 47 994Da. Expected mass: 47 994Da.
Preparation of FabHer-AlkyneAcid-Pyridazinedione conjugate (FabHer-Alkac
137d)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
Alkac PD 81 as the bridging reagent.
Observed mass: 47 866Da. Expected mass: 47 866Da.
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Preparation of FabHer-AzideMethyl-Pyridazinedione conjugate (FabHer-
Azime)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
Azime PD 120 as the bridging reagent.
Observed mass: 47 977Da. Expected mass: 47 974Da.
Preparation of FabHer-BCN-MethylStrainedAlkyne-Pyridazinedione conju-
gate (FabHer-Mestra 137g)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
Mestra PD 121 as the bridging reagent.
Observed mass: 48 090Da. Expected mass: 48 089Da.
Preparation of FabHer-MFCO-AlkyneStrainedAlkyne-Pyridazinedione conju-
gate (FabHer-MFCOAstra 137c)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
MFCOAstra PD 79 as the bridging reagent.
Observed mass: 48 418Da. Expected mass: 48 420Da.
Preparation of FabHer-Soluble-AlkyneStrainedAlkyne-Pyridazinedione con-
jugate (FabHer-Solastra 137e)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
Solastra PD 85 as the bridging reagent.
Observed mass: 48 211Da. Expected mass: 48 212Da.
Preparation of FabHer-BCN-AlkyneStrainedAlkyne-Pyridazinedione conju-
gate (FabHer-BCNAstra 137f)
The general procedure for a preparation of the FabHer-PD conjugate was followed with
BCNAstra PD 98 as the bridging reagent.
Observed mass: 48 174Da. Expected mass: 48 172Da.
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A.3.1.4 Preparation of functionalised FabHer-PD
Preparation of FabHer-Azal-PEG4 conjugate
The general procedure for CuAAC was followed with PEG4−N3 64 as the cargo molecule
and FabHer-Azal 137a as the “clickable” FabHer-PD component.
Observed mass: 48 148Da. Expected mass: 48 143Da.
Preparation of FabHer-Alkac-PEG4 conjugate 157
The general procedure for CuAAC was followed with N3−PEG4−NH2 119 as the cargo
molecule and FabHer-Alkac as the “clickable” FabHer-PD component.
Observed mass: 48 036Da. Expected mass: 48 040Da.
Preparation of FabHer-Azime-Mestra conjugate
The general procedure for SPAAC was followed with Mestra PD 121 as the cargo molecule
and FabHer-Azime as the “clickable” FabHer-PD component.
Observed mass: 48 614Da. Expected mass: 48 620Da.
Preparation of FabHer-Mestra-PEG4 conjugate
The general procedure for SPAAC was followed with N3−PEG4−NH2 119 as the cargo
molecule and FabHer-Mestra 137g as the “clickable” FabHer-PD component.
Observed mass: 48 318Da. Expected mass: 48 319Da.
Preparation of FabHer-Mestra-Tetrazine conjugate 153
The general procedure for SPAAC was followed with tetrazine 152a as the cargo molecule
and FabHer-Mestra 137g as the “clickable” FabHer-PD component.
Observed mass: 48 807Da. Expected mass: 48 802Da.
Preparation of FabHer-MFCOAstra-PEG4 conjugate 155
The general procedure for SPAAC was followed with PEG4−N3 64 as the cargo molecule
and FabHer-MFCOAstra 137c as the “clickable” FabHer-PD component.
Observed mass: 48 640Da. Expected mass: 48 639Da.
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Preparation of FabHer-MFCOAstra-Dox
The general procedure for SPAAC was followed with Dox−PEG4−N3 147 as the cargo
molecule and FabHer-MFCOAstra 137c as the “clickable” FabHer-PD component.
Observed mass: 49 253Da. Expected mass: 49 257Da.
Preparation of FabHer-Solastra-PEG4 conjugate 156
The general procedure for SPAAC was followed with N3−PEG4−NH2 119 as the cargo
molecule and FabHer-Solastra 137e as the “clickable” FabHer-PD component.
Observed mass: 48 432Da. Expected mass: 48 431Da.
Preparation of FabHer-Solastra-AlexaFluor conjugate 181
The general procedure for SPAAC was followed with AlexaFluor488-Azide (Molecular
Probes) 167 as the cargo molecule and FabHer-Solastra 137e as the “clickable” FabHer-
PD component.
Observed mass: 48 871Da. Expected mass: 48 871Da.
Preparation of FabHer-Solastra-Dox
The general procedure for SPAAC was followed with Dox−PEG4−N3 147 as the cargo
molecule and FabHer-Solastra 137e as the “clickable” FabHer-PD component.
Observed mass: 49 016Da. Expected mass: 49 013Da.
Preparation of FabHer-BCNAstra-PEG4 conjugate 155
The general procedure for SPAAC was followed with N3−PEG4−NH2 119 as the cargo
molecule and FabHer-BCNAstra 137f as the “clickable” FabHer-PD component.
Observed mass: 48 348Da. Expected mass: 48 348Da.
A.3.1.5 Preparation of dually functionalised FabHer-PD
Preparation of FabHer-MFCOAstra-PEG4-PEG4 conjugate
The general procedure for CuAAC was followed with PEG4−N3 64 as the cargo molecule
and FabHer-MFCOAstra-PEG4 as the “clickable” FabHer-PD component.
Observed mass: 48 880Da. Expected mass: 48 882Da.
Appendix A. Experimental 150
Preparation of FabHer-Solastra-PEG4-Cy5 conjugate 158
The general procedure for CuAAC was followed with sulfo-Cy5 145 as the cargo molecule
and FabHer-Solastra-PEG4 as the “clickable” FabHer-PD component.
Observed mass: 49 175Da. Expected mass: 49 176Da.
Preparation of FabHer-Solastra-Dox-PEG20k 159
The general procedure for CuAAC was followed with PEG20k−N3 144 as the cargo
molecule and FabHer-Solastra-Dox as the “clickable” FabHer-PD component.
A.3.1.6 Other
Digestion of misbridged Her-Diet 130
The pepsin digestion procedure for trastuzumab 19 was followed with misbridged Her-
Diet 130 as the antibody component. This yielded F(ab)’Her-Diet 132.
Observed mass: 48 989Da. Expected mass: 48 993Da.
Preparation of FabRit-Diet
The general procedure for the preparation of a FabHer-PD conjugate was followed with
FabRit 123 and Diet PD 104 as the bridging reagent.
Observed mass: 47 350Da. Expected mass: 47 351Da.
Preparation of FabRit-AzideAlkyne-Pyridazinedione conjugate (FabRit-Azal)
The general procedure for the preparation of a FabHer-PD conjugate was followed with
FabRit 123 and Azal PD 61 as the bridging reagent.
Observed mass: 47 464Da. Expected mass: 47 464Da.
A.3.1.7 Stability and selectivity
Stability after 8 months at 4 °C
FabHer-Diet 131, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 (50 µL, 30µm)
were buffer exchanged into PBS (pH 7.4) by repeated diafiltration into fresh buffer using
VivaSpin sample concentrators (GE Healthcare, 10 000 MWCO) and were incubated at
4 °C for ca. 8 months. Following this, analysis by LCMS revealed no trace of degradation
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of FabHer-Diet 131 (expected mass: 47 820Da, observed mass: 47 822Da, vide supra,
Figure 5.2b, page 88) and analysis by SDS-PAGE showed no degradation of the three
conjugates 131, 159 and 161 (vide supra, Figure 5.2a and Figure 5.3a and b respectively,
page 88).
Stability under acidic pH
FabHer-Diet 131, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 (50 µL, 30µm)
were buffer exchanged into acetate buffer (20mm sodium acetate trihydrate, pH 3.1)
by repeated diafiltration into fresh buffer using VivaSpin sample concentrators (GE
Healthcare, 10 000 MWCO) and were incubated at 37 °C for 24 h. Following this, analysis
by LCMS revealed no trace of degradation of FabHer-Diet 131 (expected mass: 47 820Da,
observed mass: 47 822Da, vide supra, Figure 5.2c, page 88) and analysis by SDS-PAGE
showed no degradation of the three conjugates 131, 159 and 161 (vide supra, Figure 5.2a
and Figure 5.3a and b respectively, page 88).
Stability under basic pH
FabHer-Diet 131, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 (50 µL, 30µm)
were buffer exchanged into BBS (pH 9) by repeated diafiltration into fresh buffer using
VivaSpin sample concentrators (GE Healthcare, 10 000 MWCO) and were incubated
at 37 °C for 24 h. Following this, analysis by LCMS revealed no trace of degradation
of FabHer-Diet 131 (expected mass: 47 820Da, observed mass: 47 826Da, vide supra,
Figure 5.2d, page 88) and analysis by SDS-PAGE showed no degradation of the three
conjugates 131, 159 and 161 (vide supra, Figure 5.2a and Figure 5.3a and b respectively,
page 88).
Stability in blood plasma mimicking conditions
FabHer-Diet 131, FabHer-PEG20k-Dox 159 and Her-Solastra-Dox-Cy5 161 (200 µL, 40µm)
were buffer exchanged into SBF by repeated diafiltration into fresh buffer using VivaSpin
sample concentrators (GE Healthcare, 10 000 MWCO) then, human serum albumin
(HSA) (final concentration 600 µm) and glutathione (GSH) (final concentration 20µm)
were added. The resulting solutions were then incubated at 37 °C for 7 days. Following
this, analysis by SDS-PAGE showed no reaction of the three conjugates 131, 159 and
161 with GSH or HSA (vide supra, Figure 5.4 and Figure 5.5a and b respectively, page
89).
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Selectivity control in the absence of TCEP
A solution of FabHer 127 (50 µL, 30 µm, 1 eq.) in BBS (25mm sodium borate, 25mm,
0.5mm EDTA, pH 8.0) was incubated at 37 °C for 90 min. After this time was added a
solution of Solastra PD 85 in DMF (final concentration 1.5mm, 5 eq.) and the reaction
mixture incubated at 37 °C for 1 h. The excess reagents were then removed by repeated
diafiltration into fresh buffer using VivaSpin sample concentrators (GE Healthcare, 10 000
MWCO). Following this, analysis by LCMS revealed that no reaction occurred on FabHer
127 (expected mass: 47 652Da, observed mass: 47 656Da).
A.3.2 GFP modification
A.3.2.1 Cloning and expression of protein
The gene for GFPS147C 140 in the vector pNIC28-Bsa4 was generated by Dr Rachel
Morgan as described previously.250
Sequence:
MHHHHHHSSGVDLGTDNLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRG
EGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDF
FKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNIL
GHKLEYNFNCHNVYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGD
GPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGMDELYK
Expected mass: 29 341Da. Observed mass: 29 332Da.
A.3.2.2 Preparation of GFPS147C-PD
Pre-treatment procedure for reaction with GFPS147C 140
Immediately prior to conjugation with GFPS147C 140, TCEP (10 µL, 10mm as a solution
in water, per 100 µL of protein (1.0mg·mL−1 solution)) was added, incubated on ice for
1 h and the excess reducing agent removed by repeated diafiltration into fresh buffer
(100mm sodium phosphate, pH 8.0) using VivaSpin sample concentrators (GE Healthcare,
3000 MWCO).
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Reaction of GFPS147C 140 with 1,2-diethyl-1,2-dihydropyridazine-3,6-dione
102
1,2-Diethyl-1,2-dihydropyridazine-3,6-dione 102 (5 µL, 340 µm in DMF, 10 eq.) was added
to GFPS147C 140 (100 µL, 1.0mg·mL−1, 34µm) in sodium phosphate buffer (100mm,
pH 8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were
removed by repeated diafiltration into fresh buffer (100mm sodium phosphate, pH 8.0)
using VivaSpin sample concentrators (GE Healthcare, 3000 MWCO). The samples were
analysed by LCMS.
Expected mass: 29 501Da. Observed mass: 29 503Da.
Analogous reaction conditions when applied to 1-methyl-1,2-dihydropyridazine-3,6-dione
173 in place of 1,2-diethyl-1,2-dihydropyridazine-3,6-dione 102 showed no reaction, even
after 16 h and 72 h time points.
Reaction of GFPS147C 140 with 2-(4-azidobenzyl)-4-bromo-1-(prop-2-yn-1-
yl)-1,2-dihydropyridazine-3,6-dione (mBr-Azal PD) 100 — Preparation of
GFPS147C-Azal 178
2-(4-Azidobenzyl)-4-bromo-1-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-dione (mBr-Azal
PD) 100 (5 µL, 340 µm in DMF, 10 eq.) was added to GFPS147C 140 (100 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 8.0). The reaction mixture
was incubated at 37 °C for 1 h. Excess reagents were removed by repeated diafiltration
into fresh buffer (100mm sodium phosphate, pH 8.0) using VivaSpin sample concentrators
(GE Healthcare, 3000 MWCO). The samples were analysed by LCMS.
Expected mass: 29 612Da. Observed mass: 29 613Da.
A.3.2.3 Stability of GFPS147C-PD
Reduction of GFPS147C-Azal 178 with TCEP — Preparation of GFPS147C-
AlkOH 179
TCEP (10µL, final concentration 340 µm, 10 eq.) was added to conjugate GFPS147C-Azal
178 (90µL, 1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 8.0). The
reaction was incubated at 37 °C for 1.5 h. Excess reagents were removed by repeated
diafiltration into fresh buffer (100mm sodium phosphate, pH 8.0) using VivaSpin sample
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concentrators (GE Healthcare, 3000 MWCO). The samples were analysed by LCMS.
Expected mass: 29 482Da. Observed mass: 29 484Da.
Reaction of GFPS147C-Azal 178 with glutathione
Glutathione (10µL, 5.0mm) was added to conjugate GFPS147C-Azal 178 (90 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 7.4). The reaction was
incubated at 37 °C for 72 h and then analysed by LCMS.
Expected mass: 29 332Da. Observed mass: 29 336Da.
Reaction of GFPS147C-AlkOH 179 with glutathione
Glutathione (10 µL, 5.0mm) was added to conjugate GFPS147C-AlkOH 179 (90 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 7.4). The reaction was
incubated at 37 °C for 72 h and then analysed by LCMS.
Expected mass: 29 482Da. Observed mass: 29 481Da.
A.3.2.4 Preparation of functionalised GFPS147C-AlkOH
Reaction of GFPS147C-AlkOH 179 with benzyl azide
Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.2 µL, 20mm) was added to a
solution of CuBr (2.4 µL, 3.0mg·mL−1 in acetonitrile). GFPS147C-AlkOH 179 (60 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 8.0) was added to the
premixed copper solution. Benzyl azide (3 µL, 6.8mm, 10 eq.) was added to the reaction
mixture and the mixture was incubated at 37 °C for 4 h. Excess reagents were removed
by repeated diafiltration into fresh buffer (100mm sodium phosphate, 5mm EDTA, pH
8.0) using VivaSpin sample concentrators (GE Healthcare, 3000 MWCO). The samples
were analysed by LCMS.
Expected mass: 29 615Da. Observed mass: 29 614Da.
Reaction of GFPS147C-AlkOH 179 with dansyl azide 162
Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.2 µL, 20mm) was added to a
solution of CuBr (2.4 µL, 3.0mg·mL−1 in acetonitrile). GFPS147C-AlkOH 179 (60 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 8.0) was added to the
premixed copper solution. Dansyl azide (3 µL, 6.8mm in DMF, 10 eq.) was added to the
reaction mixture and the mixture was incubated at 37 °C for 4 h. Excess reagents were
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removed by repeated diafiltration into fresh buffer (100mm sodium phosphate, 5mm
EDTA, pH 8.0) using VivaSpin sample concentrators (GE Healthcare, 3000 MWCO).
The samples were analysed by LCMS.
Expected mass: 29 801Da. Observed mass: 29 800Da.
Reaction of GFPS147C-AlkOH 179 with sulfo-cyanine5 azide 145
Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.2 µL, 20mm) was added to a
solution of CuBr (2.4 µL, 3.0mg·mL−1 in acetonitrile). GFPS147C-AlkOH 179 (60 µL,
1.0mg·mL−1, 34 µm) in sodium phosphate buffer (100mm, pH 8.0) was added to the
premixed copper solution. Sulfo-cyanine5 azide (3 µL, 6.8mm in DMF, 10 eq.) was added
to the reaction mixture and the mixture was incubated at 37 °C for 4 h. Excess reagents
were removed by repeated diafiltration into fresh buffer (100mm sodium phosphate, 5mm
EDTA, pH 8.0) using VivaSpin sample concentrators (GE Healthcare, 3000 MWCO).
The samples were analysed by LCMS.
Expected mass: 30 206Da. Observed mass: 30 204Da.
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Figure A.1: Lane 1 – ladder; 2 –GFPS147C 140; 3 –GFPS147C-Azal 178; 4 –GFPS147C-
AlkOH 179; 5 –GFPS147C-AlkOH-Benzyl 180a.
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B.1 Names of Pyridazinediones
Expanded name (handles) Number
Azal Azide–Alkyne 61
Pazal PEG Azide–Alkyne 69
MFCO-Astra Monof luoro Cyclooctyne-based Alkyne–StrainedAlkyne 79
Alkac Alkyne–Acid 81
Solastra Soluble MFCO-Astra 85
BCN-Astra Bicyclo[6.1.0]nonyne-based Alkyne–Strained Alkyne 98
mBr-Azal Monobromo Azal 100
mBr-Diet Monobromo Diethyl 103
Diet Diethyl 104
Azime Azide Methyl 120
BCN-Mestra Bicyclo[6.1.0]nonyne-based Methyl–Strained Alkyne 121
Table B.1: Main acronyms used in this thesis
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B.2 Structures of Pyridazinediones
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Figure B.1: Structure of pyridazinediones prepared with their acronyms with (a) two
“clickable” handles; (b) one “clickable” handle; (c) no reactive handle.
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